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Statement of candidate’s contribution to the work 
 
 
The research carried out in this thesis was part of a larger study funded by the Wellcome 
Trust  Foundation in which  I have been involved for almost ten years in one of the 
10/66 centres as a principal investigator. I have conducted the 10/66 pilot and cross 
sectional studies in Cuba as principal investigator and I have a role in coordinating, 
doing quality controls as well as conducting some interviews myself. These gave me a 
complete understanding of the design, measurements and procedures used in the studies, 
and a familiarity with all the variables I had used in the analysis for my PhD.   
 
Although I have worked only in one 10/66 centre (Cuba), I have been in direct and 
constant contact with the other centres, sharing experiences and difficulties that arise 
from the data collection. I have spent 12 months in London, where I have been taken 
statistical courses and conducted the analysis under supervision of my supervisors, Dr 
Ferri and Prof. Prince.  
 
I participated in the design of the study and in the development of the funding proposal 
with my supervisors. Regarding quality control, I co-ordinated the field work and 
worked closely with the research team. I supervised personally 5 % of all interviews, 
participated in the translation process and took the lead on analysis and interpretation.  
For the reliability and validation studies, I was closely involved in training data 
collectors, and coordinated the studies, double-entered the data and independently 
conducted the analyses. I worked closely with my supervisors to design the study 
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questionnaire and train data collectors. For the quantitative analyses presented in this 
thesis, I developed the analysis plan, conducted the analyses and I am responsible for the 
interpretation of the findings. I also completed the literature review to include existing 
research into demographic ageing, epidemiological transition, dementia, and other non 
communicable diseases among older people and also to review the literature related to 
the origin of admixture in Cuba and the use of population admixture to understand the 
aetiology of chronic conditions.  
 
The initial plan for my thesis was  to  have modelled dementia  prevalence, using 
mixed effects multi-level models across  the ten urban and rural sites in the seven LMIC 
included in the 10/66 Dementia Research program.  As part of the initial stages of this 
work, I took a role in the drafting of a paper  published  in the Lancet in 2008 (Annex 1) 
on  the  prevalence of dementia in Latin America, India and China . However, initial 
analyses indicated problems with the original plan - the mixed effects models would not 
converge even when one or two effects were considered at the site-level, presumably 
because of insuffient variance at site level. I therefore changed my plans for my thesis, 
to study  in detail the epidemiology of dementia (prevalence, incidence  and aetiology) 
specifically in the Cuban population , of particular interest given the island's history, and 
the high level of ancestry admixture. In the course of my work on the revised plans for 
the thesis, I have published two further related papers as first author, one on  the 
 prevalence, correlates and impact of dementia in Cuba  published 
 in Neuropepidemiology in 2008 (Annex 2) and another on the interaction between 
genetic admixture, ethnic identity, APOE gentype and dementia , published in the BMC 




Background: There is a high frequency of the risk-conferring APOE e4 allele in African 
populations, but in some studies, the risk of dementia is less than in Caucasians in  
Europe and North America. In an admixed population of older Cubans I estimate the 
prevalence, incidence, correlates and impact of dementia among older Cubans; I assess 
the effects of reported ethnicity, admixture and apolipoprotein E genotype on dementia 
prevalence and estimate the association between cardiovascular risk factors and 
dementia incidence.  
Methods: I undertook a one phase survey (baseline) of all over 65 year old residents of 
seven catchment areas in Cuba (n=2944) during 2003 to 2007. Dementia diagnosis was 
established according to DSM-IV and 10/66 criteria. APOE genotype was determined in 
2520 participants, and genetic admixture in 235 dementia cases and 349 controls.  
Baseline data was used to estimate prevalence, impact, and the effect of ethinicity, and 
apolipoprotein E genotype on dementia prevalence.  The case control study was used to 
test the hypothesis that the effect of APOE genotype on dementia is modified by ethnic group. 
An incidence wave was conducted 4.5 years after cohort inception in order to estimate 
incidence and cardiovascular risk factors associations  
Results: The prevalence of DSM-IV dementia was 6.4% and 10.8% according to the 
10/66. Both dementia outcomes were associated with older age, less education, a family 
history of dementia, shorter leg length and smaller skull circumference. Dementia, rather 
than physical health problems or depression, was the main contributor to needs for care 
and caregiver cutting back on work. The incidence rate of 10/66 dementia was 20.5 per 
1000/pyear (95% CI, 17.6-23.5). African admixture was linearly related to number of 
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APOE e4 alleles, but was not associated with the prevalence of dementia. However, 
when the effects of  ‘black’ ethnicity and African admixture were considered 
simultaneously the former was inversely and  the latter positively associated with 
dementia risk. APOE genotype was associated cross-sectionally with dementia 
prevalence, but the effect on the incidence of dementia was much attenuated, and only 
apparent among those in the youngest age group. There were no associations between 
hypertension, diabetes, lipid profile, smoking and the incidence of dementia. There was 
only weak evidence to support effect modification by APOE genotype.  
Conclusion: The prevalence and incidence  of dementia in the older cuban population 
studied is high, and the rate increases with age. These findings underscore the need to 
improve our understanding of risk factors associated with dementia in specific 
populations, as well as the need for public health programs for both patients and 
caregivers in a population that is currently undergoing rapid demographic  ageing and  
epidemiological transition. Counter to our hypothesis, African admixture may be 
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CHAPTER 1  BACKGROUND 
 
1.1  Ageing Populations  
1.1.1  Demographic Ageing  
The past fifty years have seen increasingly rapid advances in human development. One 
of the most important achievements is demographic ageing, which is happening rapidly 
in all world regions, particularly in low and middle income countries. The total global 
population is projected to rise to 9.2 billion in 2050 representing an increase of 2.7 
billion over the 2005 population of 6.5 billion. Nearly all of this future growth will occur 
in the ‘South’—i.e. Africa, Asia (excluding Japan, Australia and New Zealand), and 
Latin America where population size is projected to increase from 5.3 to 7.9 billion 
between 2005 and 2050 (United Nations, 2002, Bongaarts, 2009). 
 
This change will lead to a dramatic increase in the number and proportion of older 
persons. The global number of people aged 60 years or over will nearly triple, increasing 
from 606 million in 2000 to nearly 1.9 billion by 2050 (Bongaarts, 2009) . The rise in 
the proportion of the population aged 60 or over will increase from 19%  to 32% in 
developed regions  and from 8% to 20% in less developed regions by 2050 (Christensen 





Even more striking is the expected increase in the number of the oldest-old (80 years or 
over) at the global level from 69 million in 2000 to 377 million in 2050. These rapid 
changes will affect dramatically the demographic balance between and within 
geographic regions. In less developed regions the increase will be from 32 million to 265 
million, in other words the majority of the oldest old will be living in less developed 
countries by 2050 (World Health Organisation, 2008b, World Health Organisation, 
2008a). 
 
1.1.2  Ageing in Latin America and the Caribbean 
 
Latin America and the Caribbean countries are experiencing unprecedentedly rapid 
demographic ageing.  By 2030 the numbers of people aged 60 years or over will be three 
times the numbers in 2000. The length of time taken for the proportion of those aged 60 
year and over to increase from 8% to 15% in the Latin American and Caribbean 
corresponds to less than two-fifths the length of time it took in the United States, and 
between one-fifths and two-fifths of the time it took in an average Western European 
country to reach similar levels (Palloni et al., 2002).  
 
The most important contributors to this demographic ageing are changes in both fertility 
and mortality risk from age 0 to 60, which was experienced by many countries in this 
region after 1940. Argentine and Uruguay exhibited relative low fertility rates before the 
50’s, while Chile, Cuba and Costa Rica exhibited a rapid fertility rate decline after 1950. 
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In the remaining countries in this area this happened only after 1975 (Demographic 
Bulletin Economic Comission for Latin American and the Caribbean, 2003; Palloni et 
al., 2002).  
 
In the last half century the average life expectancy at birth in the region increased by 
approximately 20 years, from 50 to 70, and the overall fertility rate decreased by half, 
from approximately six children to fewer than three (Demographic Bulletin Economic 
Comission for Latin American and the Caribbean, 2003). Over the same period, the 
proportion of persons aged 60 years and over rose from 6% to 8%. In 2000-2025   
people aged 60 years and over will grow three times faster than the population as a 
whole and five times faster over the period 2025-2050. As a result, by 2050, one out of 
every four Latin Americans will be an older adult (United Nations, 2004) .  
 
1.1.3  The health transition  
 
As populations age, non-communicable diseases (NCDs) assume a progressively greater 
significance in low and middle income countries (LMIC). This process, referred to as the 
health transition or epidemiologic transition, can be defined as the complex changes in 
patterns of health, disease, and mortality that result from demographic and associated 
economic and societal changes in a world population in which infectious diseases are 
gradually replaced by chronic, degenerative diseases as the leading causes of death 
(Omran, 1971, Salomon J, 2002) . 
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Over the next decade deaths from infectious diseases, maternal and perinatal conditions, 
and nutritional deficiencies combined are projected to decline by 3% worldwide. 
However, deaths due to chronic diseases are projected to increase by 17% over the same 
period. Of the projected 64 million people who will die in 2015, 41 million ( 64 %) will 
die of a chronic disease (Lopez  A.D, 2006).  
 
 Latin America exemplifies the third stage of health transition. The region has 
experienced important changes in health conditions related to demographic structure, 
improvements in medical care and changing socioeconomic and environmental 
conditions, as a result of industrialisation and urbanisation.  However, paradoxically the 
increase of about 20 years in life expectancy comes together with adverse changes in life 
style and cardiovascular risk factor profile, including high fat diets, cigarette smoking 
and lack of exercise. For this reason CVDs are considered to have maximum public 
health salience in the Latin American region - more so than in stage 2 regions (China 
and India) where risk exposure levels are not yet so high. In regions in stage 4, such as 
Western Europe, North America (excluding some parts of Mexico), Australia, and New 
Zealand public health measures have led to reduced exposure levels, hence preventing or 
delaying these diseases to more advanced ages (Yusuf et al., 2001a). INTERHEART, a 
multinational, case-control study, demonstrate  that risk factors for myocardial infarction 
operate similarly in both sexes and at all ages in all regions of the world, including Latin 
America and China (Yusuf et al., 2004).  
 
NCDs account for 44% of premature deaths and are already the leading causes of death 
in all world regions apart from sub-Saharan Africa. As an illustration, the number of 
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deaths  by NCDs are double than that resulting from a combination of infectious 
diseases (including HIV/AIDS, tuberculosis and malaria), maternal and perinatal 
conditions, and nutritional deficiencies, and as a result 388 million people worldwide 
will die of one or more NCDs in the next 10 years (World Health Organisation, 2008a, 
Lopez  A.D, 2006). 
 
Two thirds (78%)  of the deaths among older people occurred in LMIC, and in these 
regions too, chronic diseases are fast replacing communicable diseases as the leading 
causes of death and disability (Alzheimer's Disease International, 2009). Of the 35 
million deaths in 2005 from NCDs, 80% occurred  in LMIC (Fuster V, 2005). This is 
partly because most of the world’s older people live in these regions - 60% now rising to 
80% by 2050. There is therefore a growing interest to put chronic diseases on global and 
national agendas. However, mental health and particularly dementias remain a low 
priority in most low and middle income countries.  The Sixty-sixth General United 
Nations  special assembly meeting on chronic disease prioritizes ischaemic heart 
disease, stroke, diabetes and cancer - dementia was not considered a priority (United 
Nations, 2011) . Nevertheless dementia is one of the most important contributors to 
disability and dependency in older people (Sousa  et al, 2009). In addition, dementia can 
be a consequence of, or at least it is associated to other chronic vascular diseases, such 
as hypertension, diabetes, stroke and their risk factors (see section 1.3, page for details) .  
 
I will therefore now consider in more details this neglected topic in developing 
countries.  
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1.2  Dementia 
        
1.2.1  Prevalence of dementia 
 
Dementia is a syndrome with a monumental impact on the quality of life of patients and 
their caregivers with a high societal cost. Primary dementias are currently incurable, and 
cause progressive, irreversible brain damage. They include Alzheimer's disease (AD) - 
the most common cause, vascular dementia, frontotemporal dementia and Dementia 
with Lewy Bodies. Dementia syndrome is characterized clinically by progressive decline 
in memory, executive function, language, and other areas of cognition, behavioural and 
psychological symptoms and the gradual loss of ability to perform all tasks of daily 
living.  
 
There is a very relevant priority in the study of geographic variations in prevalence and 
incidence of dementia. The aetiology of most dementias is not completely understood, as 
well as the methods for their prevention. However, both prevalence and incidence of 
dementia are strongly age dependent. Hence, with the ageing of the population in 
regions such as Latin America, China and India, the magnitude of the dementia problem 
in the community is growing and presents a substantial health burden for the 
community. The study of geographic variation provides a potential opportunity to 
identify important risk factors for dementia, which may also be useful for prevention.  
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 The EURODEM  meta-analysis of dementia prevalence from 12 European studies 
carried out between 1980 and 1990  reported a  general age- and gender-distribution  
similar for all studies across Europe (Hofman et al., 1991), suggested no significant 
geographic variation. The overall European prevalences for the five-year age groups 
from 60 to 94 years were 1.0, 1.4, 4.1, 5.7, 13.0, 21.6 and 32.2%, respectively. In those 
under 75 years the prevalence of dementia was slightly higher in men than in women; in 
those aged 75 years or over the prevalence was higher in women.  
 
Ten years later Lobo et al  (Lobo et al., 2000) compared, across studies, the age- and 
sex-specific prevalence of dementia and its main subtypes from 11 studies carried out in 
eight European countries reporting a 6.4 % age-standardized prevalence of dementia in 
Europe. The age pattern of the prevalence estimated seems to be stable in time, as there 
is a general similarity between the findings in his study and the results based on studies 
conducted the previous decade.  
 
Studies from Nigeria (Hendrie et al., 1995b) and northern India (Chandra et al., 1998) 
suggested a much lower prevalence ( a quarter ) of both dementia and the Alzheimer’s 
disease subtype than that observed in the European meta-analysis. The overall age-
adjusted prevalence rates of dementia and Alzheimer's disease in Ibadan, Nigeria were 
2.3% and 1.4%, respectively. The rural India study showed overall dementia prevalence 
of 1.4% and 1.1% for Alzheimer’s disease in the population aged 65 years and older. 
 
In  2005, an expert consensus group (Ferri et al., 2005) estimated age-specific dementia 
prevalence for different world regions, based on published evidence, using the Delphi 
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technique. Consensus estimates supported a lower prevalence of dementia in developing 
regions than in developed regions, particularly in sub-Saharan Africa and in south Asia 
compared with other regions.  
 
In 2009 the World Alzheimer Report (Alzheimer's Disease International, 2009) a new 
systematic review of the global prevalence of dementia, identifying 147 studies in 21 
Global Burden of Disease (GBD) world regions, the accumulated evidence suggested 
quite similar age-standardised prevalence worldwide, with the possible exception of sub-
Saharan Africa. After that, three studies in Sub Saharan Africa reported a much higher 
dementia prevalence than that reported in the  Ibadan Nigeria study (Hendrie et al., 
1995b) which was much more similar to those find in high income countries (HIC).  In a 
study conducted  in central Nigeria with a stratified, random community sample of 280 
persons aged 65 years and older, prevalence  of dementia was  reported to be  6.4% 
overall ( Ochayi et al., 2006)  and  another study conducted a door-to-door surveys  in 
elderly living in two urban cities of Central Africa and estimated a prevalence dementia 
of  8.1% (95% CI , 5.8–10.8) in Bangui (Republic of Central Africa) and 6.7% (95% CI, 
4.7–9.2) in Brazzaville (Congo) (Guerchet M  et al, 2010) .   
 
Two studies , one in a rural area of Benin (Guerche M et al., 2009) reported a 2.6 %  
prevalence of dementia  similar to that reported by Hendrie et al (Hendrie et al., 1995b) 
in Nigeria. The other study was cross-sectional (Paraïso M et al., 2011) and included 
1,162 people aged 65 and over who had lived in an urban area of Benin and found an 
overall prevalence of dementia of 3.7% (95% CI 2.6–4.8) slightly higher  than it was 
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found in a rural area, but still  close to  that recorded in  Ibadan study of 2.3% (95% CI 
1.2–3.4) overall. 
 
Although estimates of dementia prevalence might be similar in many parts of the world, 
the absolute number of people with dementia is much higher in LMIC compared to HIC. 
Ferri et al (Ferri et al., 2005) based upon systematic review of prevalence data and 
expert consensus, estimated that not only 24.2 million people live with dementia 
worldwide but also that there are 4.6 million new cases annually (similar to the annual 
global incidence of non-fatal stroke). The majority of people with dementia live in low 
and middle income countries (LAMIC), 60% in 2001 rising to 71% by 2040. Increases 
to 2040 will be much sharper in developing (300%) than in developed regions (100%) 
(The 10/66 Dementia Research Group, 2000a). 
 
The World Alzheimer Report 2009  estimated that absolute numbers are even higher that 
the previous review; 35.6 million people with dementia, the numbers nearly doubling 
every 20 years, to 65.7 million in 2030 and 115.4 million in 2050 (Alzheimer's Disease 
International, 2009). This  new estimates based in a  large number of new studies, 
particularly from low and middle income countries provide more robust and valid 
figures based on quantitative meta-analyses in 11 of the 21 GBD world regions and not 
only on expert consensus as previous ADI estimates, published in 2005 (Ferri et al., 
2005). Most of the increase in numbers is explained by the different base year for the 
estimates (2010 versus 2001). Like for like comparison indicates that the new numbers 
are 10% higher than those from the previous Delphi consensus. Compared with the 
earlier Lancet/ADI consensus estimates those for three regions were higher - Western 
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Europe (7.29% vs. 5.92%), South Asia (5.65% vs. 3.40%) and Latin America (8.50% vs. 
7.25%).  Those for East Asia were lower (4.98% vs. 6.46%).  
 
The World Alzheimer’s Report  (Alzheimer's Disease International, 2009) estimated 3.4 
million people living with dementia in Latin America in 2010,  increasing to 7.7 millions 
in 2030. Estimated numbers of people with dementia in Cuba are 130 000 in 2010, 
doubling to 260 000 by 2030 (Llibre Rodríguez J, 2008).  
 
In the most recent database search and meta-analysis in Latin American (LA) region 
(Nitrini et al., 2004), Nitrini et al., describes a regional dementia prevalence rate of 7.1% 
(CI 6.8-7.4%). This group reported slightly higher rates for women compared to men in 
all age groups, a similar finding to that was reported in the 10/66 Dementia research 
Group studies five Latin American countries using the same methodology (Llibre 
Rodriguez, et al, 2008).  However, a limitation of the Nitrini et al. meta-analysis is that 
the constituent studies used different study design and diagnostic criteria. In the 
systematic review conducted for he 2009 World Alzheimer report using Western Europe 
as the standard population, the highest standardised prevalence for any world region 
(aged 60 and over) was observed in Latin America (8.5%) (Alzheimer's Disease 




1.2.2  Incidence of dementia 
 
Studies on the incidence of dementia are much less common than prevalence studies 
partially because of the considerable resources and time required. Several studies  have 
been published  on the incidence of dementia and Alzheimer’s disease in HIC countries; 
Sweden ( Hagnell O et al.,1992; Aevarsson O and Skoog I.,1996; Fratiglioni L et.al, 
1997), Finland ( Mo¨lsa¨ PK et al., 1982.), Germany ( Fichter MM et al., 1996.), United 
Kingdom (Copeland, Davidson, Dewey, et al, 1992; Matthews F, Brayne C & Medical 
Research Council Cognitive Function and Ageing Study Investigators, 2005b), the 
Netherlands,(Ott et al., 1998a), France (Letenneur et al., 1993),  the United States  
(Bachman et al., 1992), and  Japan (Fukunishi I et al., 1991). Only a few studies have 
been conducted in LMIC, which, generally, report lower incidence rates compared to 
HIC (Chandra et al, 2001; Hendrie et al, 2001; Li et al, 1991; Nitrini  et al, 2004).  
 
In 1998 Jorm et al (Jorm and Jolley, 1998) analysed data from 23 published studies 
reporting age-specific incidence data, and they found that the incidence of dementia rises 
exponentially to the age of 90 years. East Asian countries had a lower incidence of 
dementia and AD than Europe and the United States. The annual incidence rates 
reported in the EURODEM metaanalysis (Fratiglioni et al., 2000)  are roughly one-
quarter of the point prevalence suggesting an average disease duration (from onset to 
death) of four years. 
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According to the Medical Research Council Cognitive Function and Ageing Study 
(MRC CFAS)( Matthews F et al., 2005), the largest UK-based multicentre study into 
functional and cognitive health of the elderly, the population burden of the incidence of 
dementia equates to approximately 180,000 newly occurring dementia cases each year in 
England and Wales (95% confidence interval [CI], 105,000 to 325,000). In the Canadian 
Health and Aging Study the overall age-standardized incidence rates were 21.8 (women) 
and 19.1 (men) per 1,000 nondemented persons per year. This means 60,150 new cases 
of dementia per year in Canada. 
 
In  the single longitudinal study carried out in Latin America, the Catanduva Study in 
Brazil (Nitrini et al., 2004), with  50 incident cases and 3,623 person years of follow-up 
the incidence rate of dementia was 13.8 per 1000 person-years for individuals aged 65 
years or older,  considerably lower than those from North American and European 
countries.  
 
Ferri  et al  (Ferri et al., 2005)  reported a  global incidence of dementia in 7.5 per 1000 
person years for those aged 60 and over, equating to 4.6 million new dementia cases per 
year, similar to the incidence of non-fatal stroke.  Meanwhile, the annual regional 
dementia incidence rates (per 1,000 individuals in the population) were estimated to be 
10.5 for North America, 8.8 for Western Europe, 9.2 for Latin America, and 8.0 for 
China and its western-Pacific neighbours. The lowest annual incidences were estimated 
for India and South Asia, 4.3/1000 and Africa Sub-Saharan 3.5/1000. (Ferri et al., 2005). 
Incidence was estimated from the Delphi consensus prevalence and mortality using The 
 27 
Global Burden of Disease project DISMOD-II software developed by WHO (Barendregt 
JJ et al., 2003).    
 
1.2.3  Methodological issues regarding prevalence and incidence of dementia  
 
Epidemiological research on dementia in developing countries, and also the impact of 
cardiovascular risk factors such as hypertension, type 2 diabetes and obesity, diet and 
lifestyle that may increase the risk for dementia and AD, are scarce, with very little 
available information (Fuster V, 2005, Yusuf et al., 2001b).  
 
Many studies have reported that prevalence of dementia is lower in developing countries 
than in the developed north (The 10/66 Dementia Research Group, 2000a, The 10/66 
Dementia Research Group, 2000b), strikingly so in some studies (Chandra et al, 1998; 
Hendrie et al, 1995). ADI's expert consensus panel, reviewing all available evidence, 
confirmed this trend (Ferri et al., 2005), which seems not to be explained by differences 
in survival (Chandra et al, 2001; Hendrie et al, 2001).  
 
If there is regional variation in the prevalence and incidence of dementia, and this 
difference is real, rather than a methodological artifact, and if they can be confidently 
attributed to underlying real differences in disease incidence, it will be of particular 
importance for policy to understand the influence of the genetic and/ or environmental 
aetiology. If environmental, we need to identify the adverse exposures so we can control 
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them; if genetic, then identification of the genes responsible might elucidate pathological 
mechanisms and suggest specific therapies. 
 
Geographical variation might indicate differences in population levels of exposure to 
environmental risk factor and lifestyle, such as  low levels of cardiovascular risk 
(Hendrie et al, 2004) and hyperlipidaemia (Breteler and Hofman, 1998 , Chandra and 
Pandav, 1998) in some developing countries. However, other potential risk exposures 
will be more prevalent in LMIC, for example low education, anaemia, which was found 
to be associated with AD in rural India (Pandav et al., 2004).  Regional variation could 
also be genetic or arise as a result of interaction between genes and enviroment. 
 
Methodological differences can also account for differences in disease frequency 
between LMIC and HIC studies. I describe some of the most relevants aspects related to 
the quality of epidemiological studies on dementia field.  
 
1.2.3.1 Study Design  
One of the most significant current discussions in prevalence and incidence phase 
studies is related to the study design (one or two stage design). Overall, 70% of dementia 
prevalence studies assessed in the systematic review carried out for the 2009 World 
Alzheimer Report used a multiphase survey design because of perceived efficiencies in 
interviewer time and cost (Alzheimer's Disease International, 2009) . In the standard 
two-stage method for dementia diagnosis, cognitive screening instruments exclude most 
people who do not have dementia. Attrition is generally marked between the first and 
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second phase (The 10/66 Dementia Research Group, 2000b); participants with probable 
dementia are particularly likely to refuse, to move away or to die, leading to informative 
censoring. The problem is compounded when no random sample of screen negatives is 
selected for second phase assessment (Prince, 2003, Prince, 2001, Dunn et al., 1999), as 
was the case with several previous studies from the Latin American region (Llibre 
Rodriguez et al., 2008c, Nitrini et al., 2009).   
  
1.2.3.2  Sample size 
A study of 500 participants could estimate a true prevalence of 6% with a precision of 
+/- 2.1%. Precision increases to +/- 1.2% for a sample size of 1500 and to +/- 0.8% for a 
sample size of 3000 (Alzheimer's Disease International, 2009). In general, sample sizes 
tended to be larger in LMIC studies, but in the particular case of African studies, there 
are difference in the sample size from those who reported low and higher prevalences of 
dementia, for example  in the study from central Nigeria reporting a higher prevalence of 
dementia the sample size was fewer than 300 older people (Ochayi and Thacher, 2006).  
 
1.2.3.3  Diagnostic Criteria 
Erkinjuntti et al (Erkinjuntti et al., 1997) examined the effects of six commonly used 
classification schemes — those of the third edition of the DSM (DSM-III) (American 
Psychiatric Association, 1980), the DSM-III-R (American Psychiatric Association, 
1987), the fourth edition of the DSM (DSM-IV) (American Psychiatric Association, 
1994), the ninth edition of the ICD (World Health Organization, 1978), the ICD-10 
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(World Health Organization, 1992), and CAMDEX (Roth et al., 1986) on the prevalence 
of dementia in the Canadian study of Health and Aging (CSHA), a population-based 
cohort of older people. In this report the proportion with dementia varied from 3.1% 
when ICD-10 criteria were used to 29.1% when the DSM-III criteria were used. The 
factors that most influenced diagnostic differences were long-term memory, executive 
function, and the duration of cognitive symptoms. These findings together with the fact 
that the diagnosis of dementia in illiterate and low educated individuals is a difficult task 
and can erroneously increase the prevalence of dementia in this group, provides the need 
for validation of the criteria used for diagnosing dementia.  
 
Prince (2008) draws our attention to the lack of operational definition as the main 
weakness of DSM-IV. What constitutes memory impairment, or cognitive disturbance? 
What is a significant impairment in functioning? What represents a significant decline in 
functioning? When is the disturbance better accounted for by another axis one disorder? 
(Prince et al, 2008). Reisberg (Barry R, 2006) listed  additional critiques related to 
DSM-IV criteria. Firstly, prominent dementing diseases such as vascular dementia and 
frontotemporal dementia (FTD) are characteristically not marked by impairment of 
memory (Neary D, 1998; O’Brien JT, 2003). Hence, by any criterion, including internal 
consistency as well as external validity, impairment in memory should not be a 
necessary criterion for a dementia diagnosis. Secondly, the omission on dementia 
definition of functional (ie, the ability to carry out activities) or behavioral/emotional 
changes and dementia is characterized by multiple cognitive deficits, functional deficits, 
and, commonly, behavioral/personality changes. For instance, FTD is characterized by 
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prominent behavioral and psychological symptoms during dementia presentation and 
course.  
 
Finally, differences in prevalence across studies might also be due to different 
interpretation and application of common diagnostic criteria. To illustration this point 
the DSM-IV dementia criterion might substantially underestimate the true prevalence of 
dementia, especially in least developed regions, because of difficulties in defining and 
ascertaining decline in intellectual function and its consequences.  
 
1.2.3.4  The scope of dementia diagnosis assessment 
A dementia diagnosis requires the existence of the following criteria: cognitive 
impairment (and decline from a previous level of functioning) in memory and other 
domains of intellectual function, and consequent social or occupational impairment and 
the exclusion of .other causes of cognitive impairment such as functional psychosis, 
depression and delirium. Only 43% of studies from the systematic review carried out for 
the World Alzheimer Report 2009 included multidomain cognitive testing, functional 
assessment, clinical interview and informant interview. Informant interviews were most 
likely to be omitted.  
 
This is an important issue in developing countries where, low levels of education, 




1.2.3.5  The used of standardized procedures that are culturally sensitive and the 
established criteria for the diagnosis of dementia 
In 2003, Prince and co workers develop a methodology (the 10/66 Dementia diagnostic 
algorithm) for culturally and educationally sensitive dementia diagnosis in clinical and 
population-based research (Prince et al., 2003). Later as part of this 
development/validation exercise this dementia algorithm assessments was also validated 
in Cuba against a local clinician DSM-IV diagnosis and the 10/66 dementia diagnosis. 
Agreement with the clinician diagnosis was better for 10/66 dementia (Kappa 0.79) [95 
% CI 0.74-0.83] than for the DSM-IV computerized algorithm (Kappa 0.63) [95 % CI 
0.56-0.69] (Prince et al, 2008). The 10/66 dementia diagnosis defines a broader category 
that may be more sensitive, identifying genuine cases beyond those defined by the 
DSM-IV algorithm. In 2008 we published a paper, which is part of the analysis proposed 
in this essay (Llibre Rodriguez et al, 2008) where we compared the 10/66 diagnosis 
against the DSM-IV. Using the data from the population based studies in Latin America, 
China and India we were able to show that DSM-IV criteria consistently underestimate 
the proportion of people with dementia, compared with 10/66 mild, moderate and severe 







1.2.4   Impact of dementia 
 
Dementia is a disorder with a significant impact upon:  
1.  The person with dementia who experiences marked disability,  severe impairment of  
quality of life and reduced life expectancy  (Alzheimer's Disease International, 2009). 
2.  Family and caregivers who, experience adverse psychological, physical, social, and 
financial consequences, (Brodaty H et al., 2003; Max W et al., 1995) such as higher 
levels of anxiety and depression, ( Rosenthal CJ et al., 1993) deterioration in  physical 
health, (Schulz R et al., 1990) social isolation, (Brodaty and Hadzi-Pavlovic, 1990) and 
direct (e.g., medications) and indirect (e.g., loss of earnings due to relinquishing of paid 
work) financial costs. Caregivers (CG) are crucial for maintaining people affected with 
dementia in the community, decreasing  the likelihood of nursing home admission 
(Brodaty et al., 1993).  
3.  The society, supporting  the cost of providing health and social care and the 
opportunity cost of lost productivity (Alzheimer's Disease International, 2010). 
 
According to the Global Burden of Disease (GBD) estimates for 2004, 68% of the 751 
million years lived with disability (YLD) worldwide are attributable to chronic non 
communicable diseases, and 84% of this burden of chronic-disease disability arises in 
countries with low and middle incomes (Lopez  A.D, 2006). Dementia is one of the 
main contributor to years lived with disability in persons aged ≥60 years, accounting for 
11.2% - surpassing stroke (9.5%), musculoskeletal diseases (8.9%), cardiovascular 




Dementia accounts for 4.1% of total disease burden (Disability Adjusted Life Years) 
among people aged 60 years and over, 11.9 % of years lived with disability and 1.1 % of 
years of life lost. Heart disease (32.9% of years of life lost) and cancer (22.5%) are the 
leading causes of death, nevertheless, these are only 8th and 9th in the rank of disabling 
conditions, however dementia is the second burdensome among the other chronic 
condition. (Alzheimer's Disease International, 2009).  
 
The 10/66 Dementia Research Group (Sousa et al, 2009) analysed the data from 
catchment area sites in seven countries with low and middle incomes and concluded that 
dementia was overwhelmingly and consistently the largest contributor to disability in 
elderly people. Sensory impairment, both of eyesight and hearing, and heart disease 
contributed much less to disability than suggested by the GBD.  
 
According to the World Alzheimer Report 2010 the total estimated worldwide costs of 
dementia are US$604 billion in 2010 (Alzheimer's Disease International, 2010). 
Approximatly 70% of the costs occur in Western Europe and North America. Costs were 
attributed to informal care (unpaid care provided by family and others), direct costs of 
social care (provided by community care professionals, and in residential home settings) 
and the direct costs of medical care (the costs of treating dementia and other conditions 
in primary and secondary care). As the number of persons with dementia doubles every 
20 years, costs can be expected to rise proportionately. 
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This financial burden, combined with the challenge of growing numbers of frail 
dependent older people, will produce dramatic changes in health systems and social care 





















1.3  Why Study Dementia In Cuba 
 
1.3.1  Origin of Cuban population 
 
The history of admixture in Cuba began when Europeans came for the first time to Cuba 
in 1492. When Christopher Columbus arrived to Cuba in 1492, two different Native 
American groups inhabited the island: the Ciboneys, extending across the whole island, 
and the Tainos, mainly occupying the Central and Eastern regions of Cuba (Dacal-
Moure and Rivero de la Calle, 1986).  The Caribbean was most likely populated by 
successive waves of migration originating from the Lower Orinoco Valley in South 
America, taking advantage of the close geographical proximity of the Caribbean islands. 
 
The original Cuban Indian population, which consisted of approximately 100,000 
individuals living in a neolithic society (Steward, 1949, Ortiz and Saco, 1932), was 
completely exterminated soon after the Spanish conquest beginning in 1510. This rapid 
disappearance, which took place in less than 30 years, was the result of epidemics, infant 
mortality, hunger, and collective suicides (Ortiz and Saco, 1932). Moreover, thousands 
of Indians were massacred at the beginning of the conquest in attempts by the Spanish to 
subjugate and later to break their resistance; in 1550 less than 5,000 had survived (Perez 
de la Riva J, 1972). At present roughly 500 Indians live in the most isolated mountains 
at the east region of the Island. The contribution, therefore, of the Indian population to 
the current Cuban gene pool is small so that the actual gene pool consists effectively 
only of African and European genes (Gonzalez et al., 1976, Mendizabal et al., 2008). 
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The importation of slaves from West Africa, the main sources for African slaves (Bight 
of Benin, North of Congo, Angola, the Bight of Biafra and Sierra Leone) and South-
eastern Africa (Mozambique and Madagascar) began since the sixteenth century when 
more than 1,300,000 African slaves arrived to Cuba to work in the sugar plantations 
(Pérez de la Riva, 1979). Slavery was not abolished until 1886. 
 
Immigration continued during the 18th and 19th centuries when Cuban institutions 
intensely promoted Spanish immigration, especially from the Canary Islands, but also 
from Cataluña, Andalucia, and Galicia reflecting fears of a growing African presence 
and the desire to "whiten" the Cuban population (Checa M, 2007). In addition between 
1900 and 1930 close to a million Spaniards arrived from Spain. Also, Asian individuals, 
especially from Bengal and South China, arrived to Cuba to replace the slave labor force 
when slavery became illegal in the nineteenth century. After 1847 around 125,000 
Chinese were reported to have arrived to the island to work in conditions of semi-
slavery.  (Le Riverend, 1967., Checa M, 2007). 
 
Cuba was a Spanish colony for almost four centuries (1511–1898), with an economy 
based on agricultural and the exportation of sugar, coffee and tobacco to Europe and 




1.3.2  Demographics ageing and healths indicators in Cuba 
 
Cuba is a middle income country with health indicators similar to those of developed 
countries and a rapidly ageing population of 11.6 million. By the year 2020 Cuba will be 
the country in Latin America with the highest proportion of older adults (25% aged 60 
years and over) (National Health Statistics, 2009, Ministry of Public Health, 2009). 
Despite its territorial homogeneity, the extend of demographic ageing varies between 
regions, with the proportion of people aged 60 and over varying from 9.6% in the 
municipalities of Moa in the province of Holguín to 25.4% in Plaza in the Havana City. 
The reduction of social and economic inequalities and implementation of better access to 
health service that occurred over the past six decades played a key role in the ageing 
process of the Cuban population. Health care is centrally planned and financed by the 
state. There is comprehensive coverage and free access; 99% of the population is 
registered with the catchment-area-organized family doctor system, with one doctor to 
every 160 households. 
 
The life expectancy at birth is currently 78 years (76 for men and 80 for women),  1.1 
million Cubans (10% of the population) are aged over 65 (Ministry of Public Health, 
2009, National Health Statistics, 2009) and the proportion of those over 60 years is 
16.6% and within this age group 17.4 % are aged 80 years and over (National Health 




Nowdays the infant mortality rate is only 4.8  per 1000 live births, child survival rates 
continue to rise, with under-5 child survival at 99.4%, total fertility rate is low and stable 
(1.70 in 2009—well below the 2.2 required to assure generational replacement)  
According to estimates from the Cuba’s National Statistics Office if current trends 
continue by 2030, 3.4 million Cubans will be 60 years and over, almost one-third  of the 
population, becoming the oldest nation in Latin America and the Caribbean, and, by 
2050, one of the 11 oldest countries in the world.(National Statistics Bureau, 2009; 
National Statistics Bureau , 2006). 
 
However these rapid changes are having a serious effect in the National Health system. 
The prevalence of chronic non-communicable disease in the older population has 
generally increased over time, with consequent impacts on disability and needs for 
health service intervention and long term care. Health services, despite their high 
coverage, do no always meet the needs of older people. This is a challenge that the 
system is facing at the moment and will need to consider also at macro and micro levels 
of the society ( Llibre  J,  2011).  In other words, there is an urgent need to approach to 
the paradox of the increase of life expectancy and the consequences determined by such 
processes as physical deterioration, reduced mobility, chronic illness, weakening or 
dysfunctional family, social networks, and psychological pressures in a particular social 
and economic context of a developing country where the demographic transition is 
taking place. 
 
As with the majority of Latin American and Caribbean countries, chronic diseases are 
Cuba’s number one health problem, causing 90% of all deaths, in order of frequency: 
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heart disease, cancer and cerebrovascular diseases, which together account for nearly 
60% of all deaths.(Organización Panamericana de la Salud, 2008). In relation to risk 
factors, 32% of Cubans 18 years and over smoke, 47% of women and 37.6% of men are 
overweight or obese; 13% of children aged 1-14 years are overweight, 36.5% adults are 
physically inactive (45.1% in women; men 27.5%), 50% of Cuban adults consume 
alcoholic beverages; 7.7% drink heavily or are alcohol-dependent (Reed G, 2008).   
 
1.3.3  Previous epidemiological research in dementia in Cuba 
 
Like other developing countries the importance of studying the epidemiology and the 
impact of dementia in Cuba have grown in the last two decades as a result of concerns 
about the consequences of the rapid ageing process in the area. However, only a few 
studies have been conducted on the prevalence of dementia (Anzola-Perez et al, 1997; 
Llibre et al, 2009; Llibre et al., 1999) and most were conducted in the west and central 
part of the Island.  
 
The Pan American Health Organization (Anzola-Perez et al., 1997)  undertook one of 
the first study of the prevalence of dementia in Latin America. The study consisted of a 
cross-sectional examination of noninstitutionalized individuals 60 years of age and older 
in Buenos Aires (Argentina), Santiago (Chile) and Havana (Cuba). The study had a two-
phase research design: a screening phase for the identification of persons with cognitive 
impairment and a confirmation phase for diagnosis of the presence of dementia.  
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In Cuba, four catchment area of the ‘10 de Octubre’ municipality of the capital city of 
Havana were chosen and 1628 individuals randomly selected systematically in a 
multistage sample of city blocks. The Mini-Mental State Examination (MMSE) (Folstein 
et al., 1975), translated into Spanish was used for the diagnosis of cognitive impairment. 
The study only completed the first phase reporting a prevalence of 16% cognitively 
impaired in Havana, Cuba.  As expected, lower scores of MMSE were seen in 
progressively older age-groups and among those with lower levels of education.  
 
In 1998 I conducted a door to door two phase survey in 779 older people over 60 years 
in the municipality of Marianao and in a representative sample of 340 older from the 
semi rural area of Bauta, in the province of La Habana recruited by means of stratified 
sampling.   The probable diagnosis of dementia syndrome or Alzheimer's disease was 
based on criteria of DSM III R (American Psychiatric Association, 1987) and NINCDS-
ADRDA  criteria (McKhann et al., 1984). We found a dementia prevalence of 8.2% (CI 
95% 6.3% to 10.4%) and that of Alzheimer’s disease and vascular dementia was 5.1% 
and 1.9% respectively (Llibre et al., 1999).  
 
One of the most extensive studies of dementia and Alzheimer’s disease in Cuban and 
Latin American populations is The Disability and Alzheimer’s disease Playa Study 
(EDAP)  (Llibre et al., 2009). It was a two-phase, cross-sectional, door-to-door, study 
conducted in the Playa Municipality of Havana City from September through December, 
2003, to ascertain and characterize the behavior of Alzheimer’s disease and other 
dementias, as well as associated risk factors, in residents aged ≥65 years.  The response 
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rate was a 96.4% (n= 18,351). Folstein Mini Mental State Examination (MMSE) 
(Folstein et al., 1975), Hughes Clinical Dementia Rating (Morris JC, 1993) and a 
structured interview on risk factors were applied. DSM –IV (American Psychiatric 
Association, 1994),  NICDS-ARDRA (McKhann et al., 1984) and NICDS-AIREN 
criteria  (Roman GC et al., 1993) were used to determine dementia diagnosis, as well as 
other criteria for diagnosing Alzheimer’s and other specific forms of dementia.  
Dementia prevalence was 8.2% of adults aged ≥65 year, with a slight predominance in 
males. The most frequent cause of dementia was Alzheimer’s disease, followed by 
mixed dementias. The dementia-associated risk factors were: history of stroke, arterial 
hypertension, depression, head trauma, family history of dementia, low educational level 
and advanced age. 
 
In another Cuban population community study, a door-to-door study was conducted 
from January through March 2004 in Santa Clara Municipality (located in the central 
part of the island), using the same design as the EDAP in Havana. A total of 20,064 
adults aged ≥65 years were surveyed (93.1% response rate), and a dementia prevalence 
of 7.1% (95% CI: 6.7%–7.5%) was reported, with a predominance among women. 
(Llibre Rodríguez J, 2008). Both studies have already drawn attention to the high 
prevalence of dementia in Cuba. 
 
Some studies exist of the prevalence of dementia in older Cubans living in USA. One of 
them, the South Florida Program on Aging and Health (Demirovic J et al., 2003) a cross-
sectional community-based epidemiologic study conducted between 1993–1997, 
examined a population sample of 2,759 elderly (65 years of age and older) African 
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American, Hispanic-Cuban and white non-Hispanic men and women of Dade County, 
Florida, 36 % of the sample,  990 people were white Hispanic born in Cuba (374 men 
and 616 women). The prevalence of cognitive impairment for African American men 
was 17.0% and women 16.7%; Cuban men 9.4% and women 11.4%; and white non-
Hispanic men 9.0% and women 8.5% .There are a few more methodological 
considerations of importance in interpreting results of this study. The cross-sectional 
design has its limits in ascertaining a diagnosis of dementia from a one-time clinical 
evaluation and also the low response rate of participants who were referred to clinical 
evaluation limits validity of the results. 
 
Sevush et al.(Sevush et al., 2000) studied the risk for AD conferred by APOE4 in 145 
patients with AD (80 Cuban American and 65 white non-Hispanic) and 49 control 
subjects (21 Cuban American and 28 white non-Hispanic) living in South Florida and 
reported that the relative risk of AD conferred by the Apo-E e4 allele was somewhat 
greater for Cuban Americans (OR 4.33; range: 1.27–14.79) than for white non-Hispanics 






1.4  Environmental Risk Factors For Dementia 
1.4.1  Cardiovascular risk factors  
 
Epidemiological studies have been suggested, that up to 50% of dementia might be 
preventable (Barnes and Yaffe K, 2011, Jansson E.T, 2005). As age itself is the strongest 
determinant of dementia, an intervention should be regarded as effective if disease onset 
can be postponed. Research suggests that vascular disease predisposes to AD as well as 
to vascular dementia (Hofman et al., 1997) . There is a strong evidence base from 
epidemiological cohort studies suggesting a causal role for cardiovascular risk factors 
(CVD) in the aetiology of dementia and AD (Barnes and Yaffe K, 2011, Hughes T and 
Ganguli M, 2009). Nevertheless, evidence for the associations between vascular 
conditions and dementia suggests stronger risk estimates for midlife compared to late-
life exposures (Kloppenborg RP et al., 2008). 
 
In fact few studies have examined the impact of risk factors with exposures more than a 
few years prior to dementia onset, which does not permit discrimination between a true 
independent risk factor and a prodromal or early symptom. Ideally, a life course 
approach is needed to study risk factors and identify prevention opportunities for 
dementia. 
Life course epidemiology is defined as “the study of long term effects on later health or 
disease risk of physical or social exposures during gestation, childhood, adolescence,  
young adulthood and later adult life” (Kuh D et al., 2003 ). This model takes into 
consideration both the temporal order of risk factors and their interrelationships, 
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including gene-environment and environment-environment interactions. Using this 
approach, epidemiologist must begin to examine risk factors starting not only a few 
years before clinical onset of dementia, even several  decades earlier. 
 
I would like to mention some of the most important vascular risk factors that have been 
described in the context of dementia.  
 
1.4.1.1  Blood Pressure  
In general evidence in support of an association between hypertension and dementia 
suggests that it varies according to the  time that the exposure is measured, where high 
blood pressure in midlife is associated with mild cognitive impairment (Kivipelto M et 
al., 2001) and increased risk of dementia (Whitmer et al, 2005 ; Yamada M et al, 2003) 
(Kivipelto M et al, 2002; Kivipelto M et al, 2005; Launer LJ et al, 2000), but in late life 
is associated with a reduced risk of dementia  (Guo Z et al, 1996; Ruitenberg A et al, 
2001). 
 
As hypertension decreases the vascular integrity of the blood–brain barrier (BBB), 
resulting in protein extravasation into brain tissue.(Kalaria, 2010), this can lead to cell 
damage, a reduction in neuronal or synaptic function, apoptosis, and an increase in Aβ 
accumulation, resulting in cognitive impairment. The association between high blood 
pressure and cerebrovascular disease neuropathology (infarcts, white matter lesions) 
may also contribute. 
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1.4.1.2  Smoking  
In short (Juan, et al, 2004; Luchsinger et al, 2005; Ott et al, 1999) and longer latency 
(Rusanen M et al, 2010.; Tyas et al, 2003; Whitmer et al, 2005) incidence studies, 
smoking increases the risk for Alzheimer's disease. In longitudinal studies without 
tobacco industry-affiliated authors the RR for AD among smokers was 1.45 (1.16–1.80) 
(Cataldo JK et al., 2010). The plausible mechanism including the increasing of the 
generation of free radicals, leading to high oxidative stress, and also inflammatory 
immune system, leading to activation of phagocytes and further oxidative 
damage.(Traber et al., 2000). In addition, smoking may promote cerebrovascular 
disease. 
1.4.1.3  Diabetes Mellitus  
In observational studies Type 2 Diabetes has been shown to be associated with an almost 
two-fold increased risk of AD. (Leibson 1997; Luchsinger et al, 2001; Ott et al, 1999). 
A meta-analysis conducted by Lu and colleagues (Lu FP et  al., 2009) analysed eight 
prospective population based studies reported a RR of 1.47 (1.25–1.73) for all-cause 
dementia combined. 
 
Diabetes and impairment of glucose tolerance lead to the formation of advanced 
glycosylation end products (AGEs), and amyloid plaques and NFTs contain receptors 
for AGEs (RAGEs), which also could be implicated in  the neuronal damage caused by 
Aβ,31.(Reitz et al., 2011)  
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1.4.1.4  Obesity 
 The association of body weight with the risk of AD seems to depend on the age at 
which body weight is measured (Gustafson et al, 2003; Razay & Vreugdenhil, 2005; 
Stewart et al, 2005). Studies that have analysed overweight or obesity in midlife and the 
risk of dementia or AD have overall found an increased risk ( Gustafson D et al, 2003; 
Kivipelto M et al, 2005; Rosengren A et al, 2005; Whitmer RA et al, 2005a; Whitmer 
RA et al, 2007). However there is an inverse association between adiposity in late-life 
and risk for AD (Atti AR et al, 2008; Sturman MT et al, 2008) . 
 
Profenno and colleagues in a  recent meta-analysis that included six studies on obesity 
and AD have reported  a RR 1.59, (95% CI 1.02–2.48) for the association between 
obesity and AD (Profenno LA et al., 2010).  
 
As midlife overweight or obesity increase the risk of hypertension, diabetes, and 
hypercholesterolemia it seems to be the most obvious mechanism by which obesity may 
increase the risk of dementia in late life. An atractive explanation considers the effects of 
adipose tissue, which is metabolically active endocrine tissue that secretes several 
proinflammatory cytokines, hormones, and growth factors that cross the blood-brain 
barrier and affect brain health (Gustafson, 2006b; Rosengren A et al, 2005; Whitmer RA 
et al, 2005b; Whitmer RA et al, 2007)  
1.4.1.5 Cholesterol  
The best explanation for the inconsistent findings on the association on cholesterol level 
and dementia seems to be the timing of cholesterol measurement in relation to the time 
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of dementia onset. Similar to body weight and blood pressure, high total cholesterol in 
midlife may be associated with an increased risk of cognitive impairment (Solomon A et 
al., 2007) and dementia (Panza F et al., 2006;) and AD (Kivipelto et al, 2005; Mielke 
MM  et al, 2005), while high late-life cholesterol may not affect risk  (Reitz C, 2008; 
Tan ZS, 2003) or be associated with lower risk  (Mielke MM et al., 2005). In adittion, 
recent studies have shown that cholesterol levels begin to decline before the onset of 
dementia and that more decline between mid- and late-life is associated with more 
severe cognitive impairment in late-life (Solomon A et al., 2007).  
 
Evidence exists that depletion of membrane cholesterol inhibits secretase cleavage of 
APP, thereby lowering Aβ1–40 and Aβ1–42 accumulation (Pfieger, 2003, Reitz et al., 
2011). Nevertheless  hyperlipidemia may also lead to atherosclerosis, which increases 
the risk of vascular disease, which in turn is associated with a greater risk of AD. The 
role that  cholesterol plays in neuronal plasticity, (Pfieger, 2003) or its antioxidant 
properties (Smith, 1991), or, a general wasting and loss of body mass associated with 
AD (Nourhashémi and Vellas, 2008;) may explain the association with higher late-life 
cholesterol and reduced risk of dementia in late life. The role of cholesterol in the 
pathology of dementia may also plausibly be linked with the role of the APOE genotype 
in lipid metabolism, as I will discuss later. 
 
Recent studies report associations between metabolic syndrome and incident cognitive 
decline (Yaffe et al., 2004), and insulin resistance and impaired executive function 
(Abbatecola et al., 2004).  
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Midlife obesity, midlife hypertension, and diabetes potentially contributed to a 
substantial proportion of cases of dementia and AD worldwide through vascular 
mechanisms, or production of substances that are important in metabolism (adipokines) 
and inflammation (cytokines) by adipose tissue and/or alternatively by  insulin resistance 
and hyperinsulinaemia. 
 
1.4.1.6  Cerebrovascular disease  
 Stroke is the third leading cause of death in the world (Strong K et al., 2007 , Feigin VL 
et al., 2009) with highest mortality in low- and middle-income countries. In a recent 
meta-analysis from 22 hospital-based and eight population-based cohorts Pendlebury 
and Rothwell concluded that 7.4% of patients with first-ever stroke developed poststroke 
dementia. (Pendlebury and Rothwell, 2009).  
 
As stroke is strongly associated with cardiovascular risk factors and life style, several 
mechanisms could be explaining the association of stroke and dementia. First, stroke 
may produce a direct damage of brain regions that are related to cognitive function, such 
as the thalamus and the thalamocortical projections. In addition, stroke might increase 
Aβ deposition, which in turn can lead to cognitive decline. Finally, the onset of stroke 
may induce inflammatory responses that impair memory function. 
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1.4.2  Nutritional factors 
In LMIC dietary deficiencies are common and strongly related to poverty. Deficiencies 
of folate and vitamin B12 and their consequences; anaemia, neuropathy, 
hyperhomocysteinaemia (Selhub et al., 1993), increased the risk of stroke and ischaemic 
heart disease (Robinson et al, 1998). Vitamin B12 deficiency is strikingly prevalent (> 
40%) across Latin America (Allen, 2004; Arnaud et al, 2001; Garcia-Casal et al, 2005), 
linked to gastrointestinal infections and diets deficient in meat and dairy produce (Allen, 
2004).  
Folate deficiency is endemic in those living in poverty (Garcia-Casal et al., 2005), and 
after economic crisis (Arnaud et al., 2001). Diets deficient in legumes may also have 
contributed. Micronutrient deficiency is probably more prevalent in the older but there 
are few data on this age group (Harding, 2001). Iodine deficiency has also been a major 
public health problem in most Latin American countries (Pretell et al., 2004). Iodized 
salt is now generally available but iodine content is poorly regulated (Pretell et al., 
2004). A prevalence of sub-clinical hypothyroidism of 16.1% was reported among post-













1. 5  Genetics of Dementia  
 
1.5.1  The use of population admixture to understand the aetiology of chronic 
conditions  
 
Having examined the role of the environmental factors, it is now necessary to consider 
the influence of admixture in epidemiological population studies. Genetics studies in 
admixtures population offer a unique opportunity to study the contributions of genes and 
environmental risk factors and their possible interaction to explain diseases rates in 
populations (Hendrie et al., 2004). 
 
While a variety of definitions of the term ancestry has been suggested, this thesis  will 
use the definition  of biogeography ancestry, in which a person’s origin is associated 
with the geographic location (s) of presumed ancestors inferred by comparison with 
contemporary population living in these locations (Royal C et al., 2010) .  
 
It is also difficult to ignore that societal, ethical, moral and even political perceptions 
about ancestry guide that ancestry is seen or defined from personal or group 
interpretation of such identity or actual knowledge of genealogy. 
 
 The age-specific prevalence (Hendrie et al., 1995b) and incidence (Hendrie et al., 2001) 
of dementia in Nigeria are both very low. A further notable finding is the apparent lack 
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of an association between APOE genotype and dementia (Gureje et al., 2006), confirmed 
in Kenya (Kalaria et al., 1997). Those with African ancestry tend to have a higher 
prevalence of APOE e4, but African Americans, other populations of west African 
ancestry, and Hispanics, all show weak and inconsistent associations with AD (Farrer et 
al., 1997). There is a robust association between APOE genotype and AD in Europeans 
(Farrer et al., 1997) and south Asians (Ganguli et al., 2000).  
 
Stewart (1999)  reported that age and sex adjusted stroke incidence was higher among 
black (African Caribbean) residents, with a RR of 2.2 (1.8-2.8) using data from South 
London Stroke Register (Stewart et al., 1999). Findings concur with North Manhattan 
population-based incidence study: 2.4 times increase in stroke incidence in blacks 
compared to white people. In this community-based project, both relative risks and 
population attributable fractions varied across white, black and Hispanic ethnic groups 
for the major stroke risk factors (Sacco  et al, 2001). In the USA the incidence of stroke 
was higher among African Americans and Hispanics (Sacco  et al, 1998; White et al, 
2005). These differences may be partly explained by elevated blood pressure levels 
(Chaturvedi, 2003). Conversely, African Caribbean migrants in the UK have a low risk 
of heart disease despite a high prevalence of metabolic syndrome, attributed to a low 
prevalence of smoking and low triglyceride levels (Chaturvedi, 2003).  
 
Tang et al. (2001) comparing the incidence  rates of newly diagnosed AD over a 7-year 
period from 1992 to 1999 in a community-based study of African-American, Caribbean 
Hispanic, and white older individuals residing in the communities in northern 
Manhattan, New York City (Tang M et al., 2001). In this study the incidence rate for AD 
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was significantly higher among African-American and Caribbean Hispanic older 
individuals compared white individuals at similar ages. The presence of clinically 
apparent cardiovascular or cerebrovascular disease did not contribute to the increased 
risk of disease. The majority (84%) of those identified as Hispanic were of Caribbean 
origin and 54% were from the Dominican Republic. The remaining individuals 
described as Hispanic were from Puerto Rico, Cuba, Mexico, and Central America.  
 
Measurement of individual admixture proportions (the proportions of the individual’s 
genome that are of African, European, and Native American ancestry) is now feasible, 
and studying the relationship of disease risk to admixture proportions is the most direct 
way to distinguish genetic from environmental explanations for ethnic variation in 
disease risk. 
 
Those classified in the US as ‘Hispanic’ originate from diverse mixed ancestry 
Caribbean, Central and South American populations, resulting from two-way admixture 
between Native American and European populations or three-way admixture among 
Native American, European, and West African populations (Mao  et al, 2007). However, 
patterns of admixture vary greatly among these populations. The catch-all ‘Hispanic’ 
category is therefore problematic, providing some information about linguistic and 
cultural heritage but very little about ancestry. In much of continental Latin America, 
two-way admixture dominates with little evidence of African ancestry (Wang et al, 
2008). Cuba is quite different. the indigenous population was reputedly extinct by 1700, 
and Native American admixture is minimal (Cintado et al., 2009). Importation of slaves 
from West Africa was current by 1600 and not abolished until 1886. In the 1832 census, 
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50% of the population was reported to be mulatto (mixed race) or black. Recent Cuban 
studies concur in identifying average proportions of African admixture in those who 
classify themselves as white, mixed race and black as, respectively, about 5%, 35% and 
60% (Cintado  et al, 2009). European admixture among African-Americans is much 
lower, an average of between 12% and 20% in different US cities (Parra et al., 1998) and 
very few African-Americans have as much as 50% European ancestry (McKeigue et al., 
2000). In the former British Caribbean, average European admixture levels may be even 
lower; just 7% in Jamaica (Parra et al., 1998). 
 
The high levels of African and European admixture in Cuba can be used to good effect. 
Studying the relationship of dementia risk to individual admixture within admixed 
populations is the most direct way to distinguish genetic from environmental 
explanations for ethnic differences in disease risk (McKeigue, 2005), and, by extension, 
for distinguishing gene by environment versus gene by gene explanations for ethnic 
differences in the effects of genes on disease outcomes. Furthermore, such relationships 
will confound studies of other genetic risk factors - “hidden population stratification”. 
Measurement of the confounder (individual admixture) allows us to control for 







1.5.2  APOE and other genetic risk factors for dementia 
 
The overall lifetime risk for AD in first-degree relatives of AD probands is about 38% 
by age 85 years (George-Hyslop., 2008). It has been suggested that genetic factors 
account for about 40% of the population risk for AD. In the majority of cases these 
genetic factors are manifest by the presence of multiple family members affected with 
AD (‘‘multiplex pedigrees’’) but without a clear cut mendelian pattern of inheritance. In 
his review about genetics of dementia George–Hyslop (2008) consider such cases of 
familial aggregated AD (FAD) likely reflect a complex mode of transmission such as: 
(1) one or more common independent, but incompletely penetrant, single, autosomal 
gene defects; (2) a multigenic trait; or (3) the effects of interaction between genetic and 
environmental factors (George-Hyslop., 2008).  
 
The studies of molecular genetic in families with familiar early-onset of AD (EOFAD) 
have lead  the discovery of three different genetic loci associated with a hereditary 
susceptibility to the autosomal dominant AD, namely APP (Precursor of the β Amyloid 
protein)  itself  codified by a gene located in chromosome 21, which are responsible for 
2% of the total of cases of FAD and approximately 5-20% of early onset of the familiar 
Alzheimer disease (EOFAD) (Tanzi RE, 1996), and the presenilin genes (PSN1 and 
PSN2) genes located in the chromosomes 14 and 1 respectively, which encode proteins 
involved in APP breakdown and βA generation..  The mutations on PSN1 represents 
around 30-50% of the cases of FAD (Kalaria RN, 1996).  Nowdays around 182 different 
mutations have been discovered related to the gene of the presenilin 1 (Alzheimer 
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Disease & Frontotemporal Dementia Mutation Database, 2008). Only 14 AD- linked 
mutations have been identified in PSEN2,  causing around 2% of the total of FAD, and 
occurring at a lower frequency than those found in gene PS-1 (Querfurth H.W, 2010).   
 
In late onset sporadic as well as familial cases, which constitutes at least 95% of cases, 
the apolipoprotein E (APOE) gene on chromosome 19 has been identified as a major 
risk factor (Strittmatter et al., 1993a). In addition in 2009 Genome Wide Association 
Studies (GWAS), using a case-control methodology, identified three new genes related 
to the Alzheimer’s disease of delayed onset, identified like - CLU (clusterin, also known 
like apolipoprotein J), PICALM (fosfatidil inositol together with the protein clathrin), 
and CR1 (component of the complement [3b/4b] of receiver 1). (Harold D, 2009; 
Lambert JC, 2009). 
 
The human APOE protein is a 299 amino acid glycoprotein with variable levels of 
posttranslational sialylation through O-linked glycosylation at the threonine 194 residue. 
Apolipoprotein E (APOE) is a cholesterol transport protein which also takes part in the 
repair of injured nerves (Mahley, 1988). APOE is expressed in several organs, with the 
highest expression in the liver, followed by the brain. Nonneuronal cells, mainly 
astrocytes and to some extent microglia, are the major cell types that express APOE in 
the brain (Fagan, 1999; Pitas, 1987). In plasma, APOE proteins are present on 
lipoproteins in association with other apolipoproteins, whereas in the brain APOE and 
two other apolipoproteins, apoJ and apoA-1, are predominantly present on distinct high-
density-like lipoprotein particles (Borgaonkar DS, 1993). APOE is polymorphic and 
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exists as three major isoforms referred to as apolipoprotein E2, E3 and E4. These are 
products of three alleles (e2, e3 and e4) at a single gene locus on chromosome 19. 
 
The gene of APOE in humans contain three common polymorphisms: e2 (cisteine in  
codon 112 and codon 158), e3 (cisteine in codon 112  and arginine in codon 158), and e4 
(arginina in  codon 112 and 158). (Borgaonkar DS, 1993). The expression of any two of 
these three co dominant alleles results in three homozygous phenotypes (E2/E2, E3/E3, 
E4/E4) and three heterozygous phenotypes (E2/E3, E2/ E4, E3/E4) (Kim, 2009a).  
 
The e4 allele of the apolipoprotein-E gene was first reported to be associated with an 
increased risk of AD twenty years ago (Saunders  et al, 1993; Strittmatter  et al, 1993). 
Since then, this has been the most consistently replicated genetic risk factor (Bertram et 
al., 2007). The presence of APOE e4 allele of the apolipoprotein-E gene (APOE e4) has 
been consistently associated with an increased risk of Alzheimer disease, but not all 
persons carrying the homozygous develop Alzheimer disease (AD) even when followed 
up to age 80 years and beyond (Borgaonkar DS, 1993; Mayeux R, 1993; Payami H, 
1994a; Saunders  et al, 1993; Strittmatter  et al, 1993).  
 
It has been proposed that the differential effects of APOE isoforms on βA aggregation 
and clearance play the major role in AD pathogenesis (Strittmatter et al., 1993b). Other 
potential mechanisms have not been ruled out, including the differential modulation of 
neurotoxicity and tau phosphorylation by APOE isoforms (Bertram L, 2010; Strittmatter  
et al, 1994) as well as its role in synaptic plasticity and neuroinflammation, or even the 
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possibility that the APOE e4 allele alters the risk of dementia via changes in lipids 
metabolism and vascular disease (Poirier J, 1993; Roses AD, 1994).  
 
This association seems to be affected by ethnicity, age, sex, medical history, and 
geographical location. Most of the observations report this association is less consistent 
for individuals > 80 years of age (Poirier J, 1993; Roses AD, 1994), may be stronger in 
women than in men (Payami H, 1994), and also differs between ethnic groups (Hendrie 
et al., 1995a). To illustrate this point APOE ε4 allele does not increase risk in sub-
Saharan Africans and is only weakly associated with AD in Caribbean Hispanics and 
African Caribbean people of Jamaican origin (Farrer et al, 1997; Romas SN, 2002; 
Stewart   et al, 2001). On the other hand, frequencies of the APOE e4 allele are reported 
to be relatively increased in healthy Africans and some non-Africans: for example, 14–
41% in indigenous people from Central African Republic, East Africa, Southern Africa, 
Malaysia, Australia, and Papua New Guinea, (Corbo RM, 1999; Kalaria et al, 1997; 
Sayi JG, 1997) compared with 8–12% in Caucasians and Japanese (Farrer et al., 1997).   
 
Comparative analysis showed that the APOE e4 allele was a risk factor for AD in 
African Americans, but not in Yoruba Nigerians (Gureje et al, 2006; Murrell JR, 2006) 
or in population samples from the Vihiga and Nyeri districts of Kenya (Kalaria et al., 
1997) or Kingston, Jamaica (Morgan OS, 1998).  
 
Early-onset familial AD in developed countries has not been reported to be modified by 
the APOE e4 allele. However  the APOE e4 allele was strongly associated with late-
onset familial AD among Caribbean Hispanics from the Dominican Republic and Puerto 
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Rico (Romas SN, 2002) but not in Guamanians with dementia. (Galasko D, 2007; 
Osuntokun  et al, 1995). 
 
Two longitudinal studies in the US also suggest no association between APOE e4 and 
incident AD among African Americans, while the incidence of AD seemed to be higher 
for African Americans in every APOE genotype (Evans et al, 2003; Sevush et al, 2000; 
Tang et al, 1998). In a case-control study in Florida the association between APOE e4 
and AD was as strong for Cuban Americans as for white non-Hispanics (Sevush et al., 
2000) in contrast to the absence of an observed association among Hispanics in North 
Manhattan (Tang  et al, 1998).   
 
In the only detailed population-based studies from sub-Saharan Africa, the prevalence 
and incidence of Alzheimer’s Disease (AD) and dementia in Nigeria are very low 
(Hendrie et al, 2001; Hendrie et al, 1995). However, among African-Americans, 
prevalence and incidence seem to similar (Hendrie et al, 2001; Hendrie et al, 1995), or 
even higher (Evans et al, 2003; Tang et al, 1998) than among white non-Hispanic 
Americans. Also, the prevalences of dementia in Caribbean and South American 
populations, including those where some degree of African ancestry can be quite 
common, are among the highest in the world (Llibre Rodriguez et al, 2008; Molero et 
al., 2007; Nitrini  et al, 2009; Scazufca  et al, 2008).  
 
To summarise this section, the association between APOE and dementia has been 
observed in many different populations (Kalaria et al, 2008). So far, however, African-
Americans, other populations of west African ancestry, and Hispanics show relatively 
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weak and inconsistent associations with AD, despite those with African ancestry tending 
to have a higher prevalence of the risk-conferring APOE e4 allele (Kalaria et al, 2008).  
 
The weaker APOE4 association with dementia in populations with African ancestry, 
might be explain by genetics mechanisms First, there is a variation in APOE e4 alleles 
from population to population. These alleles may differ by nucleotide changes, which 
may affect gene function, or by nucleotide changes in the noncoding regions, which may 
affect gene expression (Fullerton et al., 2000, Hendrie et al., 2004). On the other hand, 
changes in nucleotide sequence in other genes that interact with APOE e4 (for example, 
apolipoprotein receptors) may affect function and, thus, affect the effect of APOE e4 as 
a risk factor for AD.  
 
An alternative explanation could be that the lack of APOE e4 effect in people with high 
grades of admixtures is related to gene–environment interaction. The differences in 
cholesterol levels between sites and the role that APOE plays in cholesterol processing 
make an APOE–cholesterol interaction, resulting in a differential AD risk, an obvious 
possibility. Two previous  studies have reported a significant interaction between APOE 
and cholesterol in determining risk for AD suggested that cholesterol mediates some of 
the effects of  APOE e4  on AD  (Notkola et al., 1998, Evans et al., 2000)  (see section 
1.5.3). 
 
Epidemiologic studies on dementia in admixed population could provide us the 
oportunity to assess the role of genetic diversity and environmental factors in 
determining the prevalence and incidence of the disease in different populations. So far, 
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however, there has been little discussion about dementia in admixed populations living 
in Latin-Americans and Caribbean countries are still scarce in the continent.     
 
1.5.3  APOE, lipids and dementia risk  
 
Recent developments in the fields of epidemiological, clinical and pathological studies 
of sporadic Alzheimer’s disease (AD) have led to a renewed interest in the relationships 
between a deterioration of brain lipid homeostasis and vascular changes in the 
pathophysiology of this disease. These associations include the epidemiological 
evidence that most risk factors for Alzheimer’s disease are also related to vascular 
disease and premature death such as high midlife plasma cholesterol, diabetes, stroke, 
obesity and hypertension to dementia. Furthermore, the recognition of cholesterol 
transporters apolipoprotein E (APOE), APOC1 and APOJ as major genetic risk factors 
for sporadic AD support to the hypothesis  that  cholesterol has an important  role  in AD  
and is, therefore, a potential therapeutic target for disease prevention.  
 
Cholesterol is a vital component of the central nervous system (CNS) and is essential for 
axonal growth, and synaptic formation and remodeling, processes that are crucial for 
learning, formation of memories and neuronal repair (Dietschy & Turley, 2004; Leduc et 
al., 2010). Lipids rafts – membrane microdomains rich in lipids and cholesterol – 
modulate APP processing. Consequently increased intracellular cholesterol levels, which 
favour lipid raft formation, negatively regulate α-secretase activity (Xiu et al., 2006, 
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Leduc et al., 2010) but stimulate both β-secretase, and γ-secretase activities, resulting in 
an increase in βA production.  
 
However, epidemiological studies of serum cholesterol levels and risk of AD have been 
inconsistent. Some studies, including the Framingham study (Kivipelto et al, 2001; 
Notkola IL, 1998; Tan ZS, 2003) have suggested that elevation of serum total 
cholesterol, particularly in mid-life, increases risk of late cognitive impairment or 
dementia, but not others (Li, 2005; Slooter AJ, 1999; Wieringa GE, 1997) (see section 
1.3.1.5). The Ibadan Indianapolis group has previously reported in 2000 a significant 
interaction between APOE e4, cholesterol, and AD in African Americans in whom 
increasing cholesterol levels increased the risk of AD in individuals without APOE e4 
but not in individuals with the APOE e4 allele (Osuntokun et al., 1995). Prince et al. 
reported that the association between APOE and dementia does not seem to be mediated 
by cholesterol and others vascular factors (Prince M, 2000).  
 
In 2006 Hall et al published a paper (Hall KS, 2006) in which they described a 
significant interaction between cholesterol, APOE e4, and the risk of Alzheimer disease 
(AD) in the Yoruba, a population that has lower cholesterol levels and lower incidence 
rates of AD compared to African Americans. Similar to cholesterol, they did observe an 
interaction between triglycerides and APOE genotype. In others words at low levels of 
triglycerides, possession of a e4 allele was associated with an increased risk of AD. In 
this study the sample size was too small (29 AD cases) to investigate the relationship of 
lipids, APOE and dementia. Another difficulty in the interpretation of the findings arose 
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from the cross-sectional design of the study, with the clear possibility that lipid levels 
may have been influenced by the onset of dementia. 
  
 64 
1.6  Aims And Hypothesis  
 
1.6.1  Aims 
 
The main aims of this study was to describe the prevalence, incidence, correlates and 
impact of dementia among older Cubans; to assess the effects of reported ethnicity, 
admixture and Apolipoprotein E genotype on dementia prevalence and to estimate the 




The specific objects of the present study were: 
 
1) Estimate the prevalence of dementia, incidence, correlates and impact of dementia in 
populations of older Cubans with high levels of African/ European admixture.  
 
2) Assess the effects of ethnicity, admixture and Apolipoprotein E genotype on dementia 
prevalence. 
      a) Estimate the association between ethnic groups (defined by the interviewer) and 
          individual admixture 
      b) Assess the association of each (ethnic group and individual admixture) 
          with APOE genotype. 
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      c) Test the following hypotheses:     
          i) the effect of APOE genotype on dementia is modified by ethno-racial group, 
             and/ or admixture, with weaker associations among those with ‘mixed’ and  
            ‘black’ ethno-racial identity and with higher proportions of African admixture 
         ii) the prevalence of dementia is lower among those with ‘mixed’ and ‘black’ 
             ethno-racial identity, and is inversely linearly related to African admixture. 
3) Assess the effect of cardiovascular risk factors on dementia incidence, testing the 
hypothesis that: 
     i) Smoking, hypertension, diabetes, stroke, heavy alcohol use and hyperlidaemia are 
        associated with dementia incidence, 
    ii) the associations described in (i) are modified by APOE genotype, being stronger in    















CHAPTER 2  METHODS 
 
2.1  Pilot Study  
 
 
Before the cross-sectional study a preparatory study was conducted in 2003 in Havana to 
organize and plan the cross sectional survey and future follow-up 
(i) we checked  the registers of the family doctor service in a  comprehensive catchment 
area to draw a representative sample of those aged 65 and over,  
(ii) we identified the optimum procedures for carrying out participant and caregiver 
interviews, and  
(iii) assessed the feasibility of obtaining prospective data on a variety of health-related 
exposures from six-monthly health checks carried out on all over 60 year old people 
assisted by their family doctors. Three family doctor areas (each covering a population 
of around 500 of whom around 40-50 should be aged 65+) were door-knocked to check 
the accuracy of the doctors’ registers. This pilot showed excellent response rates both for 
interview and phlebotomy (98 %).Twenty people (and for each a suitable informant) 
were invited to undergo the full one stage dementia diagnosis interview. We also tested 
interviewers working in pairs; one to interview the participant and the other the 
informant; and assessed preferences for interviews in participants’ homes, family 
doctors’ surgeries and local polyclinics.  
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2.2  General Study Design, Setting and Sample 
 
 
We conducted a  one phase cross-sectional catchment area survey of all residents aged 
65 years and over living in five urban districts in Havana, Cuba (Lisa, Luyano, 
Marianao, Playa, and Plaza); and one catchment area in Matanzas (Milanes), a port city 
120 kilometers along the coast  from Havana. In each municipality, polyclinics were 
selected purposively to ensure adequate numbers of older persons, an even distribution 
of admixture, and a history of health profesionals previous participation in research.  
 
A total of eight policlinics in Havana and one Policlinic from Matanzas were included. 
A door-knocking strategy was used to identify all possible eligible participants, and to 
allocate a unique identifier (HOUSEID) to each household. Each catchment area used in 
the door knocking strategy was delimited by including all household which were at a 
maximum distance of 500 meters from the Policlinics.  For each household the gender 
and ages of all permanent residents were recorded with the name of those possibly or 
definitely aged 65 years or over on the census date. Age was formally ascertained and 
confirmed when the research workers returned to carry out the interview. Household and 
participants details were stored in secure databases which include names, addresses, and 
identifier (ID) number, and contact details for neighbours, key informant and friends to 
be used in the follow-up phase. For each participant an informant was identified to 
provide further information. The informant was chosen on the criteria either that they 
knew the participant best or had spent the longest period of time with the older person. 
Although in most cases they were co-resident of the older person and usually a family 
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member, in some cases a non co-resident family member, or friend or neighbour was 
better qualified. 
 
A total sample of 3015 eligible participants were identified from which 2944 accepted 
and were interviewed (response proportion = 97.6%), 2043 in Havana (97.3%) and 901 
in Matanzas (98.4%). Causes for non-response included refusal to participate in the 
study or failure to contact the person after five home visits. 
 
An incidence phase was conducted from 2008 to 2010 with a median follow up of 4.5 
years after the baseline interviews. From a total baseline sample of 2813, 608 (21.6%) 
were deceased, 178 could not be traced or contacted and 20 (0.7%) refused to 
participate. We could reinterview 2007 (71.3%). The cohort for the analyses of dementia 
incidence was defined as all those who were free of any dementia (either DSM-IV or 
10/66 dementia) at baseline (n=2517). The  proportions of the dementia-free cohort 
baseline who were found to be deceased was 17.8% (449), who refused, who could not 
be traced or contacted 176 (7.0%) , and who were successfully re interviewed, 1 892 
(75.2%)  (See Figure 1). 
 
In order to explore the effects of ethno-racial identity and genetic admixture on APOE 
genotype, its association with dementia, and dementia prevalence a nested case-control 
study design was used with 235 dementia cases and a randomly selected sample of 349 
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Clinical assessment  




Deceased: 608 (21.6%)  
(Verbal autopsy) 
Refused 20 (0.7%) 
Untraceable 178 (6, 3%) 
Re interviewed   
n= 1892 (75.2%) 
Deceased: 449 (17. 8%) 
Refused or Untraceable 176  
(6, 3%) 
Incident  cases         
       n= 171 
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2.3  Preparation and Training 
 
 
A total of 10 interviewers participated in a one- week planning meeting in order to 
standardize operating procedures according to the field manual as well as to train 
interviewers in the study protocol. All assessments were translated into Ibero-American 
Spanish with country-specific adaptations, where necessary.  
 
I did the most of the quality control for the study and checked all questionnaires for 
completeness and coherence before data entry, supervised each interviewer in the field, 
conducting random checks every three weeks thereafter. The first and second 
supervisors (CPF and MP) visited the areas at least twice during the fieldwork phase. 
 
2.4  Procedures 
 
 
A door knocking of all eligible households were conducted to identify those age 65 and 
above. At this moment the full interview was scheduled for a convenient time for the 
participant and informant. The interviews were carried out in the participant’s own 
homes. 
 
The interviews were carried out by polyclinic doctors (five psychiatrists, two 
geriatricians and three general medical specialists) who worked in the Policlinics of the 
areas selected. . All interviewers had one week training to get the necessary skills in the 
general protocols and also in the Geriatric Mental State clinical assessment as well as the 
neurological/ physical examination.  
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All participants received a full assessment lasting approximately 2-3 hours, which 
included interviewing of participants, physical examination and phlebotomy, and an 
informant interview. Data were collected directly onto laptop computers using 
computerized Spanish questionnaires driven by Epidata software, including conditional 
skips and interactive checking. 
 
Ethical issues – All participants were recruited on the basis of informed signed consent. 
Persons suffering from dementia who had no capacity for consent were recruited taking 
into consideration a relative’s signed agreement. The information sheet and consent 
form, were read to illiterate people. They were also asked to express their consent 
verbally, which was be witnessed, but they were not asked to sign a form they could not 
read. Participants in the study were asked to offer a gift of genetic material (blood) to the 
local research institutions Medical University Havana) who acted as custodians and 
testified that the blood drawn from participants had a scientific purpose and not 
commercial. The Medical University of Havana, the National Centre of Medical 
Genetics (Cuba), and the Institute of Psychiatry institutional ethical committees 







2.5  Measurements 
 
 
The 10/66 population-based study interview generates information regarding dementia 
diagnosis and subtypes, mental disorders, physical health, anthropometry, demographics, 
an extensive non-communicable disease and dementia risk factor questionnaire, 
disability and functioning, health service utilization, care arrangements and caregiver 
strain. I will describe in details the measures which are relevant for this thesis. Further 
details of the protocol for the 10/66 Dementia Research Group programme are provided 
in an open-access online journal publication (Prince et al., 2007).   
 
2.5.1  Outcome - The diagnosis of dementia 
 
 
Dementia was diagnosed according to our own cross-culturally validated 10/66 dementia 
diagnosis algorithm (Prince et al., 2003) and according to DSM-IV criteria (American 
Psychiatric Association, 1994). A concurrent validation conducted in the course of the 
Cuban population-based study showed that DSM-IV dementia diagnosis was specific 
but less sensitive to mild to moderate dementia; the 10/66 Dementia diagnosis 
corresponded better to local clinician diagnosis and was more sensitive to these milder 
cases (Prince et al., 2008). The outcome for most of the analyses in this thesis is ‘any 
dementia diagnosis’ comprising all those meeting either or both of these criteria. 
Diagnoses were established following.  
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(i) A structured clinical interview, the Geriatric Mental State (GMS) version B3, which 
applies a computer algorithm (AGECAT – Automated Geriatric Examination for 
Computer Assisted Taxonomy) (Copeland et al., 1986), identifying organicity (probable 
dementia), depression, anxiety and psychosis and a single hierarchically determined 
diagnosis.  
 
(ii) A cognitive test battery comprising a) the Community Screening Instrument for 
Dementia (CSI’D’) COGSCORE  (Hall et al., 1993) (incorporating the CERAD animal 
naming verbal fluency task), and b) the modified CERAD 10 word list learning task with 
delayed recall (Ganguli et al., 1996) . The CSI ‘D’ consists of 20 minutes 32 item 
cognitive test administered to the participant and a 15 minute 26 item questionnaire 
administered to the informant, enquiring after the participant’s daily functioning and 
general health (see iii below).  The cognitive score (COGSCORE), is a summary score 
from the participant cognitive test with different weighting applied to different items.  
 
(iii) An informant interview, the CSI’D’ RELSCORE (Hall et al., 1993) for evidence of 
cognitive and functional decline, with additional information on dementia onset and 
course obtained from the modified (Dementia Diagnosis and Subtype) History and 
Aetiology Schedule (Dewey and Copeland, 2001). The discriminant function score 
(DFSCORE) combined the participant score (COGSCORE) and the informant score 
(RELSCORE) into a single score. 
 
(iv) The adapted CERAD ten world list learning task was developed in the Indo-US 
Ballabgarth dementia study (Ganguli et al., 1996). Six English words were taken from 
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the original CERAD battery list: butter, arm, letter, queen, ticket, and grass. The 
remaining four (pole, shore, cabin, and engine) were replaced with corner, stone, back, 
and stick, which were deemed more culturally appropriate (Ganguli et al., 1996). In the 
learning phase, the list is read out to the participant, who is then asked to recall the 
words that they remember. This process is repeated three times, giving a total learning 
score out of 30. Five minutes later the participant is again asked to recall the 10 words, 
giving a delayed recall score out of 10; additional information for DSM-IV dementia 
diagnosis and Clinical Dementia Rating (CDR) (Morris, 1993) is obtained from; 
 
(v) an extended informant interview, the modified (Dementia Diagnosis and Subtype) 
History and Aetiology Schedule  (Dewey and Copeland, 2001) providing information on 
dementia onset and course.  
 
vi) The NEUROEX, a structured neurological assessment of lateralising signs, 
parkinsonism, ataxia, apraxia and primitive 'release' reflexes (Broe et al., 1998, Broe et 
al., 1976) . 
 
vii)  Behavioural and Psychological Symptoms of Dementia (BPSD) assessed using an 
informant questionnaire, the Neuropsychiatric Inventory (NPI-Q) (Kaufer et al., 2000). 
 
Participants were allocated to the category of 10/66 dementia when they scored above a 
cutpoint of predicted probability of dementia estimated from the logistic regression 
equation developed and validated cross-culturally in the 10/66 international pilot study, 
using coefficients from the GMS, CSI-D informant and cognitive test interviews and the 
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modified CERAD 10 word list learning tasks (Prince et al., 2003). DSM-IV dementia is 
a criterion-based diagnosis requiring impairment in memory and at least one other 
domain of cognitive function, linked to social or occupational impairment, not better 
accounted for by delirium or other mental disorder. DSM-IV dementia criteria were 
applied directly using a computerized algorithm; full details are available in an open 
access publication (Prince et al., 2008). The second approach involved the direct 
application of  research diagnostic criteria for DSM-IV and for the following dementia 
subtype diagnoses; NINCDS-ADRDA Alzheimer’s disease criteria  (McKhann et al., 
1984) , NINDS-AIREN vascular dementia criteria (Roman et al., 1993), and Lewy Body 
Dementia (McKeith IG et al., 1996). 
 
2.5.2  Main exposures 
 
2.5.2.1 Sociodemographic variables  
a)  Age was formally determined on revisit for interview, using the stated age of the 
participant, the age recorded on any official documentation, the age according to an 
informant, and, in the event of unresolved discrepancies, the age according to an event 
calendar.  
b)  Level of education (none/ some, but did not complete primary/ completed primary/ 
completed secondary/ completed tertiary); 
c)   Ethno-racial identity: Participants were classified according to self-report (or that of 
a family member) on family ancestry, coupled with the interviewer’s perception of 
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ethno-racial identity, using well-established groups used in the Cuban census – ‘Blanco - 
white’, ‘Mestizo - mixed’ and ‘Negro - black’. 
 
d) Sex, marital status, household living arrangements and availability of children for 
support, literacy, religion, affiliation and practice, community social activity, social 
support, social network, were also recorded. Similar demographic information was 
obtained on informants.  
 
e) Migration status – Residence at birth. 
 
2.5.2.2  Socioeconomic variables  
Best occupation (self and spouse), current occupational status. Sources and amount of 
income; household assets (car, television, refrigerator, telephone, mains water supply, 
plumbed inside toilet), an assets index was calculated (number of assets in the household 
categorised: 0–2; 3–5 and 6 or more assets); food insecurity (“do you ever go hungry 
because there is not enough food to eat?”) are gathered with a standardised 
questionnaire. 
 
2.5.2. 3  Health conditions 
 
a) Physical health is assessed by a standardized questionnaire containing 
information on self-reported diagnoses (diabetes, stroke, heart disease, high 
blood pressure) and eleven commonly occurring impairments (Duke University 
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Centre for the Study of and Human, 1978). Self-reported of chronic non-
communicable diseases was based on a standardized questionnaire that included 
questions such as, “Have you ever been told by a doctor that you had a stroke / 
heart attack / angina / diabetes?” and a description of episodes. 
b) Self-reported stroke was ascertained with the question “have you ever had a 
stroke that needed medical attention?” If the answer was “yes” they were asked 
“what happened?” The answer was coded positive only if the participant or 
informant gave a clear history of sudden onset of unilateral paralysis and/or loss 
of speech and/or blindness lasting for at least 24 hours; thus, previous transient 
ischaemic attacks were excluded. If the history was supportive of stroke they 
were asked “who diagnosed this stroke?” (no one /primary healthcare worker/ 
specialist). Stroke was coded only if a clinician had made the diagnosis. 
c) Hypertension: Two methods were used for diagnosis of hypertension: 
participant’s self-report (“Have you ever been told that you had high blood 
pressure? When you were first told? Were you started on treatment? Are you still 
on treatment?”) and/or blood pressure readings that met World Health 
Organization/ International Society of Hypertension (WHO-ISH) cut-off points 
(systolic pressure ≥140 mm Hg  and/or diastolic pressure ≥90 mm Hg) 
(International Society of Hypertension, 2003 ). 
d) Diabetes: Diagnosed diabetes was defined as a self-reported medical diagnosis of 
diabetes (answering ‘yes’ to the question “have you ever been told by a doctor 
that you have diabetes?”). Undiagnosed diabetes was defined as a fasting glucose 
of > 7 mmol/l, among those not reporting a previous medical diagnosis. Those 
with a self-reported medical diagnosis of diabetes and a fasting glucose of > 7 
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mmol/l were considered not controlled, while those below this threshold were 
considered controlled. ‘Total diabetes’ comprised those with diagnosed or 
undiagnosed diabetes. Those with diagnosed diabetes were asked “Do you need a 
special diet, take tablets, or have insulin injections?” and responses were coded 
as diet alone, oral hypoglycaemics, insulin, or no treatment.  
e) Obesity: Waist circumference was measured in centimetres using a flexible tape 
measure. Central obesity was defined (Buter et al., 2008) as a waist 
circumference of more than 40 inches (101.6 centimetres) in men and of more 
than 35 inches (88.9 centimetres) in women.  
f) Physical impairments: Self-reported physical impairments (Duke University 
Centre for the Study of and Human, 1978) was categorized as having none, 1-2 
and three or more of 11 limiting physical impairments (arthritis or rheumatism; 
eyesight problems; hearing difficulty or deafness; persistent cough; 
breathlessness, difficulty breathing or asthma; high blood pressure; heart trouble 
or angina; stomach or intestine problems; faints or blackouts; paralysis, weakness 
or loss of one leg or arm; skin disorders such as pressure sores, leg ulcers or 
severe burns). Impairments were rated if they interfered with activities ‘a little’ 
or ‘a lot’, as opposed to ‘not at all’(Fillenbaum and Smyer, 1981). 
g) Self reported of head injury with loss of consciousness. 
h) Disability and functioning.  Activity limitation and participation restriction 
measured by the WHO-DAS II (Chopra et al., 2004), developed by the WHO as 
a culture-fair assessment tool for use in cross-cultural comparative 
epidemiological and health services research. In this study we used the 12-item 
version (a 36 item version is also available), (Sousa et al., 2009).  
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2.5.2.4  Lifestyle  
Where possible this information was elicited from participants; we used informants only 
for more severely demented participants. The interviewer provided a reliability rating at 
the end of both the participant and informant interview, and the interview that was rated 
as most reliable was selected. If the informant and participant interview were given the 
same reliability rating, we selected the  participant interview. Eliciting this data from 
informants for all participants might slightly have reduced information bias, but would 
have increased error and missing data.  
a) Smoking: smoker, ex-smoker, non-smoker, and length of exposure; type of 
tobacco used (cigarettes, cigars, pipe tobacco, chewing tobacco, snuff); average 
number of units used per day; age at start of habit and age when the person quit, 
if habit was interrupted. Pack years were calculated for each individual 
multiplying the average number of packs per day by duration of consumption 
(number of years). This was restricted to smoked tobacco and was calculated 
separately for cigarettes, cigars and pipes.    
b) Alcohol consumption: number of units ingested per week, before and after age 
65. To determine hazardous drinking before age 65, a cutoff level was 
established: 14 units/week for women and 21 units/week for men. The maximum 
usual consumption per week was recorded in units of alcohol, by type of drink: 
one glass of beer (250 ml = 2 units), one shot of liquor (22 ml = 2 units), or one 




2.5.2.5  Mental Health 
a) Depression: Diagnostic criteria for depression. Diagnoses of DSM–IV major 
depression ( American Psychiatric Association, 1994) and ICD–10 depressive 
episode ( World Health Organization, 1992.) were both derived using a 
computerised algorithm applied to GMS (Copeland et al., 1986). The ICD–10 
(World Health Organization, 1992.) divides depressive episodes into mild, 
moderate and severe. The DSM–IV, but not ICD–10, specifies that symptoms 
should be severe enough to cause ‘clinically significant distress or impairment’ 
and excludes a diagnosis of major depression if the symptoms are better 
accounted for by bereavement. The prevalence of each condition was determined 
with respect to the past month. Information was obtained from the participant or 
a reliable informant about: past history of depression and treated diagnosis.  
b) Behavioural and Psychological symptoms of dementia assessed using an 
informant questionnaire, the Neuropsychiatric Inventory (NPI-Q) (Kaufer et al., 
2000). 
 
2.5.2.6. Genetics  
 
a) Self-reported family history of dementia was ascertained with the question: Have 
any of his/her close relatives such as parents, brothers or sisters had the problem 
of serious loss of memory, leading to problems with looking after themselves? 
We then probed for a history suggestive of dementia and age of onset. 
 81 
b) APOE Genotyping: We aimed to collect 10 ml blood samples from all 
participants, from which DNA was extracted, quantitated, and archived at the 
National Centre for Medical Genetics in Havana. Apolipoprotein E genotype was 
determined using Hhal digestion of amplified products.  Genotypes were 
determined masked to knowledge of clinical phenotypes. 
c) Admixture estimation: In a population formed by admixture between two or 
more founding populations, ancestry informative marker genotype data can be 
used to estimate the admixture of each individual (the proportion of that 
individual's genome that has ancestry from each founding population). We aimed 
to estimate admixture in 600 participants, comprising all dementia cases, and a 
randomly selected sample of controls. Sixty SNPs were used to estimate 
individual admixture, chosen from the panel assembled by Dr Mark Shriver at 
Penn State and Mike Smith at NCI (Smith et al., 2004). With an average 40% 
information content for ancestry, these 60 SNPs would be sufficient to estimate 
three-way individual admixture proportions with a standard error of less than 0.1. 
The ADMIXMAP program (Hoggart et al., 2004)  was used to generate posterior 
means of  individual admixture from the ancestry informative marker data. In 
large samples these posterior means are asymptotically equivalent to maximum 





2.5.2.7  Blood tests (normal reference values in parentheses).  
 
Biochemical tests; fasting glucose (4.2–6.4 mmol/l) and lipid profile: total cholesterol 
(3.5–6.2 mmol/l); lipoprotein fractions: high-density lipoprotein, HDL (>0.9 mmol/l); 
very low density lipoprotein, VLDL (<1.04 mmol/l); triglycerides (<1.86 mmol/l). 
Commercial reagents were used (Roche, USA). Low-density lipoprotein (LDL) 
concentrations (<3.4 mmol/l) were calculated using the Friedewald formula. 
 
2.5.2.8  Indicators of care arrangements and caregivers strain:  
 
a) Dependence was determined by an interviewer assessment, after a series of open 
ended questions on care arrangements, to a key informant: Who shares the 
home? What kind of help does the participant need inside and outside of the 
home? Who, in the family, is available to care? What help do you provide? Do 
you help to organise care? Is there anyone else in the family who is more 
involved in helping? What do they do? What about friends and neighbours, what 
do they do? The interviewer then coded whether the participant required no care, 
care some of the time, or care much of the time.  
b) Caregiver economic strain: whether the caregiver had cut-back or stopped work 
to care  
c) Caregiver psychological strain, twenty-two items assess the carer's appraisal of 
the impact their involvement has on their lives (Zarit et al., 1980, Zarit et al., 
1986).  For each item burden is quantified from 0 (no burden) to 4 (highest 
burden).  
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d) The Self Reporting Questionnaire 20, a 20 item scale of symptoms of common 
mental disorder (anxiety, depression and somatisation) (Mari and Williams, 
1985), a score of eight or above signifying clinically significant morbidity. 
 
2.5.2.9  Other measures 
a) Anthropometric measures. Skull circumference was measured using a cloth tape-
measure encircling the nuchal tuberosity and the brow. Leg length was measured, 
standing, from the highest point of the iliac crest to the lateral malleolus. All 
dimensions were measured to the nearest centimeter. 
b) Physical assessments – pulse rate, systolic and diastolic resting blood pressure 
(average of two, sitting and standing), waist circumference, waist/hip ratio, 
walking test (5 metres walk, turn and return – timed and paces counted). 
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2.6  Data Management 
 
 
All data were collected directly onto laptop computers using computerized 
questionnaires driven by epidata  (version 6.01) software. Conditional skips and 
interactive checking of data consistency were incorporated to the questionnaires. Data is 
extracted from epidata into SPSS, and all processing (cleaning, processing of derived 
variables and running of 10/66, DSMIV dementia and other diagnostic algorithms) is 
carried out using SPSS batch files. The end result is a cleaned, processed and labelled 
data set that can be exported into STATA for analysis. 
I used the 3.2 version of 10/66 data set for Cuba and Stata software version 10.0 for all 
analysis.  
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2.7 Analysis  
 
2.7.1 Prevalence phase 
 
1. Sample characteristics 
I first described the response rates for the prevalence and incidence wave interviews, the 
general characteristics of the prevalence sample, and of the incidence sample. I 
compared the characteristics (using Chi squared test or t-test as appropriate) of those 
who were reinterviewed, who died, and who were otherwise lost to follow-up between 
prevalence and incidence phases  
 
2. Prevalence of dementia 
I initially described the prevalence of 10/66 and DSM-IV dementia, and any dementia, 
by age group and gender with robust 95% confidence intervals, adjusted for household 
clustering. I then used indirect standardization for age and gender to compare the 
prevalence of DSM-IV dementia  and 10/66 dementia in Cuba with that in Europe using 
the EURODEM meta-analysis of 12 European studies (Lobo et al., 2000). I applied the 
age and gender specific prevalences observed in EURODEM to the age- and sex-
distribution of the Cuban sample to estimate expected numbers of cases in Cuba, were 
the age- and gender-specific prevalence to have been the same as in EURODEM. The 
total observed cases were then divided by the total expected cases, and multiplied by 100 
to generate a standardized morbidity ratio (SMR). Mid-point exact 95% confidence 
intervals were calculated using the OpenEpi online calculator 
(http://www.sph.emory.edu/~cdckms/exact-midP-SMR.html). I have also compared the 
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crude Cuban prevalence with other 10/66 studies conducted in Latin America 
(Venezuela, Peru, Mexico and Dominic Republic – all using the same, as my Cuban 
study) and a recently published meta-analytical review of eight Latin-American studies, 
and generated SMRs with 95% confidence intervals, using the same indirect 
standardization procedures as described above.  
 
3. Correlates of prevalent dementia 
I tested for cross-sectional associations between both 10/66 dementia and DSM-IV 
dementia and correlates of possible aetiological significance. I concentrated upon those 
for which associations were unlikely to have been explained by reverse causality; age, 
rural or urban birthplace (Jorm et al., 1987), education, family history of dementia, 
history of head injury with loss of consciousness (Jellinger, 2004, Mortimer et al., 1991), 
past history of depression (Devanand et al., 1996, Jorm et al., 1991), leg length (Kim et 
al., 2003, Mak et al., 2006), skull circumference (Schofield et al., 1997) and left 
handedness (Raiha et al., 1998, Li et al., 1992, de Leon et al., 1986, Seltzer et al., 1984). 
Crude and mutually adjusted associations were estimated using Poisson regression, 
generating prevalence ratios with 95% confidence intervals, adjusting for household 
clustering. 
 
4. APOE genotype and prevalent dementia 
I estimated cross-sectional associations between APOE genotype and the prevalence of 
dementia. Since these analyses required a fasting blood sample (from which DNA was 
extracted), I first assessed the likely generalisability of my findings, and the possibility 
of non-response bias, by comparing the characteristics of those who did, and did not 
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provide a fasting blood sample.  I then reported the distribution of APOE genotype and 
APOE allele frequency by 10/66 Dementia status, estimating the effect of APOE 
genotype on dementia prevalence using the APOE e3/e3 genotype as the reference 
category. I also compared the prevalence of dementia between those with zero, one or 
two e4 alleles, and in those with one or two, compared with no e4 alleles. Effects were 
tested using Poisson regression to generate prevalence ratios with 95% confidence 
intervals, adjusted for age, gender and education.  
 
In order to assess whether the effect of APOE genotype on dementia (10/66 Dementia 
and AD subtype) prevalence was mediated by cardiovascular risk factors, I tested the 
effect of any APOE e4 allele (versus none) controlling incrementally for a) 
sociodemographics factors and family history of dementia. and b) individually and 
separately for cholesterol and triglycerides, diabetes, stroke, hypertension, and smoking.   
 
I next assessed associations between APOE e4 allele carriage and cardiovascular  risk 
factors (hypertension, stroke, diabetes, smoking, serum cholesterol and subfractions, and 
serum triglyceride), stratified by dementia status, and in the whole sample combined. I 
tested for the main effect of APOE e4 (using Chi squared test or t-test as appropriate), 
and for possible interactions (effect modification by dementia status – using general 
linear models or Poisson regression as appropriate).  
 
Finally, I tested the hypotheses that associations between total cholesterol, cholesterol 
subfractions and triglyceride and dementia (10/66 Dementia and AD subtype) were 
modified by APOE genotype (any e4 allele versus none). For each lipid, I constructed a 
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multivariable model using Poisson regression, testing the main effect of APOE e4, the 
main effect of the lipid (per mmol/L) and the interaction between APOE e4 and the 
lipid, all controlling for the potential confounding effects of age, gender, education and 
family history of dementia. In all I tested for 10 interactions (APOE genotype x five 
lipid profile measures; total cholesterol, HDL, LDL and VLDL subfractions and 
triglyceride; for the two dementia outcomes). 
 
5. Impact of dementia 
I estimated, using Poisson regression adjusted for household clustering, the independent 
contributions of 10/66 dementia, DSM-IV major depression, and physical health 
conditions (self-reported clinician diagnosed stroke and number of physical impairments 
(Duke University Centre for the Study of and Human, 1978)  to needing much care, 
caregiver psychological morbidity and caregiver needing to cut back or give up on paid 
work to care. Population attributable prevalence fractions were calculated, estimating the 
proportion of the prevalence of the outcome that could be avoided if each of these health 
conditions were eliminated, assuming a causal relationship between the health condition 
and the outcome, and that the associations are unconfounded. We also formally tested 
for mediation of the effect of dementia through the severity of Behavioural and 
Psychological Symptoms of Dementia (BPSD) using a Sobel-Goodman mediation test to 




2.7.2  Incidence of dementia  
 
1. Incidence wave sample characteristics 
I first decribed in detail the incidence wave resource, in terms of the full baseline 
sample, the dementia free cohort at baseline, and the characteristics of the dementia free 
cohort that were reinterviewed.  
 
2. Incidence rates 
Person-years at risk for the onset of the relevant dementia outcome (DSM-IV dementia 
or 10/66 dementia) were calculated as the interval between baseline and follow-up 
assessment, or the mid-point of this interval for those that were found to have developed 
dementia. Age-specific incidence (with Poisson standard errors and 95% confidence 
intervals using the Open Epi online calculator  
http://www.sph.emory.edu/~cdckms/exact-rate.html) was estimated, by sex and by age 
in 5-year bands by dividing the number of cases by the number of person-years 
contributed in each age band.  
 
3. Hypothesis testing – the effect of APOE genotype and cardiovascular risk factors on 
the incidence (and prevalence) of dementia 
 
Since many of the subsequent analyses depended upon the availability of a fasting blood 
sample, I first compared the characteristics of the at risk dementia-free cohort who did 




I then examined the strength of the association between age, sex, educational level, 
family history of dementia and APOE genotype and cardiovascular risk factors with the 
prevalence of dementia (10/66 dementia and DSM-IV dementia) using Poisson 
regression and with the incidence of dementia (10/66 Dementia and DSM-IV dementia) 
using Cox regression models (without and with accounting for the competing risk of 
death).  The rationale for this strategy was to assess the potential extent of 
methodological bias arising from estimating associations with these risk factors 
a) from cross-sectional as opposed to cohort studies, which  are potentially affected by 
information bias, prevalence bias (associations with  survival with dementia as well as 
the incidence of dementia) and reverse causality 
b) from cohort studies given the competing risk of dementia-free death between baseline 
and follow-up, an outcome that may also be significantly associated with many of the 
risk factors under consideration.  
I therefore used  
i) Poisson regression to estimate the associations in the full cross-sectional sample,  
ii) Cox’s proportional hazards regression (generating hazard ratios, approximating to 
incidence rate ratios) in the dementia-free at risk cohort, censoring those who had died at 
baseline.  
iii) Stata’s stcrreg command to implement a competing-risks regression based on Fine 
and Gray’s proportional subhazards model (Fine and Gray, 1999). This is based on a 
cumulative incidence function, indicating the probability of failure (dementia onset) 
before a given time, acknowledging the possibility of a competing event, dementia-free 
death, and generates subhazard ratios.   
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Risk factors such as sex (men compared with women), family history of dementia 
(binary variable), APOE genotype (presence vs absence of an APOE _4 allele), 
hypertension, stroke, smoking (ever smoked versus never smoked), hazardous drinking, 
and diabetes were assessed as binary variables. The effects of age per 5 year band and 
level of education were assessed as ordinal categorical variables. The effects of,total 
cholesterol, triglycerides, and cholesterol subfractions, and pack years of smoking were 
assessed as continuously distributed variables. All models were controlled for the effects 
of age, gender and education.  
 
4. APOE genotype and incident dementia – additional exploratory analyses 
Given a considerable attenuation of the effect of APOE genotype upon incident, as 
compared with prevalent dementia, I carried out a series of further exploratory analyses 
a) testing for a dose response effect across those with zero, one or two e4 alleles 
b) testing for an interaction by age 
c) comparing ages of onset for  incident cases with and without any e4 alleles 
d) testing for an effect of APOE e4 on mortality (in the whole baseline sample), and 
assessing the extent to which any effect was either mediated by or modified by baseline 
dementia status. 
 
5. Effect modification by APOE genotype 
Finally, I replicated the analyses previously conducted using cross-sectional data, to test 
the hypothesis of an interaction between APOE genotype and lipid profile, but 
examining associations with incident rather than prevalent  10/66 dementia. The 
analyses were conducted using proportional subhazards regression and were controlled 
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for age, sex and education. I took the opportunity to extend the analyses to include tests 
for interaction between APOE genotype and other cardiovascular risk factors for which 
there have been previous  indications of possible effect modification - stroke, 
hypertension, smoking history and diabetes.  
 
2.7.3  Interaction between ethno racial identity, admixture, APOE and 
dementia 
 
1. I first describe the characteristics of the cases (any dementia, n=235) and 
controls (no dementia, n=350) selected for the genetic admixture nested 
case-control sub-study with respect to age, gender, education, ethnic 
group identity (white, mixed or black), family history of dementia, 
depression, stroke, diabetes, hypertension and smoking. All admixture 
analyses were weighted back using the probability of selection within 
each APOE genotype separately for case and control groups. 
2. Next I describe the proportions assigned to each ethno-racial identity 
(‘white’, ‘mixed’ and ‘black’), and the weighted mean individual 
admixture proportions (European, African and Native American), and, in 
the sub-sample, test for an association between them using a weighted 
one way ANOVA. 
3. I next tested for an association between ethno-racial identity and APOE 
genotype and allele frequencies using a Chi-squared test for trend, and an 
association between APOE genotype and admixture by making a 
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weighted comparison of mean admixture across groups with no, one or 
two APOE e4 alleles.  
4. I tested for an association between APOE genotype and any dementia 
with Chi-squared tests and crude and adjusted prevalence ratios derived 
from a Poisson working model (adjusted for age, sex and educational 
level). We next estimated the stratum-specific prevalence ratios for the 
association between any APOE e4 allele and any dementia in the three 
ethno-racial identity groups, and fitted a ethno-racial identity by APOE 
interaction term to the model. We also fitted an African admixture by 
APOE interaction term to the weighted Poisson model in the case-control 
sub-sample.  
5. I finally assessed the separate and joint effects of ethno-racial identity and 
admixture on dementia prevalence. In the full sample, we describe the 
crude prevalence of dementia by ethno-racial identity, and the prevalence 
of dementia standardised for age, sex and education, and age, sex, 
education and APOE genotype. Alongside the crude and adjusted 
prevalence, we also provide prevalence ratios from the analogous Poisson 
model. In the case-control sub-sample we estimated the main effect of 
admixture (100% African versus 100% European) on dementia 
controlling for age, sex, education and APOE genotype. Then, in 
hierarchical models, we estimated the separate and joint effects of ethno-
racial identity and admixture controlling only for APOE genotype, and 
then the joint effects controlling also for age, sex and education.  
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To control for population stratification, the adjusted prevalence ratio for any 
APOE e4 allele was further adjusted for ethno-racial identity, and, in the 
weighted Poisson model in the case-control sub-sample, for admixture.
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Precision calculations indicated that a sample of 3,000 would allow estimation of a 
typical dementia prevalence of 4.5% (Lobo et al., 2000) with a precision of +/-0.7%. 
Assuming that 25% of the population are exposed (one or more APOE e4 alleles - a 
typical prevalence from Caucasian populations), and that 4% of the non-exposed have 
dementia, then the study would have 80% power at 95% confidence of detecting an 
effect (odds ratio) of  1.6 or greater  for the association between APOE e4 and 
dementia.All analysis were carried out using STATA version 9.2. Numbers of missing 
values are described for each variable used in the analysis. For the multivariate analyses, 
only those participants with non-missing data for all independent variables were 
included.  
 
 Incidence Study 
 
The power calculations for the 10/66 incidence phase study were based upon the cohort 
size for all latin American countries combined. Power within the Cuban cohort alone is 
therefore somewhat limited. However, as an indication, an at risk cohort of 1,892, with a 
cumulative incidence proportion of 0.09 would generate 80% power to detect a true HR 
of 1.6 or greater for an association with hypertension assuming a 75% prevalence at 
baseline.  This power estimation was carried out using Stata 8.2 ssmenu command 
(Barthel FM et al., 2006) for sample size and power calculations in complex studies with 
failure time outcomes. 
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 Case control study 
ADMIXMAP (Hoggart et al., 2004) (http://homepages.ed.ac.uk/pmckeigu/admixmap/) 
was used to generate posterior means of individual admixture from the ancestry 
informative.  With average 40% information content for ancestry, these 60 SNPs would 
be sufficient to estimate three-way individual admixture proportions with a standard 
error of less than 0.1 marker data. 
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CHAPTER 3  RESULTS 
 
3.1  General Characteristics of the Sample 
 
3.1.1  Baseline sample 
 
Of the 3015 older people enumerated, 2944 interviews were completed (response rate = 
97.6 %); 2043 in Havana (97.3%) and 901 in Matanzas (98.4%). Sociodemographic 
characteristics are summarized in Table 1. The median age was 74 years with an 
interquartile range of 69 to 79 years; 25.4% of the sample was aged 80 years or older. 
64.9% were female and 8.9% were living alone. Levels of education were relatively 
high, with only 2.6% of illiteracy and 16.9% having achieved tertiary education. Around 
half of the participants were currently married and a third was widowed. Two thirds of 
participants had six or more household assets and  food insecurity was reported by only 
5%.  There was a high prevalence of cardiovascular risk factors and chronic non-
communicable disease; more than 40% of participants were current smokers, 73.9% of 
participants had been told that they were hypertensive, and 55.6% met WHO/ 
International Society of Hypertension criteria for hypertension, 18.5% had received a 








3.1.2  Incidence phase 
 
 
Table 1 provides the main characteristics of the participants in the incidence phase, 
stratified by follow up status. Of the 2,944 baseline sample participants, 131 from one 
policlinic were not followed up because of logistic difficulties; therefore only 2,813 
were eligible for the incidence phase. Of these, 2007 (71.3 %) were successfully re-
interviewed. There were 608 (20.6%) deaths and 198 (6.7%) were lost to follow-up. 
There were no substantial differences in the characteristics of those interviewed in the 
baseline and the subset who were successfully followed up. However there were 
differences which were statistically significant in gender, age and education  between 
those successfully interviewed at the follow up, those who died and those who were not 
traced. Those who died were older, and more likely to be women and to have lower 
education.  
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Female (MV=0) 1904(64.9%) 1332 (66.4) 365 (60.0) 139 (70.2) P= 0.005 
Age (MV=7)      
      65-69 760(25.8%) 607 (30.3) 59 (9.7%) 49 (24.7) P<0.0001 
     70-74 789(26.8%) 578 (28.9) 114 (18.8) 55 (27.8)  
     75-79 639(21.7%) 435 (21.7) 137 (22.6) 46 (23.2)  
     80+ 749(25.4%) 381 (19.0) 297 (48.9) 48 (24.2)  
Lives alone 
(MV=8) 
261(8.9%) 174 (8.7) 53 (8.7) 23 (11.6) P=0.597 
Marital status 
(MV=8) 
    P=0.963 
Married 1271(43.3%) 903 (45.1) 216 (35.8) 80 (40.4)  
Widowed 928(31.6%) 586 (29.3) 239 (39.6) 71(35.9)  
Separated/ Divorced 462(15.7%) 334 (16.7) 78 (12.9) 36(18.2)  
Never married 275 (9.4%) 180 (9.0) 71 (11.7) 11 (5.6)  
Education (MV=8)     P<0.0001 
None 75(2.5%) 42 (2.1) 26 (4.3) 5 (2.5)  
Minimal 655(22.2%) 422 (21.1) 166 (27.5) 31 (15.7)  
Completed primary 979(33.3%) 651 (32.5) 222 (36.8) 64 (32.3)  
Completed 
secondary 
728(24.4%) 540 (27.0) 109 (18.1) 56 (28.30  
Tertiary 499(16.9%) 348 (17.4) 81 (13.4) 42 (21.2)  
Socioeconomic 
indicators 
     
Number of Assets 
      0-3 
      4-5 
      6+ 
(MV=8)  
 
  78 (2.6) 
 951 (32.6) 
1891 (64.8) 
 
  47 (2.4) 
 630 (31.5) 
1323 (66.2) 
 




 10 (5.1) 





140 (4.8%) 90 (4.5) 39 (6.5) 8 (4.0) P=0.084 
Life style      
Current smoker 
(MV=9) 
563(42.5%) 369 (40.8) 136 (47.4) 37 (45.7) P=0.218 
Hazardous drinker 
(MV=17) 
105(3.6%) 66 (3.3) 31 (5.1) 6 (3.0) P=0.484 
CV diseases and 
risk factors 
     
Hypertension 
(MV=4) 
2 944 (73.9%) 1488 (74.3) 448 (73.7) 154 (77.8) P= 0.661 
Stroke (MV=6) 230 (7.8%) 113 (5.6) 88 (14.6) 15 (7.6) P=0.751 
Diabetes (MV=16) 543(18.5%) 354 (17.7) 129 (21.5) 36 (18.2) P=0.586 
MV= missing values 
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3.2  Prevalence Correlates and Impact of Dementia in Cuba 
 
3.2.1  Prevalence 
 
 
I present in table 2 the prevalence of dementia according to the 10/66 criteria, according 
to DSM-IV criteria and any dementia (10/66 and/or DSM-IV) by age group and gender. 
The overall prevalence of 10/66 dementia was 10.8% (95% CI, 9.7%-12.0%) and that of 
DSM-IV dementia 6.4% (5.6%-7.4%).  It can be seen from the data in Table 2 that the 
prevalence of both 10/66 dementia and DSM-IV dementia increases with age and it is 
higher in women than in men, particularly among the oldest old. Prevalence was 2.9 % 
(95% CI 1.7 – 4.1) in the 65–69 age group and 25.7 % (95% CI 22.6 – 28.9) in the ≥80 
age group. The distribution of dementia cases according to CDR severity was, for 10/66 
dementia 22% questionable, 38% mild, 23% moderate and 17% severe, and for DSM-IV 
dementia 1% questionable, 44% mild, 31% moderate and 24% severe.  
 
The age-specific prevalence of DSM-IV dementia in Cuba is similar but slightly higher 
than that reported in the EURODEM (Community Concerted Action on the 
Epidemiology and Prevention of Dementia Group) meta-analysis of European studies 
(Lobo et al., 2000) (see Figure 2), with an age and gender standardized morbidity ratio 
of 108.  
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Table 2. The prevalence (%) of dementia by age group and gender, with 95% 





 10/66 dementia DSM-IV dementia  Any dementia 
Female  2.9 (1.7 - 4.8)  1.9 (1.0 - 3.5)  2.9 (1.4 - 4.4) 
Male  2.9 (1.5 - 5.8)  1.1 (0.4 - 3.3)  2.9 (0.9 - 5.0) 
65-69 
n=760 
 Total  2.9 (1.9 - 4.3)  1.6 (0.9 - 2.8)  2.9 (1.7 - 4.1) 
Female  6.1 (4.3 - 8.5)  3.6 (2.3 - 5.7)  6.3 (4.1 - 8.4) 
Male  5.9 (3.7 - 9.3)  3.1 (1.6 - 5.8)  6.2 (3.4 - 8.9) 
70-74 
n=789 
 Total  6.0 (4.5 - 7.9)  3.4 (2.3 - 4.9)  6.2 (4.5 - 7.9) 
Female  9.9 (7.3 -13.2)  5.9 (4.0 - 8.6)  9.8 (6.9 - 12.7) 
Male  6.7 (4.1 - 10.8)  4.0 (2.1 - 7.4)  7.04 (3.7 - 10.4) 
75-79 
n=639 
 Total  8.7 (6.7 - 11.1)  5.1 (3.7 - 7.2)  8.8 (6.6 -11.0) 
Female 26.8 (23.0 - 30.7) 16.6 (13.3 - 19.8) 26.9 (23.0 - 30.8) 
Male 22.7 (17.3 - 28.1) 13.7 (9.3 - 18.2) 23.2 (17.7 - 28.6) 
80+ 
n=  756 
 Total 25.5 (22.4 - 28.7) 15.7 (13.1 - 18.3) 25.7 (22.6 - 28.9) 
Female 11.6 (10.3 - 13.1)  7.1 (6.1 - 8.4) 11.8 (10.3 - 13.2) 
Male   9.2 (7.6-11.1) 5.2 (4.0-6.7) 9.3 (7.6 – 11.2) 
All ages 
n=2944 
 Total 10.8 (9.7-12.0) 6.4 (5.6-7.4) 10.9 (9.8 - 12.1) 
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Figure 2. The prevalence of dementia by age, comparing 10/66 Dementia and DSM-IV 
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In Table 3 I compare the prevalence of dementia by age group in the Cuban Population 
found in this study with the previous study conducted in Cuba (EDAP) (Llibre et al., 
2009), with a recent meta-analysis of eight studies conducted in six Latin American 
countries Brazil, Chile, Colombia, Peru, Uruguay , and Cuba (Nitrini et al., 2009) and 
with the other 10/66 Latin American sites which used the same protocol as mine (Llibre 
Rodriguez et al., 2008c). 
 
The age-specific prevalence of 10/66 dementia increased from 2.9% between 65 to 69 
years aged to 40.6 % for those aged 90 years and over, whereas that of DSM-IV 
dementia increased from 1.6% to 26.4%.  For the 10/66 Latin American studies, 
including this Cuban study, age-specific prevalence of 10/66 dementia is roughly double 
that of DSM-IV dementia. Prevalences in Cuba were similar to those found in 
Dominican Republic for both diagnosis criteria, but higher compared to the other 10/66 
Latin American studies in Peru, Mexico and Venezuela. The age specific prevalences 
found in EDAP a previous study conducted in Havana (Llibre et al., 2009), more or less 
in the same period of time, are somewhat between the 10/66 and the DSM prevalence of 
dementia estimated in the present study. The same is true when we compare with the age 
specific prevalence of the Latin American meta analysis (Nitrini et al., 2009) for which 




Table 3. Comparison of crude prevalence of dementia according to age between  Cuba 10/66 study, EDAP (Llibre et al., 2009), Latin 
American 10/66 studies and  pooled data of eight studies from six Latin American countries  (Nitrini et al., 2009), (%) and 95% CI by 
age.    
* Note that the EDAP study was included in Latin America review 
 
 
Age groups (years) Prevalence studies 
Criteria  65-69 70-74 75-79 80-84 85-89 90+ ≥ 65  
10/66 2.9 (1.7- 4.1) 6.0(4.3-7.6) 8.7 (6.5-10.8) 17.8 (14.2-21.5) 33.0(26.8-39.2) 40.6(31.2-49.9) 10.8(9.7-11.9) Cuba  (n= 2944) 
DSM IV 1.6 (0.7 -2.5) 3.4 (2.2-4.7) 5.2 (3.4-6.9) 10.7 (7.7-13.7) 19.7(14.5-25.0) 26.4(17.8-35.0)   6.4(5.5-7.3) 
Cuba EDAP  
(n=18 351) 
DSM IV 3.2 (2.7-3.6) 4.4 (3.7-5.0) 7.00 (6.2-7.8) 12.3(11.0-13.2) 20.3 (17.2-23.4) 30.5(26.9-34.0) 8.2 (7.8- 8.6) 
10/66 3.9(2.3-5.6) 6.7(4.6-8.9) 12.6(9.3-15.9) 17.7(13.3-22.1) 23.1(16.8-29.5) 38.9(29.0-48.9) 11.7(10.3-13.1) Dominic Republic 
(n=  2011) DSM IV 1.3 (0.3-2.3) 3.8 (2.2-5.5)  4.8 (2.7-6.9)  7.5(4.5-10.5) 13.3(8.2-18.4) 18.9(10.9-27.0)  5.4 (4.4-6.4) 
10/66 2.7(1.0-4.3) 2.6(0.9-4.2)  8.0(4.9-11.1) 13.6(8.3-18.9) 30.5 (21.5-39.6) 48.1(34.4-61.9)  9.3(7.7-11.0) Peru Urban 
(n=  1381) DSM IV 1.9(0.5-3.2) 0.8(0.0-1.8)  2.3(0.6-4.1)  5.2(2.0-8.4)  8.2(3.0-13.5) 11.1(2.4-19.8)  3.1(2.2-4.0) 
10/66 3.3(0.7-6.0) 5.7(1.8-9.5)  6.9(1.9-12.0) 10.9(3.7-18.2) 10.5(0.3-20.7) 15.0 (0.0-32.1)  6.5(4.5-8.6) Peru Rural 
(n=  552) DSM IV 0 0  0  2.7 (0.0-6.6) 0 0  0.4(0.0-0.9) 
10/66 2.7 (1.6-3.8) 3.8(2.1-5.6)  6.9(4.2-9.7) 18.2(12.4-24.1) 25.3(16.3-34.3) 38.3(23.9-52.7)  7.1(6.0-8.3) Venezuela 
(n=  1904) DSM IV 1.9(0.5-3.2) 1.1(0.1-2.0)  2.9(1.1-4.7)  8.2(4.1-12.4)  7.7(2.1-13.3) 12.8(2.9-22.7)  0.4(0.0-0.9) 
10/66 0.4(0.0-1.2) 4.5(2.3-6.8)  9.7(5.7-13.8) 13.8(7.8-19.9) 25.0(14.9-35.1) 70.6 (46.4-94.7)  8.6(6.8-10.4) Mexico Urban 
(n=  1002) DSM IV 0.4(0.0-1.2) 2.1(0.6-3.7)  3.4(0.9-5.9)  8.5(3.6-13.3) 10.5(3.5-17.6) 35.3(10.0-60.6)  4.1(2.8-5.3) 
10/66 1.3(0.0-2.6) 4.8(2.1-7.4)  8.6(4.9-12.3) 17.9(11.7-24.1) 23.5(13.1-34.0) 53.3(24.7-81.9)  8.5(6.7-10.3) Mexico Rural 
(n=  1000) DSM IV 1.0(0.0-2.1) 1.2(0.0-2.5)  1.8(0.04-3.6)  4.1 (0.9-7.4)  5.9(0.1-11.6) 13.3(0.0-32.8)  2.2 (1.3-3.1) 
Latin American meta 
analysis  (n=31154 ) 
DSM IV  2.4  (2.1- 2.7) 3.6(3.2 -4.0)  7.0(6.4 -7.7) 11.9(10.9- 12.9) 20.2(18.6 -21.8) 33.1(30.0-36.2)  7.1 (6.9-7.4) 
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Figures 3 and 4 shows standardised morbidity ratios (SMR) for comparisons (indirect 
standardisation for age and gender.  SMR is a ratio of the observed to expected number 
of dementia cases. The observed figures come from the Latin American prevalences 
according 10/66 study samples, the EDAP (Cuba ) and Latin American Review, and the 
expected figures from applying the age-specific and sex-specific prevalence DSM IV  
and 10/66 (Cuba 10/66 study)  to the age and sex distribution of the 10/66 study 
samples, Cuba EDAP and Latinamerican Review. An SMR of 100 implies that the 
dementia prevalence in the study sample is similar to that in the reference population, an 
SMR less than 100 implies that the prevalence in the sample is lower than that in the 
reference population, and an SMR greater than 100 implies that the prevalence is higher 
than that in the reference population.  
 
According to DSM-IV criteria, dementia prevalence by age and gender group in Cuba, 
proved higher than that reported by Dominic Republic SMR 79 (65-94), Puerto Rico 58  
(47 – 71 )  Mexico 67 (49 – 91)  and  Venezuela 40 (28-54), and lower than that 
described by the Latin American review   with a morbidity  standardized ratio  by age and 
sex (SMR) of 113  (108 – 117) and the EDAP in  Cuba  123 (117 – 129). 
 
Within the 10/66 Group’s prevalence study using the 10/66 Dementia Diagnostic 
Algorithm, the prevalence of 10/66 Dementia in Cuba was almost similar than that 
reported for  Latin American urban areas., Dominic Republic SMR 102 (90 – 116), 
Puerto Rico 94 (82 – 106), Peru 92 (77 – 109) and Mexico 87 (70 – 107) and higher than 
that from Venezuela 69 (57  - 83), EDAP 72 (69 – 77) and Latin American meta analysis 
with a SMR of 77 (67 – 89).  
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Figure 3. Standardised morbidity rations (SMRs) for DSM IV dementia; indirect 
standardization for age and sex  applying the age-specific and sex-specific prevalence 
(Cuban 10/66 study) from the reference population to the age and sex distribution of the 
Latin american 10/66 study samples, Cuba (EDAP) and Latin American Review.  



























































Figure 4.  Standardised morbidity rations (SMRs) for 10/66  dementia; indirect 
standardization for age and sex  applying the age-specific and sex-specific prevalence 
(Cuban 10/66 study) from the reference population to the age and sex distribution of the 





























































3.2.3  Cross sectional correlates of dementia prevalence in Cuba 
 
Associations with dementia were similar for the 10/66 and DSM-IV dementia outcomes. 
As table 4 shows, for each outcome in the univariate analyses, dementia was associated 
with increasing age, lower levels of education, shorter leg length and smaller skull 
circumference, and with a family history of dementia. The crude prevalence ratio of 
dementia increase with increasing age for both criteria,  compared to participants aged 
65-69, participants aged 70-74 had two times higher prevalence;  for those aged 75-79 
compared to those aged 65-69, prevalence of dementia was three times higher  and eight 
times higher for those aged 80 and older. Educational level was inversely associated 
with the prevalence of dementia. As a sensitivity analysis, we also estimated the effect 
of leg length in (centimetres) and skull circumference (in centimetres) on dementia 
prevalence when deployed as linear variables. Dementia prevalence declined with each 
centimetre increase in leg length (PR 0.98, 95% CI, 0.96–0.99) and with each centimetre 
increase in skull circumference (PR 0.85, 95% CI 0.80–0.89). There were no 
associations between dementia and handedness, rural/ urban origins at birth, head injury, 
or a past history of depression treated by a doctor. 10/66 dementia, but not DSM-IV 
dementia was associated with female gender.  
 
In the mutually adjusted multivariable models the association between leg length and 
dementia was no longer apparent. On inspection of the models this was attributable to 
negative confounding by age and education. The association between female gender and 
10/66 dementia was confounded by age and skull circumference. 
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Table 4: Socio demographic characteristics, and associations with 10/66 dementia and DSM-IV dementia (n=2944) 
Associations with 10/66 Dementia Associations with DSM-IV Dementia Exposure Exposure 
prevalence (%) 10/66 Dementia prevalence 
(%) in exposed 
Crude PR (95% CI) Multiply adjusted PR1  
(95% CI)       N=2735 
DSM-IV Dementia prev 
in exposed 
Crude prevalence 
ratio (95% CI) 
Multiply adjusted 
PR1 (95% CI)   
N=2747 
Age 7 mv *       
65-69 760 (25.8%) 2.9 (1.9-4.4) 1 (ref) 1 (ref) 1.6 (0.9-2.8) 1 (ref) 1 (ref) 
70-74 789 (26.8%) 6.0 (4.5-7.9) 2.06 (1.25-3.38) 2.09 (1.21-3.61) 3.4 (2.3-4.9) 2.17 (1.11-4.25) 2.22 (1.06-4.65) 
75-79 639 (21.7%) 8.6 (6.6-11.0) 2.92 (1.80-4.74) 2.89 (1.68-4.96) 5.1 (3.7-7.2) 3.27 (1.70-6.28) 3.08 (1.48-6.41) 
80+ 749 (25.4%) 25.7 (22.7-29.0) 8.77 (5.71-13.48) 8.01 (4.90-13.11) 15.6 (13.2-18.4) 9.89 (5.51-17.77) 9.42 (4.88-18.2) 
Gender        
Female 1913 (65.0%) 11.7 (10.3-13.2) 1 (ref) 1 (ref) 7.1 (6.1-8.4) 1 (ref) - 
Male 1031 (35.0%) 9.2 (7.6-11.2) 0.79 (0.63-1.00) 1.03 (0.81-1.33) 5.2 (4.0-6.7)  0.90 (0.73-1.12) - 
Education 8 mv       
None 75 (2.6%) 27.0 (18.2-28.2) 1 (ref) 1 (ref) 12.0 (6.3-21.5) 1.00 (ref) 1 (ref) 
Minimal 655 (22.3%) 15.9 (13.3-18.9) 0.59 (0.38-0.89) 0.59 (0.37-0.94) 9.9 (7.9-12.5) 0.83 (0.43-1.59) 0.93 (0.44-1.97) 
Primary 979 (33.3%) 11.8 (9.9-14.0)  0.44 (0.29-0.66) 0.55 (0.35-0.87) 6.4 (5.1-8.2) 0.54 (0.28-1.04) 0.73 (0.35-1.54) 
Secondary 728 (24.8%) 6.5 (4.9-8.5) 0.24 (0.15-0.38) 0.41 (0.25-0.69) 4.4 (3.1-6.1)  0.37 (0.18-0.74) 0.70 (0.32-1.54) 
Tertiary 499 (17.0%) 5.8 (4.1-8.3) 0.22 (0.13-0.36) 0.36 (0.20-0.64) 3.8 (2.4-5.9) 0.32 (0.15-0.68) 0.55 (0.23-1.31) 
Residence at birth 8 mv       
City 1431 (48.7%) 9.7 (8.3-11.4) 1 (ref) - 5.5 (4.4-6.8) 1 (ref) - 
Town 715 (24.4%) 11.9 (9.7-14.4)  1.22 (0.95-1.57) - 7.8 (6.1-10.0) 1.43 (1.04-1.99) - 
Country 790 (26.9%) 11.7 (9.6-14.2)  1.20 (0.93-1.55) - 7.0 (5.4-9.0) 1.28 (0.91-1.79) - 
Head injury 14 mv       
No 2764 (94.3%) 10.7 (9.6-11.9)  1 (ref) - 6.5 (5.6-7.5) 1 (ref) - 
Head injury 166 (5.7%) 12.6 (8.3-18.7) 1.18 (0.77-1.80) - 6.0 (3.3-10.8) 0.93 (0.50-1.73) - 
Handedness 14 mv       
Right handed 2820 (96.2%) 10.7 (9.6-11.9)  1 (ref) - 6.3 (5.4-7.2) 1 (ref) - 
Left handed 110 (3.8%) 8.3 (4.3-15.1) 0.77 (0.44-1.46) - 3.6 (1.4-9.3) 0.58 (0.22-1.53) - 
Family history of dementia 10 mv       
No 2385 (81.3%) 9.9 (8.7-11.2) 1 (ref) 1 (ref) 5.6 (4.8-6.6) 1 (ref) 1 (ref) 
Yes 549 (18.7%) 14.6 (1.8-17.8)  1.47 (1.16-1.87) 1.60 (1.26-2.03) 9.8 (7.6-12.7) 1.75 (1.29-2.38) 1.73 (1.25-2.40 
Treated depression 10 mv       
No 2537 (86.5%) 11.0 (9.9-12.3) 1 (ref) - 6.4 (5.5-7.4) 1 (ref) - 
Yes 397 (13.5%) 9.7 (7.1-13.0) 0.88 (0.64-1.21) - 6.5 (4.5-9.4) 1.02 (0.68-1.51) - 
Anthropometry        
Leg length 127 mv Case – 83.8 (7.5) 2 
Non-case – 85.4 (7.4) 2 
0.98 (0.96-0.99) 3 1.00 (0.99-1.01) 3 Case – 84.3 (7.8) 2 
Non-case–85.3 (7.4) 2 
0.98 (0.97-1.00) 3 1.01 (0.99-1.03) 3 
Skull circumference 57 mv Case – 55.1 (1.9) 2 
Non-case – 55.8 (1.9) 2 
0.85 (0.80-0.89) 3 0.89 (0.84-0.95) 3 Case – 55.1 (1.9) 2 
Non-case–55.8 (1.9) 2 
0.83 (0.78-0.90) 3 0.89 (0.82-0.97) 3 
1. Adjusted for all other covariates in the model;   2. Mean (standard deviation);                          *mv= missing values 
3. Change in prevalence per one centimeter increment in the anthropometric index 
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3.2.4  The association between APOE genotype and the prevalence of 
dementia 
  
3.2.4.1  Availability of data regarding APOE genotype and cardiovascular risk 
indicators 
 
For the following analyses, of the main effect of APOE genotype on dementia 
prevalence, and the mediating and/ or effect modifying effects of lipid profile and other 
cardiovascular risk factors, I used data from those individuals who had agreed to provide 
a fasting blood sample, from which we extracted DNA to estimate APOE genotype, and 
which were also analysed for fasting glucose (allowing us to estimate undiagnosed 
diabetes – fasting glucose ≥7.0mmol/L, lipid profile (triglyceride, total cholesterol and 
cholesterol sub-fractions). Fasting blood samples were obtained from 2,520 (86.1%) of 
the 2,944 baseline sample. I carried out analyses to assess the extent of possible non-
response bias arising from the unavailability of blood samples from 13.9% of the 
baseline sample (Table 5). Specifically I tested to see whether sociodemographic 
variables and major health conditions were differently distributed between those 
providing and not providing blood samples. Men were possibly slightly under-
represented among those not providing blood samples (p=0.07). Otherwise, there were 
no large or statistically significant differences between the two groups regarding age, 
education, ethnicity, prevalence of dementia, family history of dementia and prevalence 
of self-reported stroke, diabetes, hypertension and smoking (Table 5) . 
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Table 5.  Baseline characteristics, for the baseline sample, by availability of baseline 
fasting blood sample.  
Variables  Without blood 
sample    N=408 
With blood sample 
N= 2520 
P-value 










Male sex (n/ %) 159 (39.0%) 866 (34.4%) X²=3.3, 1 df, 
p=0.07 











































X²=1.9, 2 df, 
p=0.39 
Dementia (n/ %) 47 (11.5%) 273 (10.8%) X²=0.2, 1 df, 
p=0.68 
ICD depressive 
episode (n/ %) 
19 (4.7%) 125 (5.0%) X²=0.1, 1 df, 
p=0.79 






X²=0.4, 1 df, 
p=0.53 






X²=0.4, 1 df, 
p=0.53 
Hypertension (n/ %) 295 (72.3%) 1841 (73.1%) X²=0.1, 1 df, 
p=0.75 






X²=0.7, 1 df, 
p=0.41 
Family history of 














3.2.4.2  The crude cross-sectional association of APOE genotype with dementia 
 
The distribution of APOE genotype and the APOE allele frequency, by 10/66 dementia 
status, is shown in table 6. The e2 allele was under-represented, and the e4 allele over-
represented among those with dementia. We examined the effect of APOE genotype on 
dementia prevalence using APOE e3/e3 genotypes as the reference category.  After 
adjusting for age, sex and education, APOE e3/e4 (PR=2.59, 95%CI 2.04-3.28) and 
APOE e4/e4 genotypes (PR 2.88, 95% CI 1.58-5.27) were strongly associated with 
dementia. However, there was no apparent protective effect of the e2 allele. The 
prevalence of dementia was more than double in APOE carriers compared to that in non-
carriers (adjusted PR=2.58, 95%CI 2.06-3.22). 
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Table 6. APOE Genotype and APOE allele frequency by 10/66 dementia status, with 
crude and adjusted prevalence ratios and 95% confidence intervals  
 
  Dementia  





















E3/e3 162 (59.3%) 1663(74.0%) 1825(72.4%) 1.00 (ref.) 1.00 (ref.) 












186 (68.1%) 1918(85.4%) 2104(83.5%) 1.00 (ref.) 1.00 (ref.) 













1 or 2  
alleles 




E2 0.048 0.060 0.059 X²= 61.7, 1 df, P< 0.001 




E4 0.174 0.080 0.090  
 




3.2.4.3  Mediation through cardiovascular risk factors 
 
In order to assess if the effect of APOE 4 on dementia is mediated by cardiovascular risk 
factors I then adjusted for sociodemographics factors and family history of dementia. 
and then controlling separately cholesterol and triglycerides, diabetes, stroke, 
hypertension, and smoking alone or with cholesterol and triglycerides.  Adjusting, using 
Poisson regression models, for sociodemographics characteristics (age, gender, 
education, family history of dementia) lipid profile (cholesterol, triglycerides, LDL, 
HDL and VLDL) and others vascular risk factors  (diabetes, stroke, hypertension , 
smoking and alcohol) had little effect on the central estimate prevalence ratio for the 
association between APOE e4 and both 10/66 dementia and AD (Table 7). 
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Table 7   Crude and adjusted prevalence ratio (PR) (Poisson Regression) for the 
association between one or more Apoe_4 alleles and dementia and Alzheimer’s disease 
(A.D) 
 
Crude and adjustment        10/66 Dementia 
PR            (95% CI) 
         AD 
PR          (95% CI) 
1 unadjusted 2.37         (1.88 – 2.98) 2.42        (1.78 – 3.28) 
2 age, gender and education 
and family history 
2.54         (2.04 – 3.17) 2.59        (1.94 – 3.47) 
3  + cholesterol + 
triglycerides 
2.55         (2.03 – 3.21) 2.69        (1.99 – 3.64) 
4  + diabetes  2.54         (2.02 – 3.20) 2.75        (2.04 – 3.71) 
5  + diabetes + cholesterol + 
triglycerides 
2.53         (2.01 – 3.19) 2.74        (2.03 – 3.70) 
6  + Stroke 2.59         (2.07 – 3.24) 2.63        (1.97 – 3.73) 
7  + Stroke +  cholesterol + 
triglycerides 
2.62         (2.08 – 3.30) 2.74        (2.03 – 3.71) 
8   + Hypertension 2.54        (2.04 – 3.17) 2.60        (1.95 – 3.46) 
9  +Hypertension +  
cholesterol + triglycerides 
2.56        (2.04 – 3.22) 2.70        (2.01 – 3.65) 
10 + Smoking 2.54        (2.03 – 3.17) 2.60        (1.94 -  3.47) 
11 + Smoking  +  cholesterol 
+ triglycerides 
2.55        (2.03 – 3.21) 2.70        (2.00 – 3.65) 
 12  ALL 2.61        (2.10 – 3.29) 2.79        (2.07 – 3.76) 
 
 116 
3.2.4.4  Interaction between lipids, APOE genotype and prevalence of dementia 
 
This analysis includes 2,520 participants who gave blood samples for APOE genotyping 
and lipid profile.  Table 8 displays demographics, vascular risk factors and lipid profile 
in participants according to APOE e4 genotype and dementia status.  
 
Carriage of one or more APOE e4 allele was associated with an increased prevalence of 
stroke and diabetes, and a higher mean total cholesterol, contributed mainly by the LDL 
subfraction. There was also a non-significant trend towards a higher prevalence of 
family history of dementia among carriers (22.7%) than non-carriers (18.1%) (p=0.07).  
 
Having stratified these associations according to 10/66 dementia status, it was apparent 
that there were several statistically significant interactions, with the effect of APOE e4 
carriage on the demographic and cardiovascular outcomes modified according to 
dementia status. Thus, APOE e4 carriers tended to be younger than non-carriers, 
particularly amongst those with dementia. While the prevalence of stroke was higher 
among carriers than non-carriers in those free of dementia, the trend was in the opposite 
direction for 10/66 dementia cases. The mean serum triglyceride level was higher in 
carriers than non-carriers, but only among those with dementia. Conversely, mean total 
cholesterol was higher in APOEe4 carriers than non-carrriers for dementia non-cases, 
with no such difference seen among dementia cases; however, this interaction was not 
statistically significant (p=0.25). Family history of dementia was more frequently 
reported among APOE e4 carriers than non-carriers regardless of dementia status (test 
for interaction, p=0.93). 
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Table 8 The association between APOE status and various demographic variables, and cardiovascular disease or cardiovascular risk 
factors, stratified by 10/66 dementia status 
Stratified by 10/66 dementia case status  Whole sample 
Cases (10/66 Dementia) Non-cases (10/66 
Dementia) 
Outcome APOE e4 
(n = 278) 






(n = 80) 
No APOE 
e4   
(n = 172) 
APOE e4 
(n = 278) 
No APOE  
e4  






Mean age, y (SD) 74.6 (6.8) 75.1 (7.0) 2.1, 0.15 79.0 (8.1) 82.0 (7.2) 73.4 (5.8)  74.5 (6.7 ) 0.04 
Female (n, %) 272 (65.4) 1382 (65.7) 0.0, 1.00 62 (77.5) 130 (75.6) 205 (73.7) 1248 (65.2) 0.96 
Completed 
primary 
education (n, %) 
318 (77.4) 1574 (75.1) 0.9, 0.35 51 (60.7) 107 (59.4) 267 (81.9) 1463 (76.6) 0.68 
Family history of 
dementia 
94 (22.7) 379 (18.1) 3.4, 0.07 24 (30.0) 43 (25.0)  62 (22.3)  324 (17.0) 0.93 
Hypertension 312 (75.1) 1529 (72.7) 1.1, 0.31  61 (76.3) 126 (73.3) 213 (76.6) 140 (73.2) 0.96 
Stroke 42 (10.2) 152 (7.2) 3.8, 0.05  13 (16.3)   41 (23.8)   25 (9.0)  115 (6.8) 0.03 
Diabetes 108 (29.8) 443 (24.0) 5.3, 0.02  10(12.5) 22 (12.9) 37 (13.3)  222 (13.1) 0.10 
Smoking (ever 
smoked) 
186 (45.2) 955 (45.5) 0.0, 0.86  36 (44.7) 68 (39.5) 127 (45.9)  780 (46.1) 0.31 
Mean cholesterol 
(SD) 
5.51 (1.2) 5.29 (1.2) 10.3, 0.001  5.35 (1.2) 5.31 (1.0) 5.55 (1.2) 5.29 (1.2) 0.25 
Mean HDL (SD) 1.20 (0.4) 1.19 (0.4) 0.07, 0.79 1.13 (0.4) 1.14 (0.4) 1.23 (0.5) 1.19 (0.4) 0.70 
Mean LDL (SD) 3.65 (1.3) 3.45 (1.2) 6.4, 0.01 3.52 (1.3) 3.46 (0.9) 3.66 (1.3) 3.48 (1.2) 0.37 
Mean (SD) 
triglycerides  
1.62 (0.9) 1.57 ( 0.9) 1.2, 0.28 1.75 (1.1) 1.43 (0.8) 1.59 (0.9) 1.58 (0.9) 0.03 
Mean VLDL 
(SD) 
0.69 (0.4) 0.68 (0.4) 0.5, 0.49 0.71 (0.3) 0.59 (0.3) 0.69 (0.4) 0.68 (0.4) 0.10 
1. T-test (F value and p-value) or Chi squared test (Chi square and p-value) as appropriate 
2. Test for statistical test for significance of dementia x APOE e4 interaction term, derived from general linear models (continuous 
outcome) or Poisson regression models (dichotomous outcome) fitting the main effect of dementia, the main effect of APOE and the 
interaction between them 
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As described in the background literature review (section 1.5.3), other studies had 
reported inconsistent evidence for interactions between APOE genotype, lipid profile 
and dementia AD risk. I therefore conducted further multivariable analyses to test for 
these associations, controlling for the potential confounding effects of age, gender, 
education and family history of dementia, conducting separate regression analyses for 
the outcomes of 10/66 dementia and the AD subtype. Table 9 summarises the results of 
these analyses. 
  
I tested for a total of 10 interactions (APOE genotype x five lipid profile measures; total 
cholesterol, HDL, LDL and VLDL subfractions and triglyceride; for the two dementia 
outcomes). Of these just two of the interactions were statistically significant for the 
10/66 dementia outcome, and one for AD. There was a particularly large and statistically 
significant interaction between APOE genotype and VLDL cholesterol subfraction for 
both 10/66 dementia (PR 2.39, p=0.01) and AD (PR 2.16, p=0.05) the effect in each case 
being that VLDL was inversely associated with dementia risk in the absence of an e4 
allele (10/66 dementia PR 0.44, 95% CI 0.26-0.74; AD PR 0.85, 95% CI 0.52-1.37), 
increasing the risk only in the presence of an e4 allele (10/66 PR 1.05; AD PR 1.84), and 
that the risk effect of APOE e4 was stronger at higher VLDL levels. For the 10/66 
dementia outcome, triglyceride was also inversely associated with dementia risk in the 
absence of an e4 allele (PR 0.80, 95% CI 0.65-0.99), and the risk effect of APOE e4 
increased with increasing triglyceride level.  There was also a borderline statistically 
significant interaction, in the same direction, for triglyceride x APOE for the AD 
outcome (p=0.06).  
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Table 9. Prevalence ratios (PR) and 95% Confidence Interval (CI) for the interactive 
effects of lipid profile  and APOE 4 genotype on dementia and Alzheimer’s disease 
(AD) risk controlling for age,  gender,  education and family history of dementia .  
 
 10/66 Dementia Alzheimer´s disease 
Model PR 95% CI p Value PR 95% CI p Value 
Total Cholesterol       
Total Cholesterol 
(per mmol/L) 
1.02 0.92 – 1.13 0.77 1.07  0.95 – 1.20 0.27 
Genotype (e4 vs no 
e4) 
4.45 1.56 –12.70 0.005 2.59 1.94 – 3.47 <0.001 
Interaction 0.89 0.74 – 1.08 0.24 0.96  0.75 – 1.23 0.75 
Triglyceride       
Triglyceride (per 
mmol/L) 
0.80 0.65– 0.99 0.05 0.95  0.80 – 1.13 0.59 
Genotype (e4 vs no 
e4) 
1.43 0.89 – 2.29 0.14 2.71 2.01 -  3.66  <0.001 
Interaction 1.40 1.07 – 1.81 0.01 1.34  1.00 – 1.83 0.06 
HDL subfraction       
HDL (per mmol/L) 
 
0.79 0.52 – 1.19 0.26 0.90  0.57 – 1.42  0.66 
Genotype (e4 vs no 
e4) 
2.62  1.11 – 6.20 0.03 2.55 1.79 – 3.64 <0.001 
 Interaction 0.94 0.46 – 0.93 0.87 0.65  0.28 – 1.62  0.35 
LDL subfraction       
LDL (per mmol/L) 
 
1.00 0.89 – 1.12 0.98 1.02 0.89 – 1.16 0.79 
Genotype (e4 vs no 
e4) 
3.36 1.54 – 7.32   0.002 2.52 2.01 – 3.66  <0.001 
 Interaction 0.91 0.74 – 1.12 0.64 0.94 0.71 – 1.25  0.66  
VLDL subfraction       
VLDL (per 
mmol/L) 
0.44  0.26 – 0.74 0.002 0.85  0.52 – 1.37  0.49 
Genotype (e4 vs no 
e4) 
1.39 0.83 – 2.33 <0.001 2.55 1.80 – 3.62 <0.001 
 Interaction 2.39 1.19 – 4.77 0.01 2.16  1.00 – 4.65  0.05 
 
HDL = high-density lipoprotein. 
LDL =low-density lipoprotein 
VLDL= very  low-density lipoprotein  
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3.2.5  The impact of dementia 
 
In order to assess the impact of dementia compared to that of other chronic disorders, I 
first compared the distribution of three key indicators of impact; needs of care, 
caregivers reporting cutting back on work to care and caregiver strain between those 
with 10/66 dementia, those with physical impairments but no dementia, and others (i.e. 
free of both dementia and physical impairments) (Table 10).  Those with 10/66 dementia 
diagnosis were more likely to need much care (45.2% of those with dementia, 2.3% of 
those with physical impairments but no dementia, and 0.8% of others needed much 
care), to have caregivers needing to cut back on work to care (19.0% of those with 
dementia, 1.4% of those with physical impairments but no dementia, and 0.4% of 
others), and to have clinically significant psychological morbidity (22.5% of those with 
dementia, 9.5% of those with physical impairments but no dementia, and 7.5% of 
others). I next estimated the independent effects of major chronic health conditions 
(10/66 dementia, major depression, number of physical impairments and stroke) upon 
each of the indicators of impact controlling for participant age and gender, and 
household assets.  Those with 10/66 dementia were 17.8 times more likely to need much 
care, while their caregivers were 13.4 times more likely to have cut back on work to care 
and 2.1 times more likely to have clinically significant psychological morbidity 
compared to people without dementia.  
 
The independent effect of dementia on each of these three outcomes was much higher 
than those of the other chronic conditions (stroke, depression and other physical 
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impairments. For needing much care the population attributable prevalence fractions 
were; dementia 64.6%, depression 1.5% and physical health conditions 23.1%. For 
cutting back work to care; dementia 57.3%, depression 2.3% and physical health 
conditions 17.5%. For caregiver psychological morbidity; dementia 10.6%, depression 
1.2% and physical health conditions 8.6%.  
 
The severity of behavioural and psychological symptoms (assessed on all participants) 
was independently associated with each of the three outcomes. I conducted a formal test 
(Sobel-Goodman mediation test) to test formally for the presence and extent of mediator 
effect through the severity of behavioral and psychological symptoms. The mediation by 
BPS was most prominent for the effect of dementia on caregiver psychological 
morbidity (45.9% of the effect mediated through BPS, p<0.0001). The proportion of the 
effect of dementia on needing much care mediated through BPS was 8.4% (p<0.001). 
Mediation of the effect of dementia on caregiver cutting back on work to care was 
minimal and not statistically significant (p=0.68).  
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Table 10 Associations (prevalence ratios from Poisson regression models) between 
health conditions and three indicators of impact 
 
Needing much care  
( MV=348 ) 




























































































































- 1.08  
(1.06-1.11) 
1. mutually adjusted for all health conditions, for participant age and gender and household assets 
2. mutually adjusted for all health conditions, for participant age and gender, household assets, carer age, 
carer marital status, carer gender and carer/ informant coresidence (yes/ no) 
MV= missing value
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3.3  Incidence of Dementia  
 
3.3.1     Description of the incidence wave resource. 
 
 
One hundred and thirty one participants from one policlinic (‘Gonzalez Coro’) were not 
followed-up by design, owing to practical and logistical impediments. Therefore only 
2,813 participants out of the 2,944 interviewed in the baseline were included in the 
follow-up phase of the project. The general characteristics of the baseline sample, those 
successfully re-interviewed, those who died and those who were lost to follow-up is 
described in Section 4.1 (Table 1). In total, 2,517 of 2,813 participants interviewed at 
baseline and included in the follow-up phase were free of dementia and hence eligible 
for inclusion in the ‘at risk’ cohort at baseline. Of these, 449 (17.8%) were found to be 
deceased and 176 (7.0%) refused to participate or were not traced, and 1892 (75.2%) 
were successfully traced and re-interviewed at follow-up (Table 11). These participants 
contributed 8679 person years of follow-up, with an average follow-up period of 4.5 
years. The mean age at follow-up was 78.1, two-thirds were female and levels of 
education were relatively high, but 7.7% of participants reporting illiteracy. The 
occupational attainment was distributed in a similar proportion between professional, 











Table 11. Description of the  10/66 incidence wave data resource  
 
Baseline sample No (%) 
Total baseline sample (n) 2813 
Deceased 608 (21.6%) 
Refused  20 (0.7%) 
Not traced 178 (6.3%) 
Re-interviewed  2007 (71.3%) 
Dementia free cohort (n) 2517 
Deceased 449 (17.8%) 
Refused  17 (0.7%) 
Not traced/ uncontactable 159 (6.3%) 
Re-interviewed 1892 (75.2%) 
Characteristics of dementia-free cohort that were reinterviewed 
Person years of follow-up 8679 
Median follow-up in years (25th-75th centile)  4.5  (3.9-5.2) 
Mean age at follow-up (SD) 78.1 (6.1) 
Female sex (%) 1249 (66.0%) 
Did not complete primary education (%) 414 (21.9%) 
Median assets (25th-75th centile)    6 (5-6) 
Illiteracy (%) 146 (7.7%) 
Occupational attainment  
Professional (%) 581 (32.3%) 
Trade (%) 234 (13.0%) 
Semi-skilled (%) 547 (30.4%) 





3.3.2 The incidence of dementia 
 
There were 170 incident cases of 10/66 dementia and 77 meeting criteria for DSM-IV 
dementia. Just one incident case of DSM-IV dementia did not meet 10/66 dementia 
criteria. The crude annual incidence rate for 10/66 dementia was 20.5/1000 person years 
(95% confidence interval   17.6– 23.8) and that for DSM-IV dementia was 9.0 /1000 
(95% confidence interval 7.2– 11.3) (Table 12). Incidence tended to be higher in women 
21.9/1,000 person-years, (95% CI 18.2–26.2) than men (17.8, 95% CI 13.9–23.5) for 
10/66 dementia, but similar according to DSM-IV where incidence was slightly lower in 
women 9.1 (95 % CI 6.9-12.0) than in men 9.6 (95 % CI 6.6-14.0). Incidence of both 
dementia outcomes increased exponentially with increasing age.  For those aged 80 
years and over, annual incidence of 10/66 dementia was 46.7/1000 person years and that 




  Table 12.  Annual incidence rates (per 1000 person years) for DSM IV and 10/66 dementia criteria by sex and age.  
 
 
10/66 dementia DSM-IV dementia Age group Gender  
Cases/  
pyears 
Incidence  (95 % CI)* Cases/  
pyears 
Incidence (95 % CI)* 
Female     9/1803  5.0 (2.6 - 9.6)  5/1803  2.7 (1.2 - 6.6) 




Total  16/27  5.8 (3.6 - 9.6)  9/275  3.3 (1.7 - 6.3) 
Female  32/1599 20.0 (14.5 - 28.3) 14/1599  8.8 (5.1 - 14.8) 




Total  44/250  17.6 (13.1 - 23.6) 23/2558   9.0 (6.0 - 13.4) 
Female  32/1142 28.0 (19.8 - 39.6) 13/1142 11.4 (6.6 - 19.6) 
Male  15/577 26.0 (15.6 - 43.1)   8/577 13.8 (6.9 - 27.7) 
75-79 
n=405 
 Total  47/172 27.3 (20.5 - 36.4) 21/178  11.8 ( 7.7 - 18.1) 
Female  46/926 49.6 (37.2  - 66.3) 18/995 18.1 (11.4 - 28.7) 




Total  61/131 46.7 (36.4 - 60.1) 23/140 16.5 (10.9 - 24.8) 
Female 120/5484 21.9 (18.2 - 26.2) 50/5484  9.1 ( 6.9 - 12.0) 
Male   50/2807 17.8 (13.5 - 23.5) 27/2807  9.6 ( 6.6 - 14.0) 
All ages 
n= 1,886 




3.4  Cardiovascular and Genetic Risk Factors for Dementia 
 
I examined the strength of the association between age, sex, educational level, family 
history of dementia and APOE genotype and cardiovascular risk factors with the 
prevalence of 10/66 dementia using Poisson regression and with the incidence of 
dementia using Cox regression models (without and with accounting for the competing 
risk of death).   
 
3.4.1 Blood tests 
 
Fasting blood samples were obtained at baseline from 1 888 (75.0%) of the 2517 
dementia-free cohort, and from 1888 (99.7%) of the 1892 of the dementia-free cohort 
that was subsequently successfully re-interviewed. I tested again to see whether 
sociodemographic variables and major health conditions were differently distributed 
between those providing and not providing blood samples in the interviewed incident 
cohort . Prevalence of dementia was over-represented among those providing blood 
samples (p=0.01). Otherwise, there were no large or statistically significant differences 
between the two groups regarding age, gender, education, ethnicity, family history of 








Table 13.  Baseline characteristics, for the dementia incidence cohort, by availability of 
baseline fasting blood sample.  
Variables  Without blood 
sample 
N=336 (17.8%) 
With blood sample 
N= 1 552 (82.2%) 
P-value 
Age in years 
 (mean/ sd) 
73.8 (6.1) 73.4 (6.1) F=2.4, p=0.27 
Male sex (n/ %) 120 (35.7) 518 (33.4) X²=0, 674 1 df, 
p=0.4 








   3  (0.9) 
 78  (23.2) 
116 (34.5) 
 89 (26.5) 
50  (14.9) 
 
 





   3 
 









 57 (66.3) 
 11 (12.8) 
 18 (20.9) 
 86 
 
 1092 (72.1) 
  175 (11.6) 
  246 (16.3) 
    39 
 
 
X²=1.6, 2 df, 
p=0.455 
Dementia (n/ %) 19 (5.8) 151 (10.0) X²=5,72 1 df, 
p=0.01 
ICD depressive 
episode (n/ %) 
18 (5.4)  58 (3.7) X²=1,87 1 df, 
p=0.17 
Stroke (n/ %) 
Missing values 
16 (4.8)  75 (4.8) X²=0.003, 1 df, 
p=0.9 
Diabetes (n/ %) 
Missing values 
52 (15.5) 282 (18.2) X²=1.445, 1 df, 
p=0.229 
Hypertension (n/ %) 249 (74.1) 1143 (73.6) X²=0.03, 1 df, 
p=0.862 
Smoking (n/ %)  
Missing values 
160 (47.6)  693  (44.8) X²=0.9, 1 df, 
p=0.341 
Family history of 
dementia (n/ %) 
Missing values 






3.4.2 Prospective associations of sociodemographic, genetic and 
cardiovascular risk factors with incident dementia, with and without 
accounting for competing risk of dementia-free death, compared with those 
observed cross-sectionally in the baseline data. 
 
I conducted a series of analyses to estimate and compare the strength of associations 
between potential risk factors for dementia and both 10/66 and DSM-IV dementia 
a) cross-sectionally, with the full baseline data set, using Poisson regression working 
models to generate prevalence ratios 
b) prospectively, using the at risk cohort of those free of dementia at baseline, using 
Cox’s proportional hazards regression to generate hazard ratios (HR). Those who died 
between baseline and follow-up were censored at baseline. Hence 1852 participants 
were included in this analysis 
c) prospectively, using the at risk cohort of those free of dementia at baseline, using a 
competing risk proportional subhazards regression to generate sub hazard ratios (SHR), 
accounting for the competing risk of dementia-free death. With an additional 450 
dementia-free deaths, 2302 participants were included in this analysis 
Risk factors were tested individually, but all models were controlled for the effects of 
age, sex and education.  
 
Table 14 gives the prevalence ratio (PR), hazard ratio (HR) and competing  risk (SHR) 
estimates for sociodemographic factors (age, sex and education), familial and genetic 
factors (family history of dementia and APOE genotype), cardiovascular risk factors 
(smoking, hazardous alcohol use, hypertension, stroke, diabetes and lipid profiles), and 
other risk factors of interest from the cross-sectional analysis (skull circumference, leg 
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length and head injury with loss of consciousness). All analyses were controlled for age, 
sex, and education. 
 
As previously reported, there was a significant association of increasing age (PR=1.99; 
1.76-2.26), family history of dementia (PR=1.61; CI 95% 1.28-2.04), stroke (PR=2.32; 
CI 95% 1.81-2.99) with prevalence of 10/66 dementia. APOE e4 genotype (PR 2.53; CI 
95% 2.02-3.17), and hazardous  alcohol use before the age of 65 years (PR 1.69; 95% CI 
1.18-2.41) were also associated with an increased prevalence of 10/66 dementia. 
Education level (PR 0.80; CI 95% 0.72–0.89), hypertension (PR 0.73; CI 95% 0.59–
0.90), and skull circumference (PR 0.89; CI 95% 0.84–0.95)  were inversely associated. 
Patterns of association with incident 10/66 dementia were somewhat different. The 
effect of increasing age seemed somewhat attenuated, particularly when the competing 
risk of death was accounted for in the analysis. The effect of one or two APOE e4 alleles 
was also attenuated, and only statistically significant when the competing risk of 
dementia-free death was accounted for (SHR 1.57, 95% CI 1.05-2.37). The effect of 
stroke was also attenuated and not apparent when accounting for the competing risk of 
dementia-free death. The inverse associations with education, skull circumference and 
hypertension were not apparent with respect to incident 10/66 dementia. Smoking, 
diabetes, lipid profile, leg length and head injury were not associated with either 
prevalent or incident 10/66 dementia. 
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Table 14.  Prevalence ratio, Hazard ratio and subhazard ratio (competing risk) with 95% 
confidence intervals for associations between 10/66 dementia and sociodemographic, 
familial and genetic, and cardiovascular risk factors, adjusted for age, sex and education 
 
Exposures Prevalence Ratio  
(95% CI)    
(n = 2910) 
Hazard Ratio  
95% CI)  
(n= 1852) 
Competing risk - 
SHR (95% CI)        
(n = 2302) 
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I then conducted the same set of analyses, using prevalent or incident DSM IV dementia 
as the outcomes of interest (Table 15). Findings were very similar to those for 10/66 
dementia. Prevalent DSM-IV dementia was associated with older age, a family history 
of dementia (PR 1.79, 95% CI 1.32 – 2.42), APOE 4 genotype (PR 2.73, 95% CI 2.02–
3.69) and stroke (PR 2.50, 95% CI 95% 1.80–3.49), and inversely associated with 
education (PR 0.86, 95% CI 0.75-0.99), skull circumference (PR 0.89, 95% CI 0.82-
0.96) and hypertension (PR 0.69, 95% CI 0.52-0.91). The effect of age on incident 
DSM-IV dementia was less pronounced than that on prevalent DSM-IV dementia, 
particularly when competing mortality risk was accounted for. There was no association 
between APOE genotype, or stroke and incident DSM-IV dementia. There was no 
protective effect of education, skull circumference or hypertension. Smoking, alcohol 
use, diabetes, lipid profiles, leg length and head injury were not associated with either 









Table 15.  Prevalence ratio, Hazard ratio and subhazard ratio (competing risk) with 95% 
confidence intervals for associations between DSM-IVdementia  and sociodemographic, 
genetic and cardiovascular risk factors, adjusted for age, sex and education 
 
Exposures Prevalence Ratio  
(95% CI)    
(n = 2923) 
Hazard Ratio 
(95% CI)   
(n= 1852) 
Competing risk - 
SHR (95% CI)         
(n = 2302) 
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MV=308 
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1.14  (0.49-2.67) 
MV=12 
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3.4.3 Further explorations of the association of APOE genotype with incident 
dementia 
 
Given the much attenuated associations of APOE e4 with incident dementia, I decided to 
explore these associations further using the 10/66 dementia outcome. 
 
I first assessed in more detail the pattern of associations of APOE genotype with 
incident 10/66 dementia, using competing risks proportional subhazards regression, 
controlling for age, sex and education. There was no evidence for a dose response effect. 
Relative to those with no APOE e4 alleles the SHR for those with one was 1.61 (95% CI 
1.05-2.45), and the SHR for those with two e4 alleles was 1.24 (95% CI 0.29-5.30). 
There were, however, only 25 persons in the at risk cohort who were e4/e4, and 255 who 
had one e4 allele 
 
I  next explored the effect of age on the association of APOE genotype with incident 
10/66 dementia. Table 16 compares the incidence rates of 10/66 dementia according to 
age group and APOE status.  Incidence increases sharply with age for those with no 
APOE e4 allele, but much less steeply for those with one or two APOE e4 alleles. The 
effect of APOE genotype on dementia incidence appeared to be principally confined to 
the youngest age group. For participants aged 65–69 years with one or two APOE e4 
alleles, incidence rates for dementia were seven times higher than those participants 
without APOE allele. Among those aged 80 years and over, dementia incidence was 
actually lower among APOE e4 carriers than among non-carriers. The pattern is 
illustrated graphically in Figure 5  
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The interaction of age with APOE genotype in the association with incident 10/66 
dementia was confirmed in a model testing for the main effect of APOE genotype (any 
e4 allele vs. none), the main effect of age (linear effect per five year increment), and the 
interaction between the two, controlling also for sex and educational level. The 
interaction term was statistically significant (SHR 0.71, 95% CI 0.53-0.96), indicating a 
substantial progressive reduction in the effect of APOE e4 with increasing age, from that 
estimated for the baseline age group (SHR 3.99, 95% CI 1.71-9.31). Likewise, the 
estimated effect of age for those lacking an APOE e4 allele (SHR 1.47, 95% CI 1.31-










Age group Any APOE 4 allele  Without APOE4 allele 
65 – 69  25.1 (13.1 – 48.5)   3.5 ( 1.6  –  7.3) 
70 – 74 20.3 ( 9.7 – 42.6) 18.3 (13.1 – 25.5) 
75 – 79 34.6 (16.5 – 72.6) 27.0 (19.5 – 37.5) 
80 or more 42.1 (18.9 – 93.8) 53.3 (40.6 – 70.0) 
Whole sample 27.7 (19.2 – 39.8) 21.1 (17.7 – 25.0) 
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Figure 5. Age and the incidence of dementia for persons with Apolipoprotein E4 















The clear implication of this pattern of incidence with age, is that the age of onset of 
incident 10/66 dementia cases is younger among those with one or more APOE e4 
alleles, compared with those lacking an e4 allele. Histograms illustrating the distribution 
of ages of onset are provided in Figure 6 below. 
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Figure 6 
Frequency histograms (%) showing the distribution of age of onset of 10/66 dementia 
for those with and without APOE e4 alleles 
 










no e4 allele any e4 a llele
70.00 80.00 90.00 100.00
age_onset
  
The distribution is clearly strikingly different, with that for APOE e4 carriers skewed 
towards younger ages. The mean age of onset for those with an APOE e4 allele was 76.5 
years, and that for those with no e4 alleles is 81.0 years (mean difference 4.6 years, 95% 
CI 2.0 to 7.1 years, p=0.001).   
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Finally, given that discrepancies between associations of APOE genotype with prevalent 
and incident dementia might be accounted for by differential mortality, I conducted 
survival analyses (Cox’s proportional hazards analysis) to assess the effect of APOE 
genotype on mortality in the whole sample, and separately among those with and 
without 10/66 dementia at baseline. The crude effect of any APOE e4 allele vs. none 
was HR 1.03 (95% CI 0.83-1.31). After controlling for age, sex and education this 
increased slightly to 1.09 (95% CI 0.86-1.38). Controlling additionally for baseline 
10/66 dementia, the hazard ratio for APOE e4 was 0.94 (95% CI 0.74-1.20). I then 
extended this model to test for an APOE e4 by 10/66 dementia interaction, which was 
not statistically significant, although the trend was towards a greater mortality risk 
associated with APOE e4 for those with dementia (interaction term HR 1.34, 95% CI 
0.81-2.20).   
 
3.4.4 Cardiovascular risk factors, APOE genotype and incidence of 
dementia. 
 
Finally, I replicated the analyses previously conducted using cross-sectional data, to test 
the hypothesis of an interaction between APOE genotype and lipid profile, but 
examining associations with incident rather than prevalent  10/66 dementia. The 
analyses were conducted using proportional subhazards regression and were controlled 
for age, sex and education. I took the opportunity to extend the analyses to include tests 
for interaction between APOE genotype and other cardiovascular risk factors for which 
there have been previous  indications of possible effect modification - stroke, 
hypertension, smoking history and diabetes.  
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Results of these analyses are summarised in Table 17. None of the cardiovascular risk 
factor by APOE genotype interaction terms reached statistical significance. Neither was 
there any consistent pattern or trend in the interaction effects observed across 
cardiovascular risk factors. However, consistent with the cross-sectional analyses (p 
119) there was a trend for the effect of APOE e4 to increase with the levels of VLDL 
cholesterol and triglyceride, and for higher levels of these lipids to confer risk for 10/66 
dementia in the presence of an APOE e4 allele.  
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Table 17. Proportional subhazards regression (generating subhazard ratios and 95% 
confidence intervals) testing for the interaction between cardiovascular risk factors and 
APOE genotype for the incidence of 10/66 dementia, adjusted for age, sex and education 
 
Cardiovascular 





Effect of risk 
factor among 




APOE e4 at 










1990 1.11 (0.73-1.68) 1.25 (0.47-3.32) 1.33 (0.45-3.94) 
Smoking  
(ever vs. never|) 




1791 0.72 (0.47-1.12) 1.33 (0.79-2.24) 1.71 (0.66-4.43) 
Total cholesterol 
(per mmol/L) 
1754 1.01 (0.88-1.16) 0.77 (0.07-8.03) 1.12 (0.75-1.68) 
HDL cholesterol 
(per mmol/L) 




1440 0.69 (0.39-1.20) 0.77 (0.27-2.16) 2.37 (0.68-8.28) 
Triglyceride  
(per mmol/L) 




3.5  Ethnic Identity, Individual Admixture, Apoe Genotype and 
Dementia 
 
My objectives for this analysis were  
1. to analyse the association between ethnic group identity and individual admixture 
2. to assess the association of each with APOE genotype 
3. to control for the possible effects of population stratification, by estimating the 
association  of APOE genotype with dementia, controlling for ethnic identity and 
admixture. 
4. to test the hypotheses that 
a. the effect of APOE genotype on dementia is modified by ethnic group, and/ or 
admixture, with weaker associations among those with ‘mixed’ and ‘black’ ethnic 
identity and with higher proportions of African admixture 
b. the prevalence of dementia is lower among those with ‘mixed’ and ‘black’ ethnic 
identity, and is inversely linearly related to African admixture 
 
For the purposes of this component of my study, I used  
a) Data on participants’ ethnic identity rated by the research workers when blood 
samples were taken. Of the 2520 participants who had given blood samples, data on both 
ethnic identity and APOE genotype was available on 2329 (92.4%). 
b) Data on individual admixture estimated from 60 SNPs, informative regarding 
ancestry. Given the relatively high costs of genotyping 60 SNPs for each participant, I 
used a nested case control design, selecting all 235 participants with ‘any dementia’ 
(cases, 231 meeting criteria for 10/66 dementia, 137 meeting DSM-IV dementia criteria, 
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and 133 meeting both sets of criteria) and a random selection of 349 non-cases (controls, 
meeting neither set of dementia criteria). For all subsequent case-control analyses, 
sample weights were used to weight back for the inverse of the probability of selection 
between case and control groups, and within case and control groups by APOE 
genotype. For the cases the weights were APOE e2/e3 1.00; e2/e4 1.00; e3/e3 1.11; 
e3/e4 1.68; e4/e4 1.14. For the controls, these were APOE e2/e3 5.10; e2/e4 3.50; e3/e3 
8.16; e3/e4 4.54; e4/e4 2.15.  
 
Table 18 describes the general characteristics of those included in the case control study. 
Differences between the two groups mainly reflect those noted for the whole sample (see 
p 99). Cases were older, and more likely to belong to the two lowest educational levels 
(39.5%), than controls (18.0%). The prevalence of stroke was four times higher in cases 
than in controls. Ethnic identity was similarly distributed between cases and controls, as 




Table 18.  Characteristics of the case control study samples.  




Test for difference 
in means or 
proportions 
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  22 (10.5) 
  40 (19.1) 
  26 
 
216 (68.4) 
  40 (12.7) 
  60 (19.0) 










  0 
18 (5.1) 
 








 48 (20.7) 
 
  3 
17 (4.9) 
 





Diabetes (diagnosed or 
undiagnosed) (n/ %) 
Missing values 
 58 (25.1) 
 
  4 
90 (25.7) 
 







undiagnosed) (n/ %) 
164 (70.1) 
 
   1 
255 (72.9) 
 





Smoking (ever smoked)  




  2 
154 (44.0) 
 
   0 
χ2=0.6, 1df 
p=0.43 
Family history of 




  3 
59 (16.9) 
 







3.5.1 Ethnic identity and individual admixture  
 
As can be seen from table 19 according to interviewer perceptions, 1674 (72%) 
participants were considered to be ‘white’, while 395 (17%) were considered ‘black’ and 
260 (11%) ‘mixed’. There was no association between ethnic identity and either age or 
sex. However, there was a graded association between ethnic identity and level of 
education, with those considered ‘white’ having the highest and those considered ‘black’ 
having the least education. The distribution of Ethnic identity in the sample broadly 
corresponded to the individual admixture proportions aggregated across the case-control 
sample. For the case-control sub-sample (n=584) (after weighting back to account for 
the different sampling fractions for cases and control, and for APOE genotype within 
case and control groups), the mean individual admixture proportions were; European 
81.2% (79.1-83.3%), African 16.2% (14.1-18.3%), and Native American 2.6% (2.3-
3.0%). Stratification by ethnic identity (Box-plot in Figure 6) indicated a reassuringly 
strong association between ethnic identity and individual admixture proportions, but also 
significant discrepancies. All three groups were substantially admixed with considerable 
overlap between the three ethnic identities, pure African or European ancestry being the 
exception. The mean African admixture proportion for the three ethnic groups was 5.8% 
for ‘white’, 28.6% for ‘mixed’ and 49.6% for ‘black’. A small proportion of those 
defined as ‘white’ had marked African ancestry and most of those defined as ‘black’ had 




Table 19.  Distribution of sociodemographic characteristics by ethnic identity 










Age (mean/ SD) 75.0 (7.0) 75.7 (7.7) 74.7 (6.9) F=1.7, P=0.19 
Male sex (n/ %) 579 (34.6%) 95 (36.5%) 118 (29.9%) X²= 4.0, 2df, 
P=0.14 
Education level (n/ %)     
None 37 (2.2%) 7 (2.7%) 14 (3.6%) 
Some 344 (20.6%) 55 (21.2%) 112 (28.5%) 
Primary  543 (32.5%) 87 (33.5%) 148 (37.7%) 
Secondary 429 (25.7%) 62 (23.8%) 73 (18.6%) 
Tertiary 317 (19.0%) 49 (18.8%) 46 (11.7%) 
X²= 25.6,  
1 df, P<0.001 
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3.5.2 Ethnic identity and APOE genotype 
 
There was a strong statistically significant graded association between Ethnic identity 
and APOE genotype, with lower e3 frequency and higher e2 and e4 frequencies moving 
from ‘white’ to ‘mixed’ to ‘black’ groups (Table 20). According to Ethnic identity, 
24.6% of black participants, 14.6% of ‘mixed’ participants, and 15.0% of ‘white 
participants had at least one APOE e4 allele.   
 
 Table 20  Distribution of sociodemographic characteristics, APOE genotype and APOE 
allele frequency by ethnic identity 










APOE Genotype (n/ %)    
 
No e4 allele 1423 (85.0%) 222 (85.4%) 298 (75.4%) 
Heterozygous 
(One e4 allele) 
241 (14.4%) 32 (12.3%) 77 (19.5%) 
Homozygous 
(Two e4 alleles) 
10 (0.6%) 6 (2.3%) 20 (5.1%) 
X²= 31.4, 1 
df, P < 0.001 
APOE allele frequency     
E2 0.058 0.063 0.072 
E3 0.864 0.852 0.780 
E4 0.078 0.085 0.148 
X²= 42.6, 4 
df, P = <0.001 
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3.5.3 Admixture and APOE genotype 
 
In the case-control sub-sample, there were also graded associations (after weighting 
back) between individual admixture and APOE genotype, both with respect to the 
proportion of African ancestry (higher in those with more e4 alleles) and European 
ancestry (lower in those with more e4 alleles (Table 21). Native American ancestry was 
not significantly associated with APOE genotype.  
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4.63,  p= 0.01 
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4.99,  p=0.007 
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3.5.4 Does population stratification account for the association between 
APOE genotype and dementia? 
 
In the full sample, the prevalence of ‘any dementia’ was more than double in APOE 
carriers compared to that in non-carriers (adjusted PR=2.58, 95%CI 2.06-3.22). This 
adjusted prevalence ratio was little changed after adjusting also for ethnic identity (PR 
2.47, 95% CI 1.96 to 3.12). After weighting back, the association between any APOE e4 
allele and dementia, adjusted for age, sex and educational level was naturally similar in 
the case-control sub-sample, although estimated with less precision (PR 2.54, 95% CI 
1.85-3.47). This association was also essentially unchanged after further adjusting for 
individual admixture (PR 2.57, 95% CI 1.89-3.49).  
 
3.5.5 Is the effect of APOE genotype modified by ethnic identity/ admixture? 
 
Stratifying by ethnic identity in the full sample, the association between any APOE e4 
and dementia was similar in ‘white’ (PR 2.83, 95% CI 2.18-3.68) and ‘black’ 
participants (PR 2.38, 95% CI 1.43–3.95), with no association apparent among those 
rated as having ‘mixed’ race (PR 0.87, 95% CI 0.25–2.98). However, the likelihood ratio 
test for the interaction term was not statistically significant (X²=4.42, degrees of 
freedom=2, p=0.11). In a sensitivity analysis, after merging the ‘mixed’ and ‘black’ 
groups, the interaction between APOE e4 and ethnic identity showed a non-significant 
trend towards a weaker APOEe4 dementia association among non-whites compared with 
whites (PR 0.74, 95% CI 0.45-1.24). In the case-control subsample, extending the model 
to include an APOE by African ancestry interaction term suggested that the effect 
(prevalence ratio) of any APOE e4 allele would vary continuously from PR 2.93 (95% 
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CI 1.99-4.31) in those with 100% European ancestry to 1.52 in those with pure African 
ancestry. However, the interaction term again failed to reach statistical significance (PR 
0.52, 95% CI 0.13-2.08), p=0.36. 
3.5.6 The association between ethnic identity/ admixture and dementia 
 
There were no statistically significant effects of ethnic identity on dementia prevalence, 
either before or after adjusting for compositional differences (Table 22). The prevalence 
of dementia was slightly higher among ‘black’ participants and slightly lower among 
‘mixed’ participants when compared with ‘white participants, these tendencies being 
amplified after standardizing or adjusting for age, sex and education. After further 
standardizing or adjusting for the compositional differences in APOE genotype, 
dementia prevalence among both ‘black’ and ‘mixed’ groups was slightly lower than 
among those identified as ‘white’.  
 
In the case-control subsample the prevalence ratio for 100% African versus 100% 
European ancestry was PR 0.81 (95% CI 0.41-0.63). After fitting the APOE x African 
admixture interaction term, the effect of African ancestry was estimated as PR 1.01 
(95% CI 0.43-2.39) in those without an APOE e4 allele and 0.52 in those with an APOE 







Table 22.  Crude and adjusted dementia prevalence by ethnic identity, with prevalence 
ratios 














































































Finally, I assessed the joint, independent effects of admixture and ethnic identity upon 
prevalence of dementia (Table 23). The first model (Model 1) includes the main effects 
of APOE genotype and individual admixture. The second model estimates the main 
effects of APOE genotype and ethnic identity. The third model estimates the effects of 
admixture and ethnic identity, mutually adjusted, also controlling for APOE genotype. 
The fourth model extends the third model to control also for the effects of age, sex and 
education. When the effects of admixture and ethnic identity are considered together (3rd 
and 4th models) higher levels of African ancestry are associated with a higher prevalence 
of dementia (PR 4.62, 95% CI 1.48-14.5), whereas ‘black’(PR 0.50, 95% CI 0.25-1.00) 
and ‘mixed’ (PR 0.54, 95% CI 0.30-0.96) ethnic identity is associated with a lower 
prevalence of dementia than ‘white’. These effects are statistically significant in model 
3, but attenuate slightly, and are no longer statistically significant having adjusted, in 
model 4, for the effects of age, sex and education.   
 154 
Table 23 The independent effects of admixture and Ethnic identity upon dementia 
prevalence (weighted analysis) 
 Model 1 Model 2 Model 3 Model 4 
APOE genotype     








Admixture     









Ethnic identity     
‘White’ - 1 (ref) 1 (ref) 1 (ref) 














    
Age (years) - - - 1.10  
(1.07-1.12) 
Male sex - - - 0.84  
(0.59-1.21) 
Education (per level) - - - 0.76  
(0.64-0.90) 
 
Model 1 African admixture and APOE 
Model 2 Ethnic identity and APOE 
Model 3 African admixture, ethnic identity and APOE 









Figure 8 summarize patterns of association with prevalence and incidence dementia 
according 10/66 . With regard to the genetic contribution to disease risk, APOE e4 and 
family history of dementia were associated with both prevalent and incident risk. African 
admixture and  ethno racial identity were not associated with dementia when assesed 
separately. Non modifiers risk factors as increase age was asoociated with dementia . 
Education was a protective factors for dementia prevalence like factors related with 
early  neurodevelopment as skull circunference and leg length. As we previous mention 
our study weren´t suggest that vascular risk factors such as smoking, diabetes, 
hypertension and lipid profiles  play an important role as risk factors of dementia when 


























Figure 8.   Diagram summarising patterns of associations with prevalence and incident    
                  10/66 dementia. 
                                                                  Prevalence                    Incidence              
Genes                                                           
APOE e4                                                         ↑                                    ↑ 
Family history of   dementia                           ↑                                    ↑ 
Admixture                                                       ↔                                 ↔ 
                                                                     
Environmental 
Sociodemographics 
   Age                                                               ↑                                    ↑  
   Sex                                                               ↔                                  ↔                                                                  
   Education                                                      ↓                                   ↔                                                             
   Ethnic identity                                              ↔                                 ↔ 
   Anthropometry 
      -  Skull circumference                               ↓                                     ↓                                 
      -  Leg lenght                                               ↓                                   ↔                                                                       
   Vascular risk factors 
      Smoking                                                     ↔                                 ↔ 
      Alcohol                                                       ↑                                   ↔                                         
      Hypertension                                               ↓                                  ↔ 
      Stroke                                                          ↑                                   ↑ 
      Diabetes                                                      ↔                                 ↔ 
     Cholesterol                                                   ↔                                 ↔ 
     Tryglicerides                                                ↔                                 ↔ 
     HDL                                                             ↔                                 ↔ 
Head injury                                                      ↔                                 ↔                  
 
 ↑   Risk factor  
 ↓   Protective factor 
↔ No association  
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CHAPTER 4  DISCUSSION 
 
4.1  Summary of the Results 
 
This study corroborates that dementia is an important and growing health problem for  
Cuba. The overall prevalence of 10/66 dementia was 10.8% and that of DSM-IV 
dementia 6.4%. Whatever criterion we use  dementia is at least as common in Cuba as in 
developed countries.  
 
1. According to DSM-IV criteria, after standardisation for age and gender, dementia 
prevalence  in Cuba was similar to that in the European EURODEM meta-analysis and 
higher than that recorded in other 10/66 Latin American sites. However, an even higher 
prevalence had been reported in the previous Cuban EDAP survey (SMR 113, 95% CI 
108 – 117). The prevalence of 10/66 dementia in Cuba was similar to that reported for 
other 10/66 Latin American sites in Dominican Republic, Puerto Rico, Peru, and 
Mexico, and higher than that in Venezuela.   
 
2. Both DSM-IV and 10/66 dementia were associated with older age, less education, a 
family history of dementia, shorter leg length and smaller skull circumference,  
associations which are  unlikely to be explained by reverse causality.  
 
3. The prevalence of dementia was more than double in APOE carriers compared to that 
in non-carriers (adjusted PR=2.58, 95%CI 2.06-3.22). This effect was not mediated by 
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lipid profile or other cardiovascular risk factors, although stroke and diabetes were more 
prevalent  among APOE e4 carriers, and mean total cholesterol levels were higher.   
 
4. There was a particularly large and statistically significant interaction between APOE 
genotype and VLDL cholesterol subfraction for both 10/66 dementia (PR 2.39, p=0.01) 
and AD (PR 2.16, p=0.05) the effect in each case being that VLDL was inversely 
associated with dementia risk in the absence of an e4 allele (10/66 dementia PR 0.44, 
95% CI 0.26-0.74; AD PR 0.85, 95% CI 0.52-1.37), increasing the risk only in the 
presence of an e4 allele (10/66 PR 1.05; AD PR 1.84), and that the risk effect of APOE 
e4 was stronger at higher VLDL levels. For the 10/66 dementia outcome, triglyceride 
was also inversely associated with dementia risk in the absence of an e4 allele (PR 0.80, 
95% CI 0.65-0.99), and the risk effect of APOE e4 increased with increasing triglyceride 
level.  There was also a borderline statistically significant interaction, in the same 
direction, for triglyceride x APOE for the AD outcome (p=0.06).  
 
5. Dementia, rather than physical health conditions or depression, was the main 
contributor to needs for care, to the caregiver needing to give up work to care and to 
caregiver psychological strain. Those with 10/66 dementia were 17.8 times more likely 
to need much care, while their caregivers were 13.4 times more likely to have cut back 
on work to care and 2.1 times more likely to have clinically significant psychological 
morbidity compared to people without dementia. The severity of behavioural and 
psychological symptoms was independently associated with each of the three outcomes. 
The effect of dementia on caregiver psychological morbidity was substantially mediated 
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through BPS, much more so than the effects on needs for care or on the caregiver cutting 
back on work to care. 
 
6. The crude annual incidence of DSM-IV dementia was 9.0 /1000 person years while 
that of the 10/66 dementia was 20.5/1000 person years. Incidence was similar between 
men and women for DSM-IV dementia, but higher in women thamn men for 10/66 
dementia. Incidence of both outcomes increased exponentially with age.     
 
7. Patterns of association with incident 10/66 dementia were different to those with 
prevalent dementia. The effect of increasing age was attenuated, particularly when the 
competing risk of death was accounted for in the analysis. The effect of one or two 
APOE e4 alleles was also attenuated, and only statistically significant when the 
competing risk of dementia-free death was accounted for (SHR 1.57, 95% CI 1.05-2.37). 
The effect of stroke was also attenuated and not apparent when accounting for the 
competing risk of dementia-free death. The inverse associations with education, skull 
circumference and hypertension were not apparent with respect to incident 10/66 
dementia. Smoking, diabetes, lipid profile, leg length and head injury were not 
associated with either prevalent or incident 10/66 dementia. 
 
8. The effect of age on incident DSM-IV dementia was less pronounced than that on 
prevalent DSM-IV dementia, particularly when competing mortality risk was accounted 
for. There was no association between APOE genotype, or stroke and incident DSM-IV  
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dementia. There was no protective effect of education, skull circumference or 
hypertension. Smoking, alcohol use, diabetes, lipid profiles, leg length and head injury 
were not associated with either prevalent or incident DSM-IV dementia.  
  
9. There was no dose response effect in the association of APOE genotype with incident 
10/66 dementia . However, there were only 25 persons in the at risk cohort who were 
e4/e4, and 255 who had one e4 allele. 
 
10. There was a strong and statistically significant interaction (SHR 0.71, 95% CI 0.53-
0.96) between age and APOE genotype in the effect on dementia incidence, which was 
confined to those in the youngest age group (65–69 years)than among non-carriers. 
Further analyses confirmed an earlier age of onset for incident dementia among those 
with one or more APOE e4 alleles, compared with those lacking an e4 allele. 
 
11. There was no evidence for a prevalence bias to account for the discrepancy between 
associations with prevalent and incident dementia. APOE genotype was not associated 
with mortality overall, and there was no significant interaction between dementia and 
APOE genotype in the association with mortality, although the trend was towards a 
greater mortality risk associated with APOE e4 for those with dementia (interaction term 
HR 1.34, 95% CI 0.81-2.20). 
 
12. There were no statistically significant interactions between APOE genotype and 
either stroke, hypertension, smoking, diabetes or lipid profile and the incidence of 10/66 
dementia. However, consistent with the cross-sectional analyses there was a trend for the 
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effect of APOE e4 to increase with the levels of VLDL cholesterol and triglyceride, and 
for higher levels of these lipids to confer risk for 10/66 dementia in the presence of an 
APOE e4 allele.   
 
13. Both ethnic group, and African admixture were associated with  APOE genotype 
with e4 frequency being higher in those viewed as ‘black’ and in those with a higher 
proportion of African admixture.  
 
14. One or more APOE e4 alleles was associated with dementia in ‘white’ and ‘black’ 
but not ‘mixed’ groups but neither this, nor the interaction between APOE e4 and 
African admixture (PR 0.52, 95% CI 0.13-2.08) were statistically significant.  
 
15. Neither ethno-racial identity nor African admixture was associated with dementia 
prevalence when assessed separately. However, considering their joint effects African 
versus European admixture was independently associated with a higher prevalence, and 
‘mixed’ or ‘black’ identity with a lower prevalence of dementia. 
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4.2  Strengths And Limitations 
 
The major strength of our study is the standardised design and assessment procedures, in 
a large representative catchment area sample, with high a response rate: 97.6 % in the 
cross sectional study and 75.8% in the incidence phase.  
 
The whole catchment area sampling strategy enabled us to foster links within the 
communities studied, improving response and facilitating later follow-up. A weakeness 
of the catchment area sampling strategy is that prevalence and incidence estimates may 
not be safely generalised beyond these and similar communities, but this is unlikely to 
lead to bias in estimates of association.  
 
The one phase dementia diagnostic assessment has some advantages over the two phase 
approach used in most previous dementia cohort studies (Prince, 2003). We were also 
able to gather detailed information on mental health diagnoses, physical health, risk 
exposures and care arrangements on all participants, permitting us to study the 
independent impact of dementia, relative to that of other health conditions, on outcomes 
relevant to public policy. This has been a neglected research topic. The two and a half 
hour assessments were well tolerated, as indicated by the high levels of participation in 
both baseline and follow up interviews.  
 
The diagnosis of dementia was made according to a protocol developed by the 10/66 
group using a computerized algorithm The 10/66 dementia algorithm has been carefully 
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validated in 26 low and middle income country centres (Prince et al., 2003), including 
Cuba. While sensitivity (94%) and specificity (97% in high education controls and 94% 
in low education controls) were both excellent against the gold standard of a local 
clinician’s DSM-IV diagnosis, the false positive rate, which varied between 1% and 
10% across regions and levels of education can be expected to result in a higher 
prevalence of 10/66 dementia. Conversely, the DSM-IV criterion, with its stringent 
requirement for multiple domains of cognitive function to be affected with clear 
evidence for social and occupational impairment, may be insensitive to mild yet 
clinically relevant cases (Erkinjuntti et al., 1997). In a recent publication (Prince et al., 
2008) we have shown that 10/66 dementia corresponded more closely to Cuban clinical 
dementia diagnoses than did the more restrictive DSM-IV criterion. Predictive validity 
of the two diagnoses were determined three years later at the baseline in Chennai, India; 
10/66 Dementia cases had experienced twice the mortality of those with cognitive 
impairment but no dementia (CIND), and the overwhelming majority of those that 
survived showed clear evidence of progression in cognitive impairment, disability and 
needs for care (Jotheeswaran AT et al., 2010 ). The main weakness with respect to 
ascertainment of the outcome was that dementia subtype diagnoses are not yet available 
for the incident cases of dementia that we identified in the survey. A computerized 
algorithm has been developed for the baseline data collection, but this has not yet been 
published or validated, and requires adaptation before being applied to the incidence 
wave data. Accordingly, for the prevalence wave data I used the subtype determinations 
made by the Cuban interviewers (all experienced dementia diagnosticians) having 
completed the baseline interview. The impact of this on the associations observed is 
somewhat uncertain. It is likely that associations with APOE genotype would have been 
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more pronounced for AD subtype than for all dementia subtypes combined, given 
generally weaker associations observed with vascular and mixed dementia (Verghese P 
et al., 2011). Studies of environmental risk factors (particularly cardiovascular risk 
factors and cardiovascular disease) generally show quite similar effect sizes for both AD 
and dementia; almost by definition, cardiovascular risk factors are likely also to be risk 
factors for vascular dementia.   
 
Loss to follow-up is the main potential source of bias in cohort studies. If a large 
proportion of participants are lost to follow-up due to non-response, refusal to participate 
and withdrawals, and particularly if losses are different between comparison groups, the 
result may be biased. In our study, a high proportion of the cohort could be traced 
sucessfully, and bias from loss to follow-up is likely to be small.  
 
Selection bias may arise from using only people who live at home, that is, our study did 
not including institutionalised older people, but this is unlikely to affect the prevalence 
estimate in Cuba as less than 1% of older people live in institutionalised facilities. In the 
catchment areas studied there was only one institution for older people from all Havana. 
  
Information bias may also have occurred, since the interviewers for the 10/66 surveys 
were psychiatrists, geriatricians and physicians carrying out clinical work in the same 
catchment areas where the research project was conducted. Therefore, while the 
interview was for the most part fully structured, interviewer codings could have been 
based upon prior knowledge of diagnoses or other previous clinical impressions. 
However, while we did not collect data systematically, it seemed that only a minority of 
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those identified with dementia were previously known to services, and very few 
participants had previously consulted with the clinicians carrying out the interview.  
 
There has been much interest in the potential role of African ancestry in modifying the 
effect of the APOE genotype and influencing risk for AD and other dementia (Hendrie 
et al., 2004). The highly admixed character of the Cuban population provided us with an 
ideal opportunity to study this possibility within, rather than between populations. We 
believe ours to have been the first study to have addressed this issue directly, through 
estimation of individual admixture, rather than relying merely on observations of ethnic 
type. The main weakness of the admixture study was that of the sample size. The  high 
cost of admixture genotyping across 60 SNPs meant that we could only perform this on 
all dementia cases and a random sample of controls in the cross-sectional prevalence 
phase of the study. Hence the study may have been underpowered to detect or exclude 
potentially important APOE genotype by admixture interaction effects..  
 
I am not able to attribute causality from the observed associations between health 
cardiovascular risk factors and dementia. As lipids levels and other cardiovascular risk 
factors were determined during the cross-sectional study, in late-life and close in time to 
the clinical onset of dementia, temporality can not be established and the lack of 
association might have been explained by reverse causality. For example hypotension 
and weight loss  can be a consequence as a cause of dementia.  
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4.3  Contextualization with Previous Research 
4.3.1    Prevalence of dementia in Cuba 
The prevalence of DSM-IV dementia in our study was similar to that previously reported 
in Europe. In the current sample we demonstrated that the DSM-IV criterion missed 
many of the CDR mild dementia cases (Prince et al., 2008). The current study adds to 
the evidence that the prevalence of DSM-IV dementia in Latin American settings is at 
least as high as that seen in high income countries in Europe and North America. The 
one caveat is that most Latin American studies published to date, including our own, 
have sampled from urban rather than rural settings and from countries with relatively 
low child and adult mortality.  
 
The age-specific prevalence of 10/66 dementia in Cuba was consistently higher than that 
of DSM-IV dementia, raising the possibility that use of the DSM-IV criterion may 
underestimate the prevalence of clinically significant dementia. DSM-IV dementia 
criterion underestimates the true prevalence of dementia in developing countries, 
because of difficulties in defining and ascertaining decline in intellectual function and 
occupational impairment. We have attributed this discrepancy to an under-reporting of 
cognitive decline and social/occupational impairment by relatives: our data suggest that 
this underestimation might be attributable to cultural effects on informant reports of 
intellectual decline and social or occupational impairment, specifically a much weaker 
correlation between objective evidence of memory impairment and informant reports in 
rural and least developed settings (Llibre Rodriguez et al., 2008b). 
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According to the DSM-IV criteria, age- and gender-standardised dementia prevalence 
was higher than that reported for other 10/66 sites in Latin America (Llibre Rodriguez et 
al., 2008b), although somewhat lower than that reported in a previous EDAP study in 
Cuba  (Nitrini et al., 2009). As the Cuban population is characterised by a relatively high 
degree of African admixture, and our hypothesis was that high African admixture 
protects against dementia, how can we explain the high prevalence showed by our data? 
One plausible explanation is the advanced stage of the epidemiological transition in 
Cuba, where, along with increased life expectancy, fat-rich diets, smoking and physical 
inactivity have become more common and reach all sectors of the population. In terms 
of physical activity, while just 33% of Cubans were sedentary in 1995, this figure 
increases to 43% in 2001 and 45% in 2010. The overweight trend has increased in the 
general population aged 15 years and older from 32% in 1995, to 45% in 2010; the 
prevalence of hypertension in the same age group is also high  30.9% in 2010 (Reed G 
and Bonet  M, 2011). 
 
A particularly high prevalence of vascular risk factors and of chronic non-communicable 
diseases were found in our study populations in Havana and Matanzas (Llibre  J 2011) 
hypertension 73.0% , diabetes mellitus 24.8% , ischemic heart disease 14.1%  and stroke 
7.8%. The majority of participants (85%) had more than one cardiovascular risk factor. 
One fifth of those surveyed were current smokers, and 7.5% were classified as high-risk 
drinkers before age 65 and 3.6% were still in this category. A cohort effect may have 
been in operation with respect to Cubans with an African background were born 65 or 
more years ago, many of whom would have lived in early life and early middle age  in 
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conditions of poverty, with poor access to health services, lower education and 
occupation attainment as a result of disadvantage and discrimination.  
 
4.3.2 Incidence of dementia in Cuba 
We managed to successfully trace and re-interview 1,892 (75.2%)  people out of  2,571 
older people free of dementia at baseline, and indentified  171 incident cases of dementia 
with a total of 8,679 person years of follow-up Incidence rates provide the information 
to predict future case-loads, and for this reason are crucial in planning health services for 
people with dementia and their families, particularly initiatives to promote early 
diagnosis and treatment (Alzheimer’s Disease International, 2011). Few incidence 
studies have been conducted in low and middle income countries, and the current study 
is the first longitudinal study  of dementia to be carried out in Cuba and one of the very 
first in Latin America. Our study is also the largest yet conducted in a low or middle 
income country; in Ballabgarh, India nine incident cases were identified with 1,160 
person years of follow-up (Chandra et al., 2001); in Cantanduva, Brazil, 50 incident 
cases and 3,623 person years of follow-up (Nitrini et al., 2004) . In Ibadan, Nigeria 
(2,459 at risk and 70 incident cases (Hendrie et al., 2001) and Beijing, China (825 at risk 
and 13 incident cases (Li et al., 1991)  person years of follow-up were not clearly 
specified.   
 
The crude annual incidence rate for 10/66 dementia was 20.5 /1000 person year, very 
similar to that found in the Canadian Health and Aging Study (The Canadian Study of 
Health and Aging Working Group, 2000), and slightly higher than that reported in the 
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MRC Cognitive Function and Ageing Study (MRC CFAS) in England (Matthews F et 
al., 2005). Nevertheless according to DSM-IV criteria our estimates were 9.0/ 1000 
person year, roughly the half the rates observed in the Canadian and English studies, 
both of which used DSM-IV criteria.  However, to estimate the incidence of DSM-IV 
dementia, we excluded all those with ‘any dementia’, that is either DSM-IV dementia or 
10/66 dementia from the baseline ‘at risk’ cohort. This decision is justifiable on the 
grounds that there is considerable accumulated evidence for the validity of the 10/66 
dementia diagnostic criterion. However, for the purposes of comparison with other 
studies, it might be appropriate to consider meeting criteria for 10/66 dementia, but not 
for DSM-IV dementia as still ‘at risk’ for the latter outcome. In the Cuban sample the 
annual incidence rate for DSM-IV dementia among those in this group was 154.6 per 
1000 person years (95% CI 103.9-221.8). After including this group in the ‘at risk’ 
cohort, the overall incidence rate for DSM-IV dementia increased from 9.0 to 12.0 per 
1000 person years (95% CI 9.8-14.4)  
 
 
4.3.3  Risk factors for dementia 
When analyzing the prevalence phase data, we limited ourselves initially mainly to the 
study of associations with those potential risk factors for dementia that might, arguably, 
be less affected by reverse causality and information bias; educational level, and early 
developmental factors – skull circumference, leg length and handedness (Llibre 
Rodriguez et al., 2008a). The main cross-sectional correlates of dementia (older age, 
lower education and family history of dementia) were generally similar to those 
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previously and widely reported. We confirm previous reports of shorter leg length (Kim 
et al., 2003, Mak et al., 2006), and smaller skull circumferences (Schofield et al., 1997, 
Mortimer et al., 2003) among those with dementia. Interestingly both of these exposures 
were inversely linearly associated with age suggesting the presence of cohort effects; 
older people, from earlier birth cohorts, having poorer nutrition and hence having 
developed less successfully in early life. Adjusting for age, which diminishes the 
strength of both associations, may be inappropriate. We did not replicate previous 
reports of associations between handedness (Seltzer et al., 1984, de Leon et al., 1986, Li 
et al., 1992, Raiha et al., 1998) and dementia. We also found no evidence to support 
associations with a past history of head injury (Mortimer et al., 1991, Jellinger, 2004, 
Devanand et al., 1996) or a past history of depression (Jorm et al., 1991, Devanand et al., 
1996) and dementia. Data on these exposures was collected from participants, or from 
their relatives if they were considered to give more reliable information. While recall 
bias is often thought to lead to an overestimation of such associations because of ‘effort 
after meaning’, lack of an association might conceivably be explained by random or 
systematic misclassification because of poor recall by those with dementia or their 
relatives.   
 
For the incidence phase of the study, I broadened the scope of the analysis of potential 
risk factors, to include, particularly cardiovascular risk factors (smoking, hazardous 
alcohol use, hypertension, diabetes and lipid profile. Since all of these potential risk 
factors for dementia are also likely to be risk factors for dementia-free death, I 
conducted two sets of Cox’s proportional hazards regression analyses, one with, and one 
without taking into account this competing risk. As a methodological exercise, I also 
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estimated the cross-sectional associations between these risk factors and prevalent 
dementia, in an attempt to understand better the potential impact of information bias and 
reverse causality on the estimation of these effects using cross-sectional data. In general, 
I found no evidence to reject the null hypothesis of no association between 
cardiovascular risk factors and incident dementia. Stroke, alone, was significantly 
associated with the onset of 10/66 but not DSM-IV dementia; however, this association 
attenuated and was no longer statistically significant after accounting for the competing 
risk of dementia-free death. Smoking, diabetes and lipid profile were associated neither 
with prevalent nor incident dementia. Hypertension was inversely associated with 
prevalent dementia, but appeared to have no effect on incident dementia. A history of 
hazardous alcohol use before the age of 65 was associated cross-sectionally with 10/66 
but not DSM-IV dementia. There were strong non-statistically significant trends towards 
an association with both incident 10/66 and DSM-IV dementia. This was a low 
frequency exposure, and the study was probably underpowered to detect a true 
association. The inverse associations with education seen in the cross-sectional analyses 
were not supported for incident dementia in Cuba; the effect sizes being attenuated and 
no longer statistically significant. The same pattern was seen for the cross-sectional 
inverse associations with leg length and skull circumference, with non-significant trends 
towards positive associations with incident dementia.  
 
The absence of observed associations between cardiovascular risk factors and incident 
dementia may not be surprising given that exposures were measured in late-life, and the 
relatively short follow-up period (a median of 4.1 years). A recent meta-analysis of 
cohort studies of the effect of hypertension on incident AD found a trend towards an 
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inverse association with late-life hypertension but a suggestion of a positive association 
with mid-life hypertension (Power MC et al., 2011 ). This pattern was clearly 
demonstrated in the Goteborg study, where those who went on to develop dementia in 
late-life had relatively elevated blood pressure levels up to 15 years previously, which 
then declined to levels below those of the dementia-free participants by the time of 
dementia onset (Skoog et al., 1996). 
 
A similar process may explain the lack of associations observed between lipid profile 
(total cholesterol and cholesterol subfractions, and triglyceride) and dementia in my 
study. A recent meta-analysis identified 18 prospective studies of the association 
between total cholesterol and the incidence of either dementia or cognitive decline. 
Follow-up periods ranged between 3 and 29 years (Anstey KJ et al., 2008). There was 
no evidence for any association between late-life cholesterol and either outcome, but 
there was robust and consistent evidence for associations between mid-life 
hypercholesterolaemia and incident AD, incident dementia and cognitive impairment.  
The association observed in some long-term prospective studies between decline in 
cholesterol and incident cognitive impairment (Solomon A et al., 2007) and dementia 
(Stewart R et al., 2007, Mielke M.M et al., 2010) suggests that cholesterol begins to 
decline years before the onset of dementia, possibly as a result of ongoing AD pathology 
(i.e. reverse causality (see also section 1.4.1.5 for further details). Another possible 
explanation for the failure to detect any association between cholesterol, triglyceride and 
dementia, may be that the effect of these lipids is significantly modified by APOE 
genotype. We examined this possibility using cross-sectional data – these analyses are 
discussed later in this section. 
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The absence of associations with reported smoking behaviour is perhaps more surprising 
since risk associations have previously been noted in short latency (Ott et al., 1998b, 
Juan et al., 2004, Luchsinger et al., 2005) as well as long latency studies (Tyas et al., 
2003, Whitmer et al., 2005 ).  The 10/66 Dementia Research Group has also reported an 
increased risk of AD as well as all forms of dementia, from prevalence data, when the 
smoking exposure was pack years consumption before the age of 50 ( Ferri et al.,2011). 
Earlier findings of an inverse association with smoking from case-control studies using 
prevalent cases and cross-sectional studies have been attributed to prevalence/ incidence 
bias (Neyman’s bias) due to a failure to take account of the effect of the risk exposure on 
mortality (Hill et al., 2003). However, it should be noted that there are other examples in 
the literature of a failure to replicate findings of an association between smoking and 
incident dementia (Yip et al., 2006).   
 
Hazardous alcohol user before the age of 65 was associated with dementia in the cross 
sectional study (PR= 1.69; 95% CI 1.18-2.41), but  not in the longitudinal phase. There 
are controversial findings in the literature, which some studies advocating its protective  
effects (Letenneur L et al., 2004, Peters R et al., 2008) and others its potential risk 
effects (Anttila et al., 2004).  
 
There have been reports from cohort studies of short latency associations between 
diabetes and the onset of dementia. For example in the Rotterdam study, with an average 
follow-up of only 2.1 years diabetes was found to almost double the risk of both 
dementia (RR 1.9, 95% CI 1.3-2.8) and AD (RR 1.9, 95% CI 1.2-3.1). However, more 
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recent meta-analyses suggest much more modest risk associations; pooled RRs of 1.47 
(95% CI 1.25–1.73) (Lu FP et al., 2009) and 1.54 (95% CI 1.33–1.79) (Profenno LA et 
al., 2010); with the majority  of individual studies not showing statistical significance. It 
is therefore possible that my study was underpowered to detect a relatively small true 
increase in risk for incident dementia, despite the relatively high prevalence of diabetes 
in the the ‘at risk’ cohort. There is also a suggestion from at least one study that the 
effect of diabetes on dementia risk may be extensively modified by APOE genotype, 
indeed only apparent among those with low dementia risk, lacking any APOE e4 alleles 
(Akomolafe A et al., 2006). I also examined this possibility (see later section of 
discussion). 
 
 Educational level was inversely associated with the prevalence of dementia  (PR 0.80; 
CI 95% 0.72–0.89). Neverthless, the inverse associations with education were not 
apparent with respect to incident 10/66 dementia HR 0.93 (0.81–1.08). Longitudinal 
studies have shown that  lower educational attainment is associated   with an increased 
risk of dementia in late life (Letenneur L et al., 1999, Stern et al., 1994, Evans et al., 
2003); although this finding has not been replicated in all studies (Cobb JL et al., 1995). 
Education in early life is related  to higher socioeconomic status, nutrition, and IQ, and 
influences risk factors in later life such as occupation, physical health, and health habits 
all of which may protect against the development of brain disease and consequent 
dementia, particularly vascular brain disease (Del Ser T et al., 1999). Finally  education  
increases cognitive reserve by offering long-term potentiation-induced neuroprotection 
(Addae JI et al., 2003). 
 
 175 
I did not analyze the effect of occupational attainment on 10/66 Dementia incidence.  A 
recent review identified nine out of 12 studies in high income countries  demonstrating a 
statistically significant protective effect, with a pooled OR for incident dementia for 
those with high compared with low occupational attainment of 0.56 (95% CI 0.49–0.65) 
(Valenzuela MJ and Sachdev P, 2006).  
 
4.3.4    Genetic epidemiology – analyses of  the main effect of APOE genotype 
on dementia risk, and its role as an effect modifier 
 
I found a strong association between APOE genotype and the prevalence of both 10/66 
and DSM-IV dementia, and the prevalence of AD, with effect sizes very similar to those 
reported in other settings (Farrer et al., 1997, Bertram et al., 2007). In our Cuban sample 
the risk of dementia and AD conferred by APOE e4 was also similar to that association 
reported in Maracaibo, Venezuela (Molero A et al., 2001). There have been two reports 
of studies of the association of APOE genotype with dementia among Hispanics from 
the Caribbean region living in the USA. Our findings are consistent with the report of a 
strong association among Cuban Americans living in Miami (Sevush S. et al., 2000), but 
did not concur with the absence of an association reported among Caribbean Hispanics 
living in north Manhattan  (Tang et al., 1998). As others have found (Prince M, 2000) 
the effect did not appear to be mediated by cardiovascular risk or cardiovascular disease, 
although I did find higher levels of total cholesterol, and a higher prevalence of stroke 
and diabetes among APOE e4 carriers compared with non-carriers.  
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However, the association between APOE genotype and incident dementia was, in 
comparison, much attenuated. There was only borderline statistical significance for the 
association with incident 10/66 dementia; HR 1.48 (95% CI 0.98-2.24) without and 1.57 
(95% 1.05-2.37) with accounting for competing risk of dementia-free death. For incident 
DSM-IV dementia no association was observed; HR 1.04 (95% CI 0.53-2.03) without 
and 1.09 (95%  CI 0.56 -2.11) with accounting for competing risk of dementia-free 
death. 
 
The  reason for this much reduced strength of association with incident as opposed to 
prevalent dementia is not immediately clear, and may be complex. One possible 
explanation, that APOE e4 prolongs survival with dementia rather than increasing its 
incidence seems unlikely given the weak effect of APOE genotype on overall survival, 
and the absence of an interaction between dementia status and APOE genotype as risk 
factors for mortality (see page 141). A likelier explanation is suggested by the strong 
interaction observed between age and APOE genotype in risk for onset of 10/66 
dementia, the increased risk conferred by the APOE e4 allele seeming to be confined to 
those in the younger-old age groups (see also section 4.4.3). A further analysis revealed 
that there was a very strong effect of APOE genotype on age of onset with those having 
an APOE e4 allele having a mean age of onset 4.6 years earlier than those lacking an 
APOE e4 allele who went on to develop dementia (see figure 6, p 139).  Both the 
concentration of risk among the younger-old, and the younger age of onset among 
APOE e4 carriers were noted 15 years ago in clinical samples by members of the NIMH 
genetics initiative (Blacker D et al., 1997). A similar phenomenon was illustrated in the 
US Cache County study, where APOE genotype was found to influence age of onset, but 
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not lifetime (up to 100 years) cumulative risk of dementia which was similar (72%) for 
those with and without APOE e4 alleles (Khachaturian AS et al., 2004). It may be that 
our prevalence study had already captured much of the (earlier) cumulative incidence in 
those who had their risk for early incidence raised through carriage of one or more 
APOE e4 alleles. When these individuals were eliminated from the ‘at risk’ group for 
the cohort study, it would therefore be predicted that the association, in the remaining 
cohort, with incident dementia, would be less prominent. Set against this, while there 
have been very few previous population-based studies of the effect of APOE genotype 
on the incidence of dementia, findings from the UK MRC-CFAS study do indicate a 
robust and sizeable increased relative risk (Yip AG et al., 2002). Of note, in that study, 
the size of the effect of APOE genotype increased with longer-term follow-up, up to 10 
years from baseline; at that point, relative to those with APOE e3/e3 genotype, those 
with e3/e4 had a RR of 2.3 (95% CI 1.5–3.6) and those with e4/e4 a RR of 5.0 (95% CI 






4.3.5 Interaction between genetic admixture, ethnic identity, APOE genotype 
and dementia prevalence in an admixed Cuban sample; a cross-sectional 
population survey and nested case-control.  
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In the catchment area samples of older Cubans in Havana and Matanzas cities, ‘’white’, 
mixed’ and ‘black’ ethno-racial groups were all substantially admixed, with varying 
proportions of African and European ancestry. There was a strong and statistically 
significant association between both ethnic identity and admixture, and the APOE 
genotype, the e4 allele being over-represented in ‘mixed’ and ‘black’ ethnic groups 
groups and in those with greater African admixture. The association between APOE 
genotype was evident among those identified by interviewers as ‘black’ as well as those 
identified as ‘white’, but not in those identified as ‘mixed’. There was a non-significant 
trend for the association between APOE genotype and dementia to be weaker in those 
with greater degrees of African admixture. These findings are in contrast to those from 
the Ibadan study in Nigeria, where, in the West African context, there was no association 
between APOE genotype and Alzheimer’s disease (Hendrie et al., 1995a, Gureje et al., 
2006, Osuntokun et al., 1995). However, associations were observed among African 
Americans in the Indianapolis, USA arm of the same US-Nigeria study (Hendrie et al., 
1995a, Gureje et al., 2006, Osuntokun et al., 1995). It should be noted, again, as a 
potential limitation, that our findings relate to the outcome of dementia, rather than AD 
as in the US-Nigeria study.  
 
 
Controlling for ethnic identify or admixture did not affect the association between 
APOE genotype and dementia, suggesting an absence of confounding by population 
stratification. After controlling for compositional differences in APOE genotype (the 
risk conferring e4 allele being more common in ‘mixed’ and ‘black’ ethno-racial identity 
groups), there was a non-significant trend towards lower dementia prevalence in those 
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‘non-white’ groups. A similar non-significant trend was apparent for admixture. 
However, when the joint independent effects of ethno-racial identity and admixture were 
assessed in a single model, mutual confounding was evident. In each ethnic identity, 
increased African ancestry greatly increased the risk of dementia. At every level of 
African ancestry, those with ‘mixed’ and ‘black’ ethno-racial identities had a lower risk 
of dementia. Our findings on the effect of admixture on dementia prevalence are 
inconsistent with suggestions from a recently published Brazilian brain bank study, in 
which higher levels of African admixture were associated with lesser degrees of 
Alzheimer-related neuropathology (Schlesinger D   et al., 2011). However, while this 
latter finding is supportive of the hypotheses that genes linked to African ancestry might 
protect against AD, one cannot exclude the possibility that it  may have been accounted 
for by selection biases for inclusion into the brain bank (with those with more African 
ancestry and AD being less likely to be included).  
   
We have therefore established a link between admixture and APOE genotype, with a 
higher frequency of the risk-conferring e4 allele in those with greater degrees of African 
admixture. This tendency has been noted between populations with and without African 
ancestry (Farrer LA, 1997), but never before confirmed with respect to individuals with 
differing proportions of individual admixture. All things being equal, in a population 
with significant African admixture, this would be expected to result in a greater 
incidence and prevalence of dementia. However, in our sample this was offset by a large 
attenuation of the effect of APOE e4 in those with more African ancestry. This 
interaction was not statistically significant, and larger samples will be required to 
measure this with more precision and exclude type II error. Also, there was no 
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significant graded effect modification by ethnic identity in the larger sample, with the 
attenuation of effect being confined to those in the ‘mixed’ group.  
 
Another balancing effect on overall prevalence may be in operation given that the effects 
of ‘mixed’ or ‘black’ ethno-racial identity on the one hand, and African genetic 
admixture on the other seem to be operating in opposing directions in influencing 
dementia risk. Genetic admixture, externally observable physical characteristics 
including skin colour, and self-reported ethnicity are related to each other, but in 
complex ways (Parra et al., 2004, Airhihenbuwa et al., 2000). These are therefore related 
yet by no means collinear constructs, and mutual confounding is feasible. The new 
respectability of observer assessments of ‘ethno-race’ in epidemiological research arise 
precisely from their ability to identify the externally observable physical characteristics 
that are hypothesised to lead to social, economic and health disadvantage. Much 
research in the US has focussed upon black ethnic identity as a socially determined, 
contextually bound construct, linked to disadvantage and discrimination, and mediating 
health disadvantages. Thus, in the 1990s darker skin colour among African-Americans 
was found to be inversely associated with income, education and occupational status, 
and to be a stronger predictor of adult occupational status than was parental 
socioeconomic position (Jones, 2001). More recently, darker skin colour has been shown 
to be independently associated with experiences of racism (Keith and Herring, 1991). 
Protective income gradients in hypertension are evident for light-skinned but not dark-
skinned African-Americans, an effect hypothesised to be explained by psychosocial 
stressors linked to skin colour, including racism (Klonoff and Landrine, 2000). Of 
relevance to our finding of an apparent protective effect of non-white ethno-racial 
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identity on dementia risk, some benefits of such self-identification have been reported; 
for example factors reflecting participation in and belonging to African-American 
culture were associated with a range of positive health behaviours (Sweet et al., 2007).  
 
One of the weaknesses in the current study is that we did not adequately separate out 
self-perceptions from observer ratings of ethnic identity. A related issue is that 
ascertainment of race using interviewer’s perception might affect the estimate of the 
prevalence of dementia in different ethnic groups and introduce bias in  the associations 
reported. However, our estimates of African and European ancestry by SNP admixture 
analysis correlate more or less as one would have predicted with the interviewer’s 
perception of race (black, mixed or white) (ANOVA for linear association p < 0.001). 
This provides some concurrent validation for both the SNP estimating procedure and the 
interviewer perception. The main conclusion to be drawn is that a proper understanding 
of the role of genetic admixture in determining disease risk may require measurement of, 
and control for each of these and other related socio-cultural factors, including 
socioeconomic position and acculturation (Klimentidis et al., 2009, Jones, 2001) . 
Although strongly correlated, the effects of admixture and ethno-racial identity on health 
outcomes can and should be distinguished when assessing genetic and environmental 
contributions. 
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4.3.6     Effect modification of the effect of cardiovascular risk factors on 
dementia risk, by APOE Genotype   
I did not find any  significant difference in effect of cardiovascular risk factors on 
incident dementia risk by APOE genotype (p 136). Neither was there any consistent 
pattern or trend in the interaction effects observed across cardiovascular risk factors.  
Stroke and APOE e4 are independent risk factors for dementia. Synergetic effects 
between cerebrovascular disease and APOE e4 on the risk of cognitive decline were 
reported in a European community-based study of 353 men (Gerrish et al., 2012). I did 
not find  an interaction of APOE and stroke  for the incidence of 10/66 dementia.  The 
same results were found in the Canadian Study of Health and Aging, where the joint 
presence of stroke and APOE e4 was associated with a greater risk of dementia 
compared with absence of these two factors, althought the effect of stroke on dementia 
did not seem to be modified by APOE e4  (Keage et al., 2012).  A probable explanation 
seems to  be that stroke and APOE e4 may lead to dementia via independent 
mechanisms.  
 
Our study provided some evidence to support effect modification by APOE genotype of 
the association between smoking and dementia (SHR in APOE 4 carriers = 1.97  versus 
SHR in APOE 4 non carriers = 0.89), but this interaction was not statistically significant. 
The association  between smoking, dementia, and APOE genotype is controversial. The  
Rotterdam Study (Ott et al., 1998b), reported  an increased risk of dementia and AD 
associated with smoking in those without the APOE e4 allele. However, due to the 
disproportional mortality rates between smokers and nonsmokers who are APOE e4 
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carriers, the question remains whether there are additional factors in the causal chain 
possibly related to vascular disease.  
 
Diabetes mellitus was not an independent risk factor for dementia  in the overall Cuban 
Study sample. We also did not find effect modification by APOE genotype. The 
Kungsholmen project (Hampton et al., 2011) reported no interaction between DM and 
the APOE ε4 genotype, while the Honolulu-Asia Aging study (Peila R et al., 2002) 
observed a higher RR among diabetic patients with an APOE e4 genotype.  
 
In a meta-analysis conducted by Anstey et al (Anstey KJ et al., 2008), only two of seven 
studies reporting data on the interaction between total cholesterol and APOE e4 allele in 
the association with dementia had significant effects. In a population-based study of 
elderly Yoruba living in Ibadan, Nigeria,  Hall et al found (Hall KS, 2006) that  
increasing levels of cholesterol and LDL were associated with increased risk of AD in 
individuals without the APOE e4 allele, but not in those with APOE e4. They also 
reported  a significant interaction between triglycerides, APOE4, and AD risk, but in the 
opposite direction; increased levels of triglycerides were not associated with an increase 
in the risk of AD for individuals without the e4 allele.  
 
I also found stronger effects of triglyceride and VLDL cholesterol on dementia risk 
among those with an APOE e4 allele. These interactions were statistically significant in 
the cross-sectional analysis, with a non-significant trend in the same direction in the 
incidence analysis. VLDL transports endogenous triglycerides, phospholipids, 
cholesterol and cholesteryl esters. It functions as the body's internal transport mechanism 
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for lipids.  VLDL levels have been correlated with accelerated rates of atherosclerosis 
and are elevated in a number of diseases and metabolic states.  
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4.4  Conclusion 
 
The prevalence and incidence of dementia in the older Cuban population is relatively 
high, and the rates increase with age. These findings underscore the need to improve our 
understanding of risk factors associated with dementia in specific populations, as well as 
the need for public health programs for both patients and caregivers in a population that 
is currently demograpically  ageing and well advanced in the epidemiological transition. 
 
Regarding dependence I demonstrated that dementia is one of the most important 
contributors to needs for care, to the caregiver needing to give up work to care and to 
caregiver psychological strain. 
 
In this community-based population longitudinal study, some well-known risk factors 
for dementia, are confirmed but not others. Older age, a family history of dementia and  
APOE e4 genotype  were independent risk factors for incident 10/66 dementia.  
Smoking, diabetes, lipid profile, leg length and head injury were not associated with 
either prevalent or incident 10/66 dementia. New cohort studies are needed to study the 
effect of cardiocascular risk factors  from mid- to late-life.   
 
In our Cuban sample the risk of dementia and AD conferred by APOE e4 was 2.5 times 
higher than in APOE e4 non carrier after controlling the effect of age, gender and 
education and family history, which tended to increased slightly after adjusting for 
serum total cholesterol, other risk factors and vascular disease. The study shows that the 
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relationship between APOE e4 and incident dementia is stronger in younger old persons 
than in older old persons and that this change must be taken into account in models of 
dementia . 
 
We found a significant interaction between triglycerides and dementia, but not for 
cholesterol. For individuals with an APOE e4 allele, increasing level of triglycerides and 
VLDL were associated with increased risk of dementia. APOE genotype needs to be 
considered when assessing the relationship between lipid levels and dementia risk in 
population studies. 
 
APOE genotype is strongly associated with ancestry. Larger studies are needed to 
confirm whether the concentration of the high-risk allele in those with African ancestry 
is offset by an attenuation of its effect. Counter to our hypothesis, African admixture 
may be associated with higher risk of dementia, once the effect of discernable ethnic 
group status is controlled for. Although strongly correlated, effects of admixture and 
ethnic identity should be distinguished when assessing genetic and environmental 








4.5  Implications  
 4.5.1 Implications for Clinical Practice 
Epidemiological studies into dementia can generate awareness, inform policy, and 
encourage service development. Results presented in this thesis indicate that dementia is 
an increasing health and social problem in countries like Cuba with an important burden 
for families, services and society.  
 
Health systems in LMIC tend to prioritise delivery of care for communicable diseases 
and services related to maternal and child health.  There is also the tendency to focus on 
the development of treatments for chronic diseases while falling to adopt a broader 
perspective integrating the delivery of care for all chronic diseases within primary and 
secondary care  (Reddy K, 2011 ). 
 
 In Cuba an integrated approach to chronic conditions began in 1999 and had been 
completed as a strategic plan through to year 2000 (Tang M.X et al., 1996, Reed G, 
2008) when programs addressing to national prevention and management of chronic 
diseases including hypertension, diabetes, atherosclerosis, stroke and coronary heart 
disease were implemeted by the Minister of Public Health. As part of this strategy, 
strengthened primary health care through the adoption of the family doctor-and-nurse 
model, locating health professionals at the neighborhood level, and training them to 
promote health, were considered to be important  issues for the management of risk 
factors and NCDs. The point was to prioritize attention to NCDs at the same level as 
maternal-child health and infectious diseases. Nevertheless, more concerted attention is 
 188 
already being paid to these diseases and their risk factors through generating better 
media messages, enforcing legislation, using leverages such as pricing, and above all, 
pursuing coordinated multisectoral initiatives. 
 
With the rapid ageing process and the increase in numbers of people with dementia 
clinicians need to be aware and well trained for early detection, treatment and support 
for the people with dementia and their families.  Doctors and in particularly those from 
the primary level should be able to make an early diagnosis of dementia,  prevent and 
manage comorbilities and optimise physical health, cognition, activity and well-being of 
their patients. The detection and treatment of behavioural and psychological symptoms 
enhances the good quality of life for patients and their caregiver, and at the same time, 
may reduce the proportions of those who need nursing homes. They will also need to be 
prepared to provide information and long-term support to carers. 
 
Packages of care (combinations of treatments) for dementia have been proposed to 
achieve optimal outcomes in improving and managing the condition (Prince et al., 
2009).  The principal goals in managing dementia in health care are: detection and early 
diagnosis through dissemination of information about the condition; optimization of 
physical health, cognition activity, and wellbeing through regular physical assessments 
and cognitive stimulation intervention; detection and treatment of BPSD through 
dissemination of information and pharmacological treatments; and the provision of 
information and long – term support for carers (Prince et al., 2009). 
According to the Alzheimer’s disease International the minimum actions recommended 
for dementia care are  (Prince M et al., 2007):   
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1. Provide treatment in primary care  
2. Make appropriate treatment available 
3. Give care in the community  
4. Educate the public about the condition  
5. Involve communities, families and consumers in advocating for dementia 
6. Established national policies, programmes and legislations for dementia  
7. Develop human resources through training of health workers to care for dementia 
patients  
8. Create links with other sectors like non governmental organizations  
9. Monitor community health 
10. Support more research  
 
As a developing country, Cuba has limited economic resources and cost-effective 
responses could be adapted and expanded to improve dementia care. This strategy could 
be centred in the enormous human resources  to allow the implementation of the 
National Strategy. LMIC as India has succesfull implemented national strategies on 
dementia ( Alzheimer’s and Related Disorders Society of India, 2010).   
 
I summarise the main features of the proposed packages of care for dementia in Cuba:   
1. Raising awareness about the importance of early diagnosis and intervention on 
dementia, providing information, education and families suport .  
2. Strengthening the health system in  particularly training of the health and social care 
workforce at  primary level .  
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3. More research should be commissioned towards biomedical research, risk factors, 
quality of life, and health services.   
4. All primary care services should have basic competency in the assessment of 
cognitive impairment, making and imparting a provisional dementia diagnosis, and 
initial management of dementia and refer to the indicated specialist. 
5. Increase the availability of specialised health workers in the dementia field, such as 
geriatrician, neurologist, psychiatrics, nurses, psychologist and social workers at the 
primary health level, to confirm early stage dementia diagnoses and formulate care 
management plans. 
6. The availability of effective drug and non-drug interventions for people with 
dementia and their carers should be publicised to health and social care professionals 
through initial training and ongoing professional development, and to the public through 
population health promotion, and health and social care facilities. 
 
Better understanding of genetic risk factors for dementia, and gene-envirnoment 
interactions, may help in the future to identify individuals at higher risk to develop 
dementia, and to provide targeted advice on behavioural and lifestyle risk factor 
management. In the Cuban context, knowledge of individual admixture, and the genes 
linked to ancestry that might play a role in dementia risk, could have a part to play in 
future health care. However, our findings, while interesting, do not have any immediate 
clinical applications. More research is required, with larger study samples, to address 




  4.5.2. Implications for Health Services Programme 
   
I believe that the prevalence and incidence estimates contained in this thesis constitute 
the best currently available basis for Cuban policymaking, planning and allocation of 
health and welfare resources regarding dementia. 
As trend for life expectancy is to increase, numbers of people with dementia will 
continue to grow, particularly among the oldest old and more and more among whom 
comorbidity is a particular issue. An urgent political priority will be formulation of 
policies and plans to scale up provision and finance their long term care needs, including 
support for family carers.  
 
There are three experiences to provide care and promote health at the primary levels in 
Cuba, which at a modest cost , have provided useful support for older care. The Senior 
Centers (Casas de Abuelos), of which there are 233 in the country and 25 in Havana 
supported by the health system, offer caregiving, meals, and social and recreational 
activities during the day for older adults (Ministry of Public Health, 2009). This is 
especially important for those who either live alone or are home alone while other 
family members are at work or school. In another sphere, the Older Adult University, an 
outgrowth of the University of Havana, now has over 600 classrooms in local in-
stitutions and centers across the country—many in the capital— bringing continuing  
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education opportunities to the community level. Inter-generational concerns, living an 
active life at an older age, and other issues particularly relevant to this age group are 
central to the curriculum. The third institution are Senior Circles (Circulos de Abuelos ), 
supported by family doctors and polyclinics, offer a good example of how a small 
investment can impact many peoples’ lives—in this case, offering opportunities for 
regular exercise promoting physical and mental health, plus essential social contact. By 
2005, over 700,000 older adults across Cuba were participating in these circles 
(Malagón Y et al., 2007). 
    4.5.3. Implications for promotion and prevention 
The high prevalence of  dementia  in the elderly population means that intervention is 
likely to have a high impact  and be cost effective. A comprehensive effort to address the 
chronic disease epidemic and cardiovascular risk factors as risk factors for dementia will 
be most effective when clinical prevention is combined with population-level prevention 
policies. 
 
While my study has not provided additional evidence to support the role of 
cardiovascular risk factors and cardiovascular disease as aetiologic factors for dementia, 
the evidence from other studies is strong, particularly those that assessed the effects of 
mid-life as opposed to later-life levels of exposure. Primary disease prevention measures 




Primary prevention should focus upon targets suggested by current evidence; improving 
access to education, detection and control of hypertension, hyperlipidaemia, diabetes, 
obesity  and metabolic syndrome factors, and physical inactivity, should in principle 
have an important impact on the future prevalence and incidence of dementia 
worldwide. If all of the risk factors were eliminated, then a total of up to 50.7% of all 
cases of AD worldwide might be prevented (Barnes and Yaffe K, 2011). The most 
promising strategies in terms of yield of cases prevented would come about through the 
elimination of physical inactivity (12.7% of AD cases prevented), smoking (13.9%) and 
low education (19.1%)  (Solomon A. et al., 2007).  
 
World Health Organisation (WHO) estimates that up to 80 percent of cardiovascular 
disease, stroke, and type 2 diabetes could be prevented by eliminating shared risk factors 
such as tobacco use, unhealthy diet, physical inactivity, and the harmful use of alcohol 
(World Health Organization, 2006) . Continuing to strengthen primary health care would 
be the most promising strategy for management of risk factors and disease. At 
population level, cost-effective measures include the implementation of tobacco-free 
policies, tobacco taxation, comprehensive bans on advertising of tobacco products, food 
labeling, salt reduction through voluntary agreements with the food industry, educational 
efforts, and combination drug therapy for those at high risk of cardiovascular disease.  
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4.5.4 Implications for research 
Cross sectional studies such as the 10/66 surveys provide local estimates on prevalence 
of diseases, inform the community, policymakers and health services about the 
contribution of these conditions for future prioritarisation, and promote understanding 
about the societal cost of dementia. 
 
However, there is a continuing need for such studies, to investigate changes over time in 
risk factors, chronic disease prevalence and incidence, functioning, disability and 
dependence. Longitudinal studies are one of the methods that can be used to measure 
such trends. Panel surveys with repeated representative prevalence phase samples can 
also be adopted to achieve the same goal without the logistic and feasibility issues that 
may arise from a longitudinal design. Data from repeated waves will be able to provide 
us with details on differences in these trends, their possible causal explanations, and the 
extent to which these trends are attributable to increased surveillance and earlier 
diagnosis, increases survival with disease, or to cohort differences in the underlying 
disease-disability processes (Jagguer et al.  2007). Effectiveness of implemented 
interventions can also be assessed through such studies and its results may influence 
planning for future health programmes tailored to the population under study. 
 
The 10/66 cross-sectional study in Cuba was conducted from 2003 to 2006. I have now 
received further funding from the Cuban government to repeat the cross-sectional 
surveys in the same catchment area sites approximately 10 years on. This will allow me 
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and my research group to provide Cuban policymakers with information about the 
course of the chronic disease epidemic among older people, and the specific impact 
upon dementia prevalence, disability, dependence and care.  
 
The research conducted to date has highlighted the burden of dementia in Cuba for 
individuals and their families.  It is important that more research to undertand and treat 
the problem locally is developed. The World Health Organization has developed 
evidence based guidelines for the management of dementia (m GAP) (World Health 
Organization, 2008b)  to be used in primary care,  and it is important to test new 




We have found some evidence that that APOE genotype modifies the association 
between both triglicerides and the VLDL cholesterol subfraction and dementia. However 
we measured cholesterol and lipid profile in late life. Ideally, future research should be 
conducted using longer term follow-up between middle age and late life. Any such study 
would be costly and requires a long-term funding commitment. However, the benefits of 
such long-term chort research extend far beyond a better undertstanding of the aetiology 
of dementia.  
 
We clearly found a linear trend of increased APOE e4 alleles with dementia and with 
increased African ancestry, but I failed to demostrate that the association between APOE 
e4 alleles and dementia was significantly modified by African ancestry. However,  we 
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have conducted this analysis in a small subsample and hopefully will be able to carry on 
this analysis with the whole sample as material has been stored. Although are results are 
not conclusive it highlights the trend and the importance to further research in this area 
to confirm whether the concentration of the high-risk allele in those with African 
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